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Angiogenesis is a complex process coordinating cell migration, prolifer-
ation, and lumen formation. Changes to the microenvironment regulate an-
giogenesis through mechanotransduction and cytokine signals. In pulmonary
hypertension, something in the process becomes abnormal, resulting in changes
to the microenvironment and the formation of a glomerulus of dysfunctional
capillaries, called a plexiform lesion. Endothelial cells, expressing CD117
(CD117+ EC clones) increase in the plexiform lesions of pulmonary hyper-
tension, independent of pro-angiogenic VEGF signaling. We hypothesize that
the mechanical environment and the macromolecular composition of the ex-
tracellular matrix, both, contribute to the aberrant angiogenesis. When we
changed the mechanical environment, we changed the angiogenic potential
and cellular phenotype of CD117+ Endothelial cell clones. Turbulent flow,
pathologic substrate stiffness, and pathologic stretch increased Endothelial-
to-mesenchymal markers, such as acta2, cnn1, snail, and slug in CD117+ EC
clones while CD117- ECs showed minimal change. We perturbed the mechan-
ical environment of CD117+ EC clones and identified changes in Bone Mor-
phogenic Protein-2, an often overlooked pro-angiogenic cytokine. We coupled
changes in the mechanical environment to Rho GTPase intracellular signaling,
to predict how changes to the mechanotransduction would affect angiogene-
sis through a computational model. In our model of angiogenesis, we found
vessel synchronicity to depend on both which cell undergoes mitosis, and also
at which phase of GTPase cycling the cell undergoes mitosis. We believe
changes to the GTPase cycling may be the mechanism linking mechanotrans-
duction to the abnormal vessels found in pulmonary hypertension. We are the
first group to look at the role of the ECM composition, independent of stiff-
ness. Our results show diseased ECM composition alone leads to phenotypic
changes indicative of PH progression. In conclusion, these results provide a
possible cytokine implicated in the mechanotransduction of PH, established a
computational model of angiogenesis which provides a mechanotransduction
mechanism of disease progression, and established that the ECM composition
alone is capable of phenotypic changes leading to disease progression.
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1
Lung diseases such as pulmonary hypertension affect hundreds of thou-
sands of patients. Even though advances in therapies have relieved symptoms
and prolonged survival [1], there are no cures for these diseases outside lung
transplantation. Lung transplantation maintains low survival rates, limited
donors, and donor incompatibility [2, 3, 4]. The disease initiators are likely
increased pulmonary arterial pressure leading to vascular remodeling in pul-
monary arterial hypertension [5].
1.1 Lungs
The primary purpose of the lungs is to facilitate gas exchange. To fa-
cilitate gas exchange, the lungs move air from outside the body, through the
upper respiratory tracts and into the lower respiratory tract. As we inhale air,
it travels to the alveoli where a thin cellular layer allows the oxygen to diffuse
into the blood (Figure 1.1). The thin layer where tiny pulmonary capillaries
and alveoli come in contact is termed the air-blood barrier.
Functionally, most of the lungs is conducting zone, hollow passageways for
air. These regions have a large purpose to purify the air of contaminants, and
to humidify the air. The airway mucosa is a layer of epithelial cells sitting on
the basement membrane, with a connective tissue, lamina propria, underneath.
Interspersed throughout the epithelium are goblet cells which produce mucus,
designed to trap foreign objects. To clear the mucus, cilia on the apical surface
of the epithelium beat rhythmically to sweep the mucus toward the larynx to
be coughed out or swallowed.
In general, the epithelial layer becomes thinner and less ciliated deeper
2
Figure 1.1. The respiratory system. A) shows the location of the respiratory
structures in the body. B) is an enlarged view of the airways, alveoli (air sacs), and
capillaries (tiny blood vessels). C) is a closeup view of gas exchange between the
capillaries and alveoli. CO2 is carbon dioxide, and O2 is oxygen. Reproduced with
permission from [6]
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in the lungs, to minimize the diffusion distances. Once air passes into the
respiratory zone, it diffuses across the air-blood barrier. In the alveoli, the air-
blood barrier thickness is reduced to 0.5 μm for optimal gas exchange. In this
layer, the basement membranes of the pulmonary capillaries and the alveoli
are in contact with one another. This allows gas exchange to occur effectively.
In healthy lungs, airways can restrict blood flow and air flow. Smooth
muscle of the bronchioles or arterioles can constrict, decreasing the diameter of
the tubules. Decreasing the tubule diameter changes the air flow or blood flow,
respectively. If these tubules are constricted chronically, vessel remodeling can
occur and lead to pulmonary hypertension or other lung diseases.
1.2 Pulmonary Hypertension
Pulmonary hypertension (PH) is a pathological condition affecting the
heart and lungs. PH presents in patients of all ages, although females aging
30-60 are 2-3 times more susceptible to PH [7]. Increased pulmonary arte-
rial pressure ≥ 25 mm Hg is the definition of PH. Other diseases, Chronic
Obstructive Pulmonary Disease (COPD) or pulmonary fibrosis, often lead to
PH and together increase mortality and decrease quality of life of afflicted
patients [8, 9]. The World Health Organization breaks pulmonary hyperten-
sion into 5 subcategories, broken down in Table 1. Group II and III are the
most common causes of PH [10], referred to as associated pulmonary hyper-
tension. The recommended treatment for associated PH in these contexts is
to treat the underlying disease [7]. This work will focus on Group I, Pul-
monary Arterial Hypertension (PAH), but will briefly touch on changes in
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Group III because of COPD. Pulmonary arterial hypertension is also referred
to as primary pulmonary hypertension, idiopathic pulmonary hypertension,
and idiopathic pulmonary arterial hypertension.
Table 1. World Health Organization categorization of pathologic pulmonary hy-
pertension. Adapted from [11]
Category Example
Group I: Pulmonary Arterial
Hypertension
Idiopathic Pulmonary Hypertension
Heritible
Drug or Toxin Exposure
Associated with Systemic Disease
Group II: Pulmonary Hypertension
due to Left Heart Disease
Left Ventricular Diastolic Failure
Left Ventricular Systolic Failure
Valvular disease
Group III: Pulmonary Hypertension
due to Lung Disease
Chronic Obstructive Pulmonary Disease
Interstitial lung diseases
Group IV: Chronic Thromboembolic
Pulmonary Hypertension
Blood clots in lungs
Group V: Pulmonary Hypertension
due to other diseases
Blood disorders
Other systemic Disorders
1.3 Circulatory system of the lungs
The circulatory-system side of the lungs is complicated. First, it has to
accept the entire volume of blood which will be pumped system-wide by the
left ventricle. While there are about 10-40 billion capillaries in the systemic cir-
cuit, there are approximately 280 billion pulmonary capillary segments, which
take part in oxygen exchange [12, 13]. These oxygen-exchanging capillaries
establish the conventional pathway of the pulmonary arterial tree; however,
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in the lungs supernumerary arteries exist. These arteries are anastomotic,
with no known function [14]. The supernumerary arteries branch off at nearly
90-degree angles and are 1/10th the size of the parent artery. Additionally,
these supernumerary arteries have a “baffle valve” at their openings [15], and
are often undetectable during angiograms [16]. These supernumerary arteries
have been implicated as the primary site of the plexiform lesion formation in
PAH.
1.4 Endothelial Cell Hierarchy
Four cell lineages are required to form functional vessels, endothelial cells,
pericytes, smooth muscle cells, and fibroblasts. Endothelial cells form the
lumen of the vessel. Under normal conditions, the lumen is a single-cell layer,
which allows gases, wastes, and nutrients to diffuse to the surrounding tissues.
Even though the endothelium is a tightly controlled layer of cells, endothe-
lial cells express a large diversity of phenotypes and proliferative capabilities.
These phenotypes can vary between arteries/veins, large/micro vessels, or or-
gan specific phenotype variations [17]. There is a difference in proliferation and
functional capabilities of endothelial subpopulations, as shown in [18, 19, 20].
In commonly researched endothelial cell lines, such as human umbilical vein
endothelial cells (HUVECs) or human aortic endothelial cells (HAECs), highly
proliferative subpopulations of endothelial cells, endothelial progenitor cells,
were identified [21]. In vivo, the microvasculature is home to more of these pro-
genitor cells than larger vessels [19]. One marker used to identify these highly
proliferative endothelial cells, CD117, is a receptor for stem cell factor. CD117
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is not endothelial specific, but instead a marker of a stem-like cell, it likely
plays a role in the high proliferative capacity of these cells [22]. Clonal expan-
sion of these cells gives rise to cells termed Colony-forming endothelial cells
(CD117+ EC clones). Investigations into the role of these highly regenerative
cells in healthy functional environments are minimal, and even less in disease
states. Research has shown that a single cell from this CD117+ EC clonessub-
population, can generate functional vessels [22]. CD117+ EC cloneshave been
suggested to maintain homeostasis and contribute to regeneration and repair
of the vascular bed [23]. In the endothelial heirarchy, CD117+ ECs may serve
in a managerial role, organizing the vascular response. CD117+ EC clonesare
upregulated in PAH [24], plexiform lesions in PAH derived from monocolonal
endothelial cells (subsection 1.6.1), and in the Sugen/Hypoxia animal model
of PAH [25], indicating a translational role for these cells. We need more
investigations to identify the mechanisms by which CD117+ ECs contribute
pulmonary vascular bed maintenance and the translational relevance.
1.5 Extracellular Matrix
To maintain the vascular bed, endothelial cells must break down ECM,
migrate, and undergo tube morphogenesis [23]. The ECM is a reservoir of
cytokines and growth factors, which provide biochemical and biophysical cues
to maintain the vasculature [23] and regulate wound healing [26]. The compo-
sition of ECM varies between the basement membrane and interstitial space,
indicating there can be differences in the cytokines and growth factors. Fib-
roblasts plated on fibrotic scaffolds take on a myofibroblast phenotype [26].
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Endothelial cells prefer attaching to fibronectin [27], which has been shown to
retain the “stemness” of CD117+ ECs [28], but is only a minor component
of the basement membrane [29]. Endothelial cells undergoing Endothelial-to-
Mesenchymal Transition (EnMT) convert the basement membrane, consist-
ing of laminin and collagen type IV, to collagen type I and III, fibronectin,
and smaller quantity proteins, as found in the interstitial space. Composition
and stiffness of ECM influence cell differentiation, migration, and adhesion.
Changes in ECM composition can have a direct impact on the stiffness. In
pulmonary hypertension, vascular remodeling changes include periarteriolar
thickening, degeneration of elastic laminae, and increased thickness of the vas-
cular smooth muscle layer [5]. The increased thickness of the tunica media is
due to smooth muscle cell hypertrophy and hyperplasia. Smooth muscle cell
hypertrophy and hyperplasia increases ECM protein deposition, which leads
to changes in the substrate stiffness experienced by endothelial cells.
1.6 Angiogenesis
All the cells in our body require oxygen for long-term survival. Blood
transports oxygen from our lungs to distal regions of our bodies through
blood vessels. Hypoxic regions, areas not supplies with enough oxygen, re-
lease chemokine signals to induce new vessel formation, termed angiogenesis.
Angiogenesis specifically defines new capillaries forming from existing vessels
(Figure 1.2). New blood vessel formation begins with pro-angiogenic cytokines
activating an endothelial cell. The endothelial cell undergoes partial EnMT
(see subsection 1.7.1), where it begins migrating and breaking down the nearby
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ECM. The vessel elongates through cell migration and proliferation, eventu-
ally coming into contact with another vessel. The immature sprout intersects
with an existing vessel before the vessel matures and fluid perfuses through
the lumen.
Forming new vessels requires endothelial cells and support cells. En-
dothelial cells initiate new vessel formation and line the lumen. Support cells
of capillaries are pericytes, and function similar to smooth muscle cells. Sup-
porting cells found in arteries and veins are pericytes, smooth muscle cells,
and fibroblasts.
Pro-angiogenic 
Cytokines
Partial EMT
Migration
ECM Degradation
Elongation
Proliferation
Stabilization
Maturation
Profusion
a b c
Figure 1.2. Overview of angiogenesis. a) Pro-angiogenic signal activates an
endothelial cell, which undergoes partial EnMT, breaking down the ECM, and mi-
grating toward the angiogenic signal. b) migration and proliferation allow vessel
elongation until intersecting with another vessel. c) the vessel stabilizes and ma-
tures, and fluid begins perfusing through the the lumen.
Three different layers in arteries and veins separate cells, the tunica in-
tima, tunica media, and adventitia. The tunica intima forms a barrier, only
allowing small molecules to diffuse through. The tunica media houses smooth
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muscle cells and few fibroblasts, and is primarily responsible for changes in
the vessel diameter through smooth muscle contraction. The adventitia is
predominentely fibroblasts, immunomodulatory cells and extracellular matrix,
and is the first region activated to respond to vascular stress and injury [30].
Capillaries, on the other hand, are solely the tunica intima. In the tunica in-
tima, endothelial cells form the vessel lumen, pericytes wrap themselves around
the endothelial cells and thin basement membrane encloses them.
1.6.1 Vascular remodeling in PAH
PAH is characterized by vascular remodeling of the three layers of the
vascular wall, the intima, the media, and the adventitia (Figure 1.3. Increases
in pulmonary arterial pressure are due vascular lesions, most commonly in the
intima [31]. Early on in PH, endothelial cells become apoptotic and die [32].
At the center of plexiform lesions, monoclonal endothelial cells exist which
may indicate tumor suppressor gene dysfunction [33], or favor the emergence
of apoptosis resistant endothelial cells [31]. As PAH progresses, these intimal
lesions become fibrotic, while endothelial cells proliferate. However, the central
core of the plexiform lesions decrease expression of TGFβ signaling in the cells
[34].
Medial remodeling occurs in precapillary vessels, that contain smooth
muscle cells. Remodeling occurs through smooth muscle cell hyperplasia and
hypertrophy. The hypertrophy is been linked to decreased sensitivity of smooth
muscle cell proliferation to TGFβ, while other smad signaling pathways remain
intact, or even enhanced. TGFβ-induced gain-of-function alterations begin to
10
Normal
PH
a
b
Figure 1.3. Vascular remodeling associated with PAH. a) normal vasculature and
cross-section. b) Chronic occlusion leads to flow changes and hypoxia downstream.
Angiogenesis to build shunts is one method the body uses to restore flow. In PAH,
abnormal angiogenesis leads to plexiform lesions, glomerular structures of capillary
networks. Cellular changes include cell hyperplasia and activation. Cells become
more fibroblast-like, increasing ECM production and contractility.
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explain the increased smooth muscle cell growth and fibroblast activation.
The adventitia is primarily fibroblasts, ECM and immune cells. Collagen
deposition in PH nearly doubles the adventitial wall thickness. Fibroblasts
quickly react to hypoxia and shear stressors of vessels [35]. They quickly
respond to chronic hypoxia with drastic increases in cellular proliferation. In
addition to increased proliferation, fibroblasts increase smooth muscle cell pro-
liferation, recruit inflammatory and progenitor cells, create a path for angio-
genesis, or migrate and activate into myofibroblasts [31].
1.7 Mechanotransduction
Cells, chemical signals, and forces combine for specific cells responses.
Mechanotransduction is cells translating mechanical forces into biomolecu-
lar responses, resulting in a cellular response. Cells can detect exogenous
forces, including shear stress or mechanical load, while cells exert actomyosin-
generated contractile forces. Signals can induce or inhibit migration, prolifer-
ation, and differentiation, which are required for angiogenesis, while abnormal
forces contribute to disease pathologies.
1.7.1 Endothelial-to-Mesenchymal Transition
Embryonic EnMT was controversial in 1921 [36], yet correlation with dis-
ease came recently [37]. EnMT is a specialized form to epithelial-to-mesenchymal
transition, in which a stimulus causes epithelial cells to become mesenchymal-
like. Epithelial-to-mesenchymal transition contributes to cancer metastasis
[38]. EnMT progresses the cancer by forming cancer-associated fibroblasts
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Healthy PH
(a)
Healthy PH
(b)
Healthy PH
(c)
Figure 1.4. Mechanical changes associated with PAH. a) constricted regions of
vessels alter the flow dynamics changing the shear stresses which alters endothelial
cell phenotype. b) increased cellular contraction leads to ECM production which
combine to increase the substrate stiffness, leading to cell phenotype changes. c) pul-
satile blood flow through constricted vessels increases radial stretch of vessels. Ad-
ditionally, increased stiffness and contracted regions are less susceptible to stretch,
causing nearby regions to compensate leading to increased strain.
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which regulate tumor microenvironment [39]. In EnMT, cells lose cell-cell
adhesion, and endothelial cell markers, gain mesenchymal markers, increase
invasion potential, and increase motility [40]. EnMT causes pulmonary vas-
cular remodeling [41], similar to pulmonary hypertension, and other fibrotic
diseases [42], such as pulmonary fibrosis. These mesenchymal transitions are
primarily through Transforming Growth Factor- β (TGFβ) signaling pathways.
Numerous physiological and pathological pathways require TGFβ, so it is
tightly regulated. The TGFβ pathway goes through canonical (SMAD) protein
signaling or non-canonical (non-SMAD) pathways, both of which contribute
to EnMT [43, 44]. Cells sense substrate stiffness through integrins which
attach to ECM and activate latent TGFβ [45]. Taken together this shows
that endothelial cells placed on stiffer substrates release more TGFβ from
the ECM, enhancing EnMT. EnMT correlates with latent TGFβ activation
initiating signaling cascades.
EnMT is a reversible process in which mesenchymal-to-endothelial tran-
sition can induce angiogenesis from mesenchymal cells. Bone morphogenic
proteins (BMPs) are growth factors which inhibit the TGFβ EnMT path-
way, and induce mesenchymal-to-endothelial transition. One study looking
at transdifferentiation of mature fat cells found BMPs to increase endothe-
lial differentiation and angiogenesis [46]. BMP-2 partially reverses the effects
of TGFβ induced endothelial to mesenchymal, when given with exogenous
TGFβ [47]. This suggests not only that BMP-2 can reverse the effects of
EnMT but also capable of inhibiting some of the TGFβ pathway.
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1.8 Techniques to Study Angiogenesis
Angiogenesis requires cell migration, proliferation, and tubule formation.
Therefore, each of these aspects requires investigation to determine the an-
giogenic potential of endothelial cells. In vitro assays exists to measure each
of these outcomes. Cell migration is commonly performed through Boyden
chamber or gap closure assays. Cell proliferation is measured directly through
counting or nucleoside incorporation assays, or inferred through metabolic ac-
tivity. Tubule formation is determined through gel angiogenesis assays. Tis-
sue engineering requires functional vessels to maintain a blood-tissue barrier,
therefore recellularizing decellularized scaffolds can be used to measure the
barrier integrity of vessels, migration. and proliferation. Computational mod-
els, however, allow investigators to research isolated aspects of angiogenesis
without confounding factors. Additionally, computaitonal models allow re-
searchers to identify key parameters and take them beyond the physiological
boundaries; these models, while not realistic, can determine important aspects
physiological function that may not be noticed experimentally. Ideally, a com-
putational model would be able to incorporate all aspects of angiogenesis, the
intracellular and extracellular mechanisms and barriers, but are currently lim-
ited by processing power. Even if all of these methods indicate angiogenic
potential, the only way to determine successful vessel formation is through in
vivo angiogenesis. Each method only measures one, sometimes two, aspects of
angiogenesis, so positive results in all assays still may not produce functional
vessels.
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1.8.1 Proliferation Assays
Cell proliferation measurement assays include cell counting, metabolic de-
hydrogenase activity, or nucleoside incorporation assays. Using trypan blue
with a light microscope allows researchers to count live and dead cells to calcu-
late total cell numbers. While there are techniques that automate this process
they are no more accurate than manual counts [48], which are prone to sam-
pling error. Colorimetric assays quantify metabolic dehydrogenase activity,
corresponding to cell viability. There are many different precursor chemi-
cals that reduce formazan through cell dehydrogenases; however, changes in
metabolic activity is a limitation to all metabolic assays [49]. DNA assays
may provide the most accurate method to compare cell proliferation, unless re-
searchers are investigating drug-DNA interactions [50]. There are two common
methods to measure DNA in samples, BrdU and PicoGreen. BrdU gets incor-
porated into DNA during DNA synthesis and is therefore a measure of mitosis.
PicoGreen is a fluorescent nucleic acid stain for quantifying dsDNA. However,
PicoGreen also quantifies DNA from dead cells requiring other method to con-
firm. There are a number of concerns with all methods and multiple methods
should be used in conjunction with one another to ensure scientific rigor if
possible.
1.8.2 Vessel Formation Assays
Tube formation is one of the most specific tests for angiogenesis in vitro
[51]. There are three described methods of forming capillary networks [52].
In all methods, endothelial cells combine with ECM hydrogels and tubular
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networks spontaneously form. The most common method utilizes a preformed
matrigel hydrogel with endothelial cells plated on top. The tubular networks
on the surface may, or may not, contain lumens [53, 54]. To form more mature
vessels with lumens, cells can be resuspended in ECM protein before plating,
or sandwiched between ECM. Resuspended cells result in more dense capillary
networks, while sandwich methods are easier to image.
The aforementioned methods allow visualized capillary networks to form,
but do not provide information about sprouting angiogenesis, which is required
in vivo. Cells grown to confluence on ECM hydrogels invade the gel, forming
lumens, in response to pro-angiogenic growth factors. Alternatively, cells are
grown as spheroids, then resuspended in ECM gel so they can sprout out-
ward. In both methods, capillaries containing lumens can be differentiated
from migrating cells [52].
Angiogenesis requires migration, proliferation, tube formation, and mat-
uration. Each method described identifies a specific aspect of angiogenesis,
and therefore should be used in conjunction with one another to improve the
translation of angiogenic or anti-angiogenic results.
1.8.3 Re-vascularization for Tissue Engineered Lungs.
Tissue engineering from pulmonary scaffolds is currently the closest to
replacing donor-recipient lung transplantation. By removing the cells from
a donor organ and replacing them with healthy cells from the recipient, we
may reduce the immunogenic reactions while increasing the number of lungs
available for transplantation.
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However, the major hurdle in the field of lung tissue engineering is reestab-
lishing a fully functional air-blood barrier. Optimized methods are only achiev-
ing 75% endothelial cell coverage in rat lung recellularization [55], human re-
endothelialization was not nearly as successful. To achieve 75% coverage of
rat lungs, Ren et al. injected 40 million HUVECs into the pulmonary vas-
culature [55]. A different group claims enhanced re-endothelialization using
10 million rat lung microvascular endothelial cells [56]. Fully functional vas-
culature requires a myriad of cell types, an extraordinary number of cells for
recellularization, cellular proliferation to complete the coverage, and differen-
tiation of ECs to form mature functional vessels. Many groups use stem cells
for recellularization [57, 58, 59, 60, 61]; stem cells have high proliferation rates
and can differentiate into a host of mature cells.
1.8.4 Computational Models of Angiogenesis
A great deal of work exists from developing computational models to an-
swer questions about angiogenesis (reviewed in [62, 16, 63]). Models range
from molecular signaling cascades involved with angiogenesis, how individual
vessels form from individual cells, drug delivery and tissue engineering angio-
genesis, and in vitro models of angiogenesis. Models of cell migration, through
actomyosin contractility, express oscillatory pertrusion and retraction of the
cell membrane [64]. Computational models of tubule elongation exist, where
the tip cell pulls and the stalk cells proliferate, effectively pushing the tip cell
forward [65]. Cell-ECM friction has been included in a force-balance equation
to help model angiogenesis [66]. Few models of angiogenesis incorporate cell
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mechanical forces explicitly [63], while fewer investigate the mechanical effect
on intracellular signaling in angiogenesis.
1.9 Experimental Platforms to Study Mechanotransduction
Endothelial cells exist in a highly dynamic environment including oscil-
lating shear stresses, cyclic stretch, and substrate stiffness. ECM composition
contributes to the mechanical environment, and investigators have looked at a
more complete microenvironment in fibrosis and emphysema [26, 67, 68]. Each
mechanical stimulation modality offers insight into cell behaviors not be seen
in other modalities. Endothelial cells are well suited for in vitro investigations
because they are normally found in monolayers.
1.9.1 Shear stress due to flow
The primary mechanical environment endothelial cells experience is shear
stress due to flow. Shear stress regulates many aspects of mechanotransduc-
tion. There are two primary mechanisms to apply shear stress to a system in
vitro [69]. A rotating cone or plate, as is used for rheometry, uses a motor
to spin the cone or plate, creating shear stress. A cone is preferred as it can
create a homogenous shear stress, whereas a parallel plate increases the shear
stress as the radius gets larger. The second type is a flow chamber system,
commonly a parallel plate flow chamber, in which there are openings on both
ends of the chamber and fluid is pumped across the cell surface.
Blood pressure, velocity, and vessel diameter decrease dramatically before
arriving at the capillary networks, although the cross-sectional area increases
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considerably. This produces low shear stresses (<10 pa) in the microvascular
networks [70]. Even though the shear stresses are low, extreme branching, in-
creased vessel stiffness, or thrombosis can create regions of disturbed capillary
flow [71, 16]. Endothelial cells respond quickly to changes in sheer stress, after
detecting changes in capillary flow [71].
1.9.2 Mechanical Strain
Functioning elastic, hollow organs, such as the bladder or lung sense de-
formation [72]. In the lung, endothelial cells experience radial, circumferential,
and axial stretch, from pulsatile blood flow and the normal respiratory cycle of
inhalation and exhalation. There are many methods for inducing strain for in
vitro experimentation. Individual cells can be stretched through micropipettes,
optical traps, and atomic force microscopes. While stretch through these meth-
ods offers precise control over strains, they have small strain ranges and low
throughput, only stretching one cell at a time. Commercial systems, such as
the Flexcell (Flexcell International Corporation), stretch a population of cells
for larger scale investigations. There are many different strain levels, actua-
tor types, substrates, sizes, frequencies, directions, and waveforms available
for investigating cell response to stretch [73]. These commercial systems have
well-characterized strain profiles, homogenous strain patterns, and adaptable
stretching modes.
Cyclic mechanical stretch regulates a myriad of endothelial cell functions.
Stretching endothelial cells causes increased Rho GTPase activity [74] which
plays a role in both stress fiber formation and angiogenesis. Physiologic
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stretch levels increase angiogenesis and pro-angiogenic factors [75]. Stretch
regulates EC proliferation, with pathologic stretch proliferation being a major
player in increased vascular resistance [75], a primary cause of PAH. Stretch-
ing beyond physiologic parameters increases protease production, which con-
tributes to athlerosclerosis [76]. These changes—along with decreased apopto-
sis, increased inflammation, increased ROS, and vasoconstriction—in patho-
logic stretch conditions lead to blood vessel changes termed vascular remodel-
ing.
1.9.3 Substrate Stiffness
Normal tissue cells exert aforce on their surroundings but also react to ex-
ternal stiffness. A lot of work has investigated the effects of substrate stiffness
on cell phenotype. In response to stiffer substrates, cells generally increase ad-
hesion, increase actin fibers, increase contractility, decrease migration speed,
and increase proliferation [77]. In soft tissues, such as the lung, increasing
substrate stiffness often indicates disease. PAH outcome is better predicted
using pulmonary arterial stiffness, compared to pulmonary arterial pressure
[78, 79]. In fact, repairing the substrate stiffness may repair some patholo-
gies; fibroblasts isolated from fibrotic lungs lose contractility when placed on
physiological, instead of pathological, stiffnesses [80].
1.10 Models of PH
There are two major models which recapitulate certain aspects of PAH,
monocrotaline and Sugen 5416 with chronic hypoxia (Su/CHx). Monocro-
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taline is a good model for reproducing right ventricular hypertrophy but does
not reproduce vascular remodeling or lesions found in PAH [81]. Sugen 5416
is a vascular endothelial growth factor receptor inhibitor, and, when combined
with hypoxic conditions, Sugen causes angioobliterative lesions similar to plex-
iform lesions [32, 82, 83]. The changes due to Su/CHxincrease pulmonary arte-
rial pressure, vascular remodeling, and dysregulate the TGFβ–BMP signaling
pathways [84].
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CHAPTER 2
RESEARCH DESIGN
Rationale and Major Hypothesis
Endothelial cells show phenotypic changes in response to pathological
mechanical changes, but recently a stem-like population has been isolated
(CD117+ EC clones) capable of forming functional vessels. It is important
to understand if all endothelial cells respond to micro-environment changes
equally or if a sensitive sup-population exists capable of responding to changes.
If there is a sub-population that is more sensitive to these changes it is im-
portant to determine a mechanism by which these stem-like ECs could alter
their angiogenic potential. The TGFβ signaling family is a major contribu-
tor to health, development, and disease, with TGFβ and bone morphogenic
proteins often regulating each other. In disease this balance becomes dysreg-
ulated, leading to micro-environmental changes. Computational models offer
the ability to investigate relevant, but extreme/unrealistic scenarios to bet-
ter understand the physiologic conditions. This project investigates each of
these scientific questions increasing the knowledge base surrounding the micro-
environment and angiogenesis.
We hypothesize that healthy ECM and healthy mechanical environment
combine to promote angiogenesis of endothelial progenitor cells. To test our
hypothesis, we decellularized rat lung tissue from healthy tissue and tissue
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from a model of pulmonary hypertension. We then coated polyacrylamide
gels or silicone membranes with the ECM proteins and added the endothelial
progenitor cells. We expanded these in vitro results to investigate ex vivo and
in silico and characterized the phenotype changes through mRNA quantifi-
cation, morphology changes, and cell staining, permeability assays, and cell
proliferation.
BMP2 Angiogenesis↑ Strain↓ Stiffness
Angiogenesis↑ Strain↓ Stiffness
ECM
composition Disease Propagation
Rho 
GTPase
Elongation/
migration Angiogenesis↑ Strain
BMP2 Angiogenesis↑ StrainECMcomposition Tissue Engineering
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Aim 1
Aim 2
Aim 3*
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Aim 4
Overview
Figure 2.1. Overview of project aims. Aim 1 investigates mechanical pertur-
bations on angiogenesis. Aim 2 Investigates the role of ECM, independent of the
mechanical environment, on cell phenotype. Aim 3 is a computational model of
angiogenesis based on Rho GTPase cycling. Aim 4 investigates the role of strain on
tissue engineered lung vasculature. The overall connection is ECM composition +
mechanical stimuli works through Rho GTPases to induce angiogenesis leading to
functional or diseased vasculature.
Specific Aims
2.0.1 Specific Aim 1
Quantify angiogenic potential of CD117+ ECs due to mechanical en-
vironment changes of altered substrate stiffness, flow rate, turbulence, and
stretch, through matrigel angiogenesis assays, qRT-PCR, and immunofluores-
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cence staining.
2.0.2 Specific Aim 2
Investigate the role of ECM in cell phenotype changes of CD117+ ECs
and fibroblasts subjected to changes in substrate stiffness or changes in stretch,
and quantify changes through qRT-PCR, and immunofluorescence staining.
2.0.3 Specific Aim 3
Establish a computational model of tension-driven angiogenesis that in-
corporates intracellular-level mechanics to induce cell migration and then a a
tension-dependent, probability-based mitosis to allow for vessel elongation.
2.0.4 Specific Aim 4
Investigate CD117+ endothelial cells ability to recellularization of tissue
engineered scaffolds through dextran permeability assays and resazurin stain-
ing in pilot studies.
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Table 2. Summary of project contributions to the field
Aim What we know? What is unknown? What this project addresses?
1 There is diversity in en-
dothelial cell population.
How do CD117+ ECs
respond to mechanical
changes?
We assessed CD117+ EC pheno-
type changes in response to me-
chanical stimuli.
2 Stiffness and ECM com-
bined with stiffness can
alter cell phenotype.
How does cell phenotype
change in response to ECM
independent of stiffness?
We assessed CD117+ EC pheno-
type changes in response to ECM
changes independent of stiffness.
3 GTPases are necessary
for cell contraction and
migration.
Can we create a computa-
tional model to predict stabil-
ity of angiogenic vessels?
We created a computational
model of angiogenesis, coupling
Rho GTPase mechanical activity
to predict tension-dependent mi-
tosis.
4 Tissue engineered lungs
need a functional air-
blood barrier to be suc-
cessful.
Can CD117+ ECs improve
recellularization of tissue en-
gineered scaffolds?
We investigated the air-blood
barrier after recellularizing rat
lungs with CD117+ endothelial
cells.
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3.1 Rationale
Angiogenesis occurs through the combined effects of cell proliferation, mi-
gration, biochemical signals, and the mechanical environment (substrate stiff-
ness, shear stress, and stretch). The endothelial cell of a blood vessel activates
after receiving a signal and breaks down the basement membrane. A cell mi-
grates, becoming the tip cell. Sprout elongation occurs through proliferation
and haplotaxis, the tip cells migrates forward while attached to the stalk cells
through cell-cell junctions such as Vascular Endothelial Cadherin (VECAD).
Without cell proliferation, the sprout would not extend very far.
HUVECs are a heterogenous population of endothelial cells, only guaran-
teed to 15 population doublings. While endothelial cells were long considered
a homogeneous population, a considerable heterogeneity exists and few cells
contribute to disease progression [85]. This represents another significant ob-
stacle for tissue engineering, what endothelial cell population can proliferate
significantly more while retaining endothelial markers. Many groups have
turned to various endothelial progenitor cells, yet these putative EPCs rarely
integrate into remodeled endothelium [86]. Contrastingly, Endothelial Colony
Forming Cells (ECFCs) have high proliferative potential, and capacity for
vasculogenesis. Investigators isolate these ECFCs by colony formation, and
use markers for to ensure endothelial lineage. Cell sorting for endothelial lin-
eages commonly used include positive selection for stem-cell (such as CD144,
CD117) and endothelial markers (such as CD31, vWf), while negatively se-
lecting for hematopoietic markers (such as CD45, CD14). After receiving
a pro-angiogenic signal, a single lin−CD31+CD105+CD117+ cell can form a
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functional blood vessel [22].
Of the biochemical signals, the most well known vascular endothelial
growth factor (VEGF) is a major cytokine to induce angiogenesis. Other
known pathways include fibroblast growth factor (FGF), and Bone Morpho-
genic Protein-2 (BMP2) . Bone morphogenic proteins are a sub-class of pro-
teins in the TGFβ family, which often balance TGFβ signaling to maintain
homeostasis. Although BMP2 preferentially binds to Bone morphogenic pro-
tein receptor type 2, it can also bind with TGFβreceptors to induce EMT
[87]. BMP-2 partially reverses the effects of TGFβ induced endothelial to
mesenchymal, when given concurrently with exogenous TGFβ [47].
One study looking at transdifferentiation of mature fat cells found BMPs
to increase endothelial differentiation and angiogenesis [46]. BMP2 is signif-
icantly upregulated in non-small cell lung carcinomas [88], and increases EC
proliferation and migration [89, 90]. BMP2 can induce angiogenesis [91, 90],
independent of VEGF [92], and is increases expression in response to increased
shear stresses [93, 94], and increased stretch [95].
The mechanical environment plays a pivotal role in disease-associated an-
giogenesis; mechanotransduction attempts to restore flow around disturbed
regions. Increased angiogenesis occurs on decreased stiffnesses [23], sprouting
only occurs in regions of low shear stress low turbulence [96], and in response
to increased stretch [97]. Here we investigate the role of mechanical stimuli
on endothelial cell phenotype and angiogenic potential. We hypothesize
changes to the mechanical environment alters the angiogenic po-
tential of CD117+ EC clones. Specifically, we expect that disturbed
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flow, increased stretch, and increased stiffness will increase increase EnMT
markers of CD117+ EC clones, while decreasing their angiogenic potential.
3.2 Methods
3.2.1 Polyacrylamide gel formation
We used Polyacrylamide gels (PAG) of stiffnesses approximately 20 kPa
and 1 kPa for stiffness experiments. We used 1 kPa to mimic normal lung
tissue and 20 kPa to mimic severely stiff arteries [98], and combined them
with healthy and diseased ECM to better isolate the role of stiffness and
composition in disease progression. We made PAGs based on the detailed
protocol in Appendix A.2. For initial experiments and immunohistochemistry
staining, we made our own PAGs, otherwise we purchased Softwell EasyCoat
polyacrylamide coated plates (Matrigen, SW6-EC).
3.2.2 Cell culture
We used CD117+ EC clones for experiments. We received the rat-lung-
derived, clonally-expanded, GFP-expressing, CD117+ endothelial cells from
Dr. Farkas. We used passages 4-8 for experiments. We cultured cells on tissue
culture plates coated with rat tail collagen in Endothelial Growth Medium for
Microvascular vessels-2 (EGM-MV2). The day after passaging, we changed
cell media and every two to three days after that. We passaged cells at 80%
visual confluence.
One hour prior to passaging, we added 50 μg/ml rat tail collagen in 0.02
N acetic acid to tissue culture plates. We incubated the plates at room tem-
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perature for 1 hour. We then rinsed the plates twice with PBS, discarding the
PBS each time.
To passage cells, we removed the media from cells and rinsed the cells twice
with PBS (Phosphate-buffered saline) . We then detached the cells by adding
0.25% trypsin/EDTA in an incubator for 10 minutes. We used a microscope to
ensure complete detachment. We neutralized the trypsin using media, placed
the cell solution in a conical tube, and then spun the resulting solution down at
300 rcf (relative centrifugal force) . We discarded the supernatant, resuspended
the cells in media and added them to the collagen-coated plates. We changed
the media 24 hours after passaging.
3.2.3 Mechanical Environments
We coated capillary tubes, PA gels, and BioFlex plates with 0.05 mg/ml
RTC for 1 hour at room temperature. We then rinsed the wells with PBS and
added 10,000 cells/cm2. Cells attached for 24 hours and then we changed the
media and the cells were cultured for 48 additional hours (Figure 3.1).
3.2.4 Phenotype shifts measured through qRT-PCR mRNA quan-
tification
A detailed protocol for qRT-PCR is written in section A.4. In brief,
mRNA was isolated using a Qiagen mRNeasy kit protocol. Before converting
to cDNA using iScript (BioRad) we balanced the mRNA to 25 ng/ul. Then
we combined 4 ul cDNA with a mastermix consisting of individual forward
and reverse primers (Table 3), and SYBR green in a PCR plate. We covered
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Figure 3.1. Overview of mechanical environment methods. a) Cells were added
to a capillary system. After 48 hours, the capillary tubes were cut in half, with the
inlet considered turbulent and the outlet being considered laminar flow. b) Cells
were cultured on collagen-coated polyacrylamide gel plates for 48 hours. c) Cells
were cultured on collagen-coated silicone plates and subjected to equibiaxial stretch
for 48 hours.
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the plate, placed it on a plate shaker for 2 min and centrifuged at 1,200 RPM
for 2 min. To run qPCR, we placed the plate on a CFX Connect Real-Time
System (BioRad) for thermocycling. We set the cycles were set to 95◦C for
15 seconds, 58◦C for 30 seconds, and then 72◦C for 15 seconds to promote
denaturing, primer annealing, and extension, respectively.
Table 3. Table of primers used for qRT-PCR
Gene Forward Sequence Reverse Sequence Product ID
18s GCAATTATTCCCCAT
GAACG
GGGACTTAATCAAC
GCAAGC
ACTA2 AAACCACCTATAACA
GCATC
AGACAGAATATTTGC
GTTCTG
R ACTA2 1
Bmp2 CTATATGCTCGACCT
GTACC
CTCATTTCTGAAAGTT
CCTCG
R BMP2 1
Itgb5 GACCTTAATCTCTTC
TTCACTG
CCTCAAGGTAAAAGA
CTGTG
R ITGB5 1
SNAI1 TGTAATAAGGAGTAC
CTCAGC
AGAAAGGCTTCTCAC
CAG
R SNAI1 1
SNAI2 AAAACCAGAGATCCT
CACC
ATCAGTTAAGAGGAG
AAAGG
R SNAI2 1
Pecam1 AAAACCACAATTGAG
TACCAG
ACTTAGCTTGACGTT
CTTTG
R PECAM1 1
Vwf AAAATCCTGGATGAA
CTTCTG
GACTCAGGGTGATTT
TCTTC
R VWF 1
Vcam1 CTGATTATCCAAGGC
TCTTC
CCATTAACAGACTTT
AGCACC
R VCAM1 1
Col1a1 TGGATTCCAGTTCGA
GTATG
AGTGATAGGTGATGT
TCTGG
R COL1a1 1
Eps8 AAACACCAGAAAGCA
CAAG
GTAATAAACACCAAG
GTGGG
R EPS8 1
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3.2.5 Matrigel Angiogenesis
We used tubule formation to determine angiogenic potential through Ma-
trigel Angiogenesis Assays. We sandwiched 20 μl of matrigel between non-stick
microscope slides and coverslips (diameter-12 mm), and placed them in a 37◦C
incubator for 30 minutes. After gelation, we removed the slides and placed
the matrigel coated coverslips inside the wells of a 24-well plate. We rinsed
twice with 2% Anti-Anti in PBS. We then added 20,000 cells per cm2 in fresh
media. To determine the effects of BMP2, we added 100ng/ml rhBMP2, or 1.5
μg/ml BMP2 Neutralizing Antibody (NAb). After 24 hours, we took images
and quantified tubule formation using AngioTool [99].
3.2.6 Statistics
We compared the results by One-way ANOVA with Tukey’s post-hoc
comparison test, for groups of three or more. We used Student’s t-test to com-
pare the means of groups unless an F test determined differences in variance in
which case Welch’s Correction was used. We determined statistical significance
at P<0.05, using GraphPad Prism Version 7 statistical software [100]. Signif-
icance levels were broken down as follows: *p<0.05, **p<0.01, ***p<0.001,
p<0.0001. All graphs are displayed as mean ± stdev All experiments were
performed in n=3 experiments with duplicate groups unless otherwise noted
in the figure caption.
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3.3 Results and Discussion
3.3.1 Polyacrylamide gel stiffness
We confirmed the stiffness of the 20 kPa gels to be 20.66 ± 4.57 kPa
through atomic force microscopy. That is within the range established in
[101]. But we could not measure the stiffness of softer substrates; the tips used
to quantify the stiffness were not flexible enough to measure the stiffness of
softer substrates. Due to these limitations we began purchasing commercially-
available 25 kPa and 1 kPa polyacrylamide gels, to maintain quality and im-
prove throughput.
3.3.2 CD117+ EC clones establish a better barrier
Using trans-epithelial electrical resistance, we measured the barrier formed
by CD117+ EC clones significantly increased over CD117- ECs. To account
for initial differences, we normalized both groups to 10 hours after cell seed-
ing. We used a low frequency of 4000 Hz because low frequencies (<10,000
Hz) restrict the current through the presence of intercellular junctions [102].
We subtracted the initial resistances remaining timepoints which subsequently
peaked at approximately 1050 Ω (65 hours) and 715 Ω (55 hours) for CD117+
and CD117- cells, respectively (Figure 3.2). The peaks correspond to com-
plete confluence of the dish (based on manufacturer guidelines). Initial barrier
formation over the first day was similar between groups, but timepoints as
early as 35 hours showed significant differences (p<0.01). There was one time-
point that did not have significance, at 55 hours. Experiments using similar
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parameters are in agreement with our results [102, 103], while the range can
be from 250 Ω to 5000 Ω from unspecified conditions [104, 105, 106]. These
results indicate that CD117+ EC clones form a more intact barrier; a barrier
that vascular diseases, like PH, damage, supporting the use of CD117+ EC
clones as a cell therapy [107].
(a) (b)
Figure 3.2. CD117+ EC clones form a better barrier after 72 hours. 100,000 cells
were plated on RTC-coated ECIS plates for up to 75 hours after cell attachment.
The transendothelial resistance was measured throughout. Initial differences were
normalized to to cell attachment. a) time trace of TEER values over duration
of the experiment. Confluence was achieved after 65 hours with a peak of 1050
Ωfor CD117+ EC clones. Confluence was achieved after 55 hours with a peak
of 715 Ωfor CD117+ EC clones. b) specific binned times to show significance.
Significance between TEER values began after 30 hours and continued throughout
the experiment except at 50 hours. n=3, **** p<0.01
3.3.3 CD117- ECs display minimal phenotype shift to major me-
chanical changes
Endothelial cells depleted of CD117 demonstrate minimal phenotypic
changes when subjected to stiffness or stretch changes. CD117- endothelial
37
cells increased Acta2 (mRNA for α-smooth muscle actin) and Tagln (mRNA
for trangelin) mRNA production in response to stretch and stiffness changes,
respectively (Figure 3.3). All common markers of EnMT, increased substrate
stiffness was expected to increase Acta2 [108], Col1a1 (mRNA for collagen
type 1α) [109], and Cnn1 (mRNA for calponin 1) [108] mRNA production of
endothelial cells. Stretch increases Acta2 and Cnn1 in HUVECs [110]. In
other cell types, stretch increases Acta2, Cnn1, and Tagln [111], as well as
BMP2 [112], Col1a1 [113], and Tgfb1 [114].
Endothelial cells are expected to respond to mechanical changes primarily
through actin and actin associated proteins. Smooth muscle actin in neces-
sary for cellular contraction, and therefore takes part in adhesion, migration,
and mechanotransduction. Transgelin is an actin cross-linking protein sen-
sitive to cell shape. Calponin 1 stabilizes actin polymerization. Increases
in all of these markers indicates actin polymer maturation and cross-linking
which help cells respond to mechanical changes and transmit mechanical sig-
nals. Mechanotransduction causes many phenotypic changes, including in-
creases to the extracellular matrix. Collagen type I is a major component of
the ECM. Because CD117- ECs show minimal phenotypic in response to me-
chanical changes, these results support a hierarchical system of ECs wherea
sub-population of ECs plays a managerial role providing paracrine signaling
for other ECs.
This study is limited in that it was only performed once; it is challenging
to get depleted populations of ECs to proliferate minimizing the ability to con-
duct CD117- EC experiments. However, the results show that any mechanical
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perturbation implicated in disease progression is primarily not through CD117
depleted populations. But these results also suggest that targeting CD117+
EC clones may be a more effective treatment strategy.
(a) (b)
Figure 3.3. CD117- ECs are minimally responsive to mechanical environment
changes. a) CD117- endothelial cells subjected to stiffness for 48 hours display min-
imal changes in EnMT markers. After 48 hours on diseased stiffness substrates,
non-progenitor ECs displayed only one significant increase, Tagln. b) CD117- en-
dothelial cells subjected to stiffness for 48 hours display minimal changes in EnMT
markers. After 48 hours of pathological stretch, non-progenitor ECs displayed only
one significant increase, Acta2. * p<0.05, *** p<0.001, n=1
3.3.4 BMP2 increases angiogenesis
Exogenous BMP2 addition increases angiogenesis of CD117+ EC clones while
inhibitors decrease angiogenesis below vehicle control. While CD117+ cells are
associated with the vascular remodeling found in PAH [24], they appear to be
independent of VEGF changes in PAH [115], suggesting an alternative acti-
vation mechanism. BMP2 plays a role in migration, proliferation, EnMT and
angiogenesis, which contribute to pulmonary hypertension. BMP2 inhibits
39
mesenchymal transition [116, 117], and vascular smooth muscle cell prolifer-
ation [1]. BMP2 is often not included as one of the major pro-angiogenic
cytokines, but plays a major role in branch formation of zebrafish [118, 92]
and tumor angiogenesis [91, 90].
Adding exogenous BMP2 (80 ng/ml) to endothelial cells during a matrigel
angiogenesis assay increases vessel length, significantly (p<0.001), by approx-
imately 40% (Figure 3.4). Conversely, adding 1.5 μg/ml BMP2/4 neutralizing
antibody decreases vessel length significantly (p<0.05) compared to vehicle
control groups. BMP2 appears to play a paradoxical role in PAH. BMP2 het-
erozygous knockdown increases hypoxic PAH development [119], and prevents
VSMC muscularization suggesting BMP2 prevents PAH [120]. Conversely,
BMP2 prevents endothelial apoptosis [90, 121], which contributes to plexi-
form lesion development. Outside of PAH, up-regulating BMP2 production in
tissue engineering may help to increase vessel formation in tissue engineered
scaffolds by influencing cardiovascular progenitor differentiation as shown in
[122].
3.3.5 CD117+ EC clones change in response to turbulence
Endothelial progenitor cells subjected to turbulent flow conditions appear
to decrease tubulogenesis on matrigel, while increasing EndMT markers (Fig-
ure 3.5). Significant increases in mRNA transcripts α-SMA, Tagln, and Cnn1
from turbulent regions indicates increased EndMT of cells in turbulent re-
gions . Turbulent shear stresses increase endothelial dysfunction and promote
EnMT [123, 124, 125], supporting our results. Matrigel angiogenesis assays
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Figure 3.4. BMP2 increases CD117+ EC clones angiogenesis. 20,000 cells were
plated on matrigel for 24 hours. After 24 hours they were stained with calcein
AM, images were taken and vessel formation was quantified using AngioTool [99].
Adding 80 ng/ml of exogenous BMP2 during angiogenesis assay increases the vessel
length by 40% over vehicle control. adding 1.5 μg/ml BMP2/4 neutralizing antibody
decreases vessel formation by 25% below vehicle control.
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of cells exposed to the different shear stress conditions indicate more angio-
genic potential from cells extracted from laminar regions. However, it appears
that there are a different number of cells, which can significantly alter the
results of matrigel angiogenesis assays [126], and will be quantified in future
experiments.
3.3.6 CD117+ EC clones changes in response to substrate stiffness
Increased stiffness is one of the most highly investigated mechanical changes
to known to cause EnMT. CD117+ EC clones show slight increases in prolif-
eration on 20 kPa compared to 1 kPa gels (Figure 3.6a), which many other
investigations show [127, 128]. Cells added to collagen coated polyacrylamide
gels display different morphologies and cell spreading on 1 kPa versus 20 kPa
gels (Figure 3.6b, 3.6c, 3.6d). Increases substrate stiffness increase cell spread-
ing, in agreement with our results, and change cell phenotype.
CD117+ EC clones cultured on 20 kPa stiffnesses express EnMT pheno-
typic markers (Figure 3.7). CD117+ EC clones have significant increases in
mRNA markers for smooth muscle actin (Acta2), Calponin-1 (Cnn1), integrin
β5 (ITGB5), Snail (Snai1), Slug (Snai2), Transgelin (Tagln), Transforming
Growth Factor β-1 (TGFβ1), and Transforming Growth Factor β-2 (TGFβ2) .
Increases in Snail, Slug, Twist, and TGFβ are common indicators of
endothelial-to-mesenchymal transition [129]. In PAH, a reduction in BMP-
Receptor 2 signaling increases EnMT through slug [130]. Twist over-expression
occurs in the EnMT progression of PAH [131]. Another group has shown loss
of vWF with increased substrate stiffness [108], but they used a much higher
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(a) Laminar (b) Turbulent
(c)
Figure 3.5. CD117+ EC clones decrease tubulogenesis and increase EnMT tran-
scripts in response to turbulent flow. CD117+ subjected to normal flow conditions
for 48 hours were removed from the capillary for qPCR or replated on matrigel to
investigate angiogenic potential. a) Representative image of angiogenic potential
of ECs from laminar sections of the capillary tubes. b) Representative image of
angiogenic potential of ECs from turbulent sections of the capillary tubes. c) qPCR
results from cells exposed to shear stress demonstrat increased EnMT markers in
response to different flow styles. Scale bar = 200 μm, n=1, * p<0.05, ** p<0.01
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Figure 3.6. CD117+ EC clones demonstrate proliferation and morphological
changes in response to substrate stiffness. a) CD117+ EC clones demonstrated in-
creased proliferation in response to increased stiffness. CD117+ cells were exposed
to 1 or 20 kPa polyacrylamide gels coated with collagen for 48 hours. CCK8 ab-
sorbance was normalized to the average absorbance of 1 kPa wells. n=1, 2 replicate
wells b) Average cell surface area of cells plated on different substrate stiffnesses nor-
malized to 1 kPa. n=1, 2 replicate wells, 3 images from each well, **** p<0.0001
c) Representative image of cells plated on 1 kPa polacrylamide gels coated with col-
lagen. d) Representative image of cells plated on 2 kPa polacrylamide gels coated
with collagen. scale bar 100 μm
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(a)
(b)
Figure 3.7. CD117+ EC clonesincrease EnMT markers in response to substrate
stiffness changes. a) CD117+ EC clones demonstrate significant increases in Acta2,
Calponin-1, Integrin-β5, and Transgelin marker production, with increases in Col-
lagen type I and III markers produciton in response to increases substrate stiffness.
n=3 b) CD117+ EC clones demonstrate significant increases in Snail, Slug, TGFβ1,
and TGFβ2 and increases in fibronectin, Id1, and Twist1 marker production in re-
sponse to increases substrate stiffness. n=1, 2 replicates unless otherwise noted. *
p<0.05, ** p<0.01, *** p<0.001
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stiffness range (196-491 kPa) which is outside the physiological range of the
lungs. These results suggest that CD117+ EC clones are more susceptible
to stiffness activation compared to CD117 depleted cells. However it is still
unclear whether CD117+ EC clones can elicit phenotypic changes of CD117-
ECs, in response to mechanical changes. Broader implications of these results
indicates CD117+ EC clones to be a propagating factor in the progression in
PAH.
We hypothesize that CD117+ EC clones are less sensitive to the initial
hypoxia-induced apoptosis which occurs early on in PAH (collaborator data
not shown). Because they are have increased proliferative capacity, they hy-
perproliferate in response to the apoptosis of CD117- ECs. At the same time,
changes to the mechanical environment increase mechanotransduction through
endothelial cells increasing EnMT, reinforcing PAH propagation.
3.3.7 Characterizing the CD117+ EC clones response to mechani-
cal strain
CD117+ EC clones demonstrate increases in proliferation after 24 hours
of 15% strain (Figure 3.8). Increased cyclic stretch increases endothelial cell
proliferation [132] CD117+ cells increased expression of EnMT markers Col1a1
and Slug and decreased endothelial marker VCAM under conditions of static
or 15% stretch compared to 5% stretch conditions. Many other groups cite 5%
as physiological pulmonary stretch conditions, with higher leading to injury
and vascular remodeling [133, 134, 75, 132, 135]. Physiologic stretch levels
increases smooth muscle markers, such as α-SMA, while higher physiologic
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strain of 10% also decrease endothelial markers such as vWF [110]. Other
groups have similarily shown uniaxial cyclic strain (12%) increases Col1a1
production compared to static conditions in ligament cells [113]. Investigations
of cyclic stretch (10%) on BMP2 production demonstrate increased BMP2
production in stretch compared to static controls [95, 136]. Cyclic stretch
causes some of these similar phenotype changes in other cells, but few of
them have been investigated with endothelial cells. Cyclic stretch appears to
play a significant role in both the angiogenic potential and EnMT of CD117+
endothelial cells.
After stretching cells for 48 hours, cells were replated on matrigel to assay
for angiogenesis. Stretch (5% and 15%) both significantly increase angiogen-
esis (p<0.05) over static controls. Cells stretched with BMP2/4 neutralizing
antibody, display significantly decreased vessel length (p<0.01) compared to
stretch groups (Figure 3.10). This reinforces research that showing stretch
increases BMP2 production [137, 95, 136], and BMP2 is a pro-angiogenic cy-
tokine [118, 92, 91, 90], but also offers a specific cytokine and mechanical
mechanism involved angiogenesis of PAH. Combined with the phenotypic re-
sults, our data suggests cyclic stretch increases angiogenesis through BMP2
signaling.
3.4 Conclusion
We show here that CD117+ EC clones are important for barrier forma-
tion. We have also show CD117+ EC clones angiogenesis is at least partially
controlled by BMP2. These findings indicate CD117+ EC clones may have
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Figure 3.8. CD117+ EC clones increase proliferation in response to stretch,
measured through CCK8 colorimetric analysis. n=1, 2 replicates
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Figure 3.9. CD117+ EC clones phenotype changes due to mechanical strain.
Static conditions decreases angiogenic/endothelial markers BMP2, vWF, and
VCAM while increasing EnMT markers, Slug and Col1a1 compared to physiologi-
cal 5% stretch group. 15% stretch conditions increase pro-angiogenic BMP2, EnMT
Col1a1 and Slug expression over 5% stretch group. Stretch with BMP2 neutraliz-
ing antibody increased Acta expression while decreasing BMP2 and vWF expression
compared to 5% stretch group. n=2 for BMP2 neutralizing antibody (NAb) groups,
n=3 for all other groups. * p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001
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(a) (b)
(c) (d)
Figure 3.10. Stretch induced angiogenesis is inhibited with BMP2 NAb. CD117+
EC clones were exposed to stretch and BMP2 NAb for 48 hours, then plated on
matrigel for 24 hours. A) average vessel length results from images quantified with
AngioTool. B-D) Representative image of CD117+ EC clones forming vessels from
static, 5% stretch and 5% stretch with BMP2 NAb, respectively. n=3; * p<0.05 **
p<0.01. scale bar 100 μm
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a regulatory role in the heterogenous endothelial population. Therefore, har-
nessing the signaling of the CD117+ EC clones may provide a targetable cell,
which has been implicated in PH, to stop disease progression or be used to
enhance the angiogenic capabilities of endothelial cells for wound healing or
tissue engineering. We believe that mediating the managerial role of CD117+
EC clones will provide a better way to inhibit or enhance angiogenesis.
CD117+ EC clones respond better to mechanical stimuli compared to
the CD117- ECs population. We believe acute changes without positive feed-
back to the mechanical environment cause transient phenotypic changes, but
changes to the ECM are less transitive, more likely to lead to disease. The
increased sensitivity to the mechanical environment can increase paracrine
expression affecting CD117- cells. We hypothesize using antibodies to tar-
get cell-surface molecules CD117 and VE-Cadherin with a therapeutic BMP2
blockade would affect the entire EC population and may be a method to pre-
vent abnormal angiogenesis while keeping therapeutic dosages to a minimum.
Since many endothelial investigations use heterogenous populations of
ECs which are co-cultures of a variety of endothelial cells, therefore there is
no reason to explicitly co-culture CD117+and CD117- ECs. However, future
studies could slowly incorporate CD117+ cells to define an effective manage-
rial ratio of CD117+ EC clones to CD117- ECs, and investigate changes in
pathologies. Future work should also investigate the cytokine effects of the
mechanically-stimulated, CD117+ EC clones, conditioned media on CD117-
ECs to test the paracrine signaling abilities of CD117+ EC clones.
These findings contribute significantly to the pathogies of vascular disease,
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such as PAH. In PAH, a mutation to the BMP2-receptor frequently exists [138],
which suggests there may be an excess production of BMP2 for signaling. That
BMP2 is then free to to be a ligand to other receptors that may have delete-
rious effects, such as the TGFβ-receptor [139]. Up-regulation of BMP2 with
increased stretch may be therapeutic, promoting angiogenesis when the me-
chanical environment changes. However, when combined with BMP2-receptor
mutations, BMP2 may increase canonical TGFβ signaling pathways, leading
to EnMT and propagating disease. Other investigations should investigate the
effects of BMP2 when the BMP2-receptor is mutated, specifically co-localizing
BMP2 with other receptors to identify other signaling pathways.
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4.1 Rationale
Angiogenesis is new blood vessels forming from the pre-existing vascu-
lature and is a fundamental process in physiologic development and wound
healing. It is distinct from new de novo vessel formation, termed vasculogen-
esis, and arteriogenesis, which is modifying existing vasculature. It is further
divided into intussusceptive angiogenesis, where a new vessel separates from an
existing vessel, and sprouting angiogenesis, in which an endothelial cell pushes
out from an existing vessel. In pathologic contexts, angiogenesis contributes
to cancer metastasis and pulmonary hypertension [140, 141, 138].
Angiogenesis begins with increasing vascular permeability leading to base-
ment membrane degradation. Then an endothelial cell migrates and a sprout
forms. The migrating tip cell “pulls” on the stalk cells, promoting stalk cell
elongation and proliferation, which then “pushes” the tip cell forward [142].
These processes require Rho GTPase activity [143].
Rho GTPases are important signal transducers in signaling pathways that
regulate cell migration[144], proliferation [145, 146], survival, and death [147].
Additionally,Rho GTPases are important in barrier function and basement
membrane degradation.
Rho GTPase activity is both mediated by mechanotransduction and can
induce mechanical forces through actomyosin contraction. Inhibitors of the
Rho GTPase pathway inhibit cyclic stretch-induced angiogenesis [134]. Con-
stitutively active Rho GTPase, p31-activated kinase, increases cell contractil-
ity [148]. Coordinated Rho GTPase activity polymerizes actin, depolymerizes
actin, and causes cellular contraction, resulting in cell migration [149]. Angio-
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genesis is a more complicated process, synchronizing the Rho GTPase signal-
ing from mechanotransduction and chemokine cues to facilitate collective cell
migration toward a specific outcome of new vessel formation.
We have a established a minimal model of sprouting angiogenesis coupling
cellular mechanics and Rho GTPase activity. To form a functional vessel, the
sprout must remain attached to the wall of the parent vessel whilst trying
to migrate outward. We based this model off of our previous collective cell
migration model [150]. Our model predicts sprout elongation through cellular
mitosis and vessel stability occurs through Rho GTPase activity. Specifically,
vessel elongation is more stable when mitosis occurs concurrently with Rho
GTPase peak activation. Additionally, vessels are more stable when mitosis
occurs toward the tip cell stalk cells, with trail cell mitosis disrupting vessel
GTPase activity.
4.2 Method
Our previous work coupled mechanical tension, Rho GTPase activity, and
collective cell migration; we expand this model tether cells to a parental vessel
wall, to develop a lumen, and to use junctional forces to predict mitosis.
4.2.1 Single cell model
The first stage in angiogenesis is cell activation. Once a cell becomes ac-
tivated and breaks down the basement membrane, it migrates outward, with
forward movement restricted by cell-cell junctions between the tip cell and the
parent vessel wall cells. We used our previously established model of collective
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cell migration as the basis for our model [150], in which we modified a mini-
mal mechanotransduction-biochemical signaling model established by [151] as
a framework for our GTPase activity. Rho GTPase activity, coupled to cellular
mechanics, governs extension/ contraction of an individual cell (Figure 4.1a).
Cyclic mechanochemical feedback signaling lead to cellular extension and con-
traction. Low active Rho GTPase promotes cellular extension, increasing cel-
lular tension. Increasing cellular tension, drives GDP-GTP exchange on Rho
GTPases, increasing the active Rho GTPase concentration. High active Rho
GTPase levels cause cellular contraction through actomyosin cross-bridge cy-
cling, which decreases cellular length, reducing cellular tension and completing
the cycle. A positive feedback mechanism responsible for self-activation of Rho
GTPases also exists [152] and is incorporated into our model.
We modeled a single cell as a spring, grounded to the fixed substrate
though two viscous dashpots, governing the cellular mechanics (Figure 4.1b).
We then incorporated cell polarity through a tension-dependent viscosity term
which increases the tension while the cell is contracting allowing forward mo-
tion. In this model, extension-contraction cycles cause forward migration,
which cell-cell junctions restrict with cells of the vessel wall.
The base model is described and characterized in [150, 151], and therefore
briefly described here.
Cells have a Rho GTPase-dependent resting length L0(G), which drives
cellular contraction, defined by:
L0(G) = l0 − φ
Gp
Gph +G
p
(4.1)
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(c) Multicellullar mechanical model
Figure 4.1. Graphical depictions of the mechanochemical, individual cell, and
multicellular model. a) Schematic of the mechanochemical interactions governing
Rho GTPase activation and cellular contraction to cellular tension and Rho GTPase
inactivation. b) Individual cell model. The model governs governs the front (xf ;
Equation 4.6) and back (xb; Equation 4.7) of the cell. The cell, a Hookean spring
(spring constant, k), attaches to the substrate via two viscous dashpots, one at the
cell front (ηf ) and one at the cell back (ηb) and retains cell-cell junctions (kw) with
the parental vessel. c) Multicellular model of 2n − 1 cells, mechanically coupled
through cell-cell junctions, modeled as Hookean springs (kjunc), and maintaining
cell-cell attachments (kw) with the vessel wall. Only odd numbered cells have labels
for simplicity.
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where l0 is a fixed resting length, φ is the amplitude of the Hill function,
Gh is the normalized half-maximal GTPase activity, and p is a growth rate
constant. The difference between cell length, L, and L0 defines the cellular
tension, indicated by:
T = L− L0(G) (4.2)
which identifies that cellular tension depends on GTPase activity.
Zmurchok et al. normalized the initial GTPase activity, governed by the
following equation:
dG
dt
=
(
b+ f(T ; β) + γ
Gn
1 +Gn
)
(GT −G)−G (4.3)
where b is the basal GTPase activation, f(T, b) is the tension-dependent
feedback of the activation rate, γ is the positive feedback activation, G is
active GTPase, and GT is the total GTPase in the cell. Therefore, the first
term is activation of inactive GTPase (Ginactive = Gt − G), and the second
term represents GTPase inactivation.
The equation for the tension-dependent activation is:
f(T ; β) =
β
1 + e−αT
(4.4)
producing by a sigmoidal function as described in [150], with β defining the
feedback strength, and α acting as a decay constant.
The difference between the front node, xf , and the back node xb defines
cell length, L (Eq. 4.5).
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L = xf − xb (4.5)
The nodes are each governed by a force balance:
ηf (T ; δ)
dxf
dt
= −kT (4.6)
ηb
dxb
dt
= kT − kuwT uw − kdwT dw (4.7)
where k is the Hookean spring constant for the cell, ηf and ηb are the cell
front and back viscosities.
We previously established a front-back polarity [150], which the front
viscosity ηf = k
εf
, where εf is tension-dependent. εf depends on both cell
tension, T, and front-back asymmetry, δ, defined as:
εf (T ; δ) = εb(1− δ) + 2δε
b
1 + eαT
(4.8)
where δ is a measure of the polarity between the front and back nodes.
However, we keep back viscosity constant ηb = k
εb
, where εb is a normalized
extension/contraction rate. Therefore, at low tensions front viscosity is low,
allowing cellular protrusion. Conversely, with high tension front viscosity is
high, restricting the front node’s ability to move backward.
4.2.2 Equations of tethered cells forming a vessel
We extended the individual cell model to represent a 2-dimensional angio-
genic vessel, where y is explicitly unchanging, constraining vessel elongation
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to x-axis elongation (Figure 4.1c). Cells maintain individual Rho GTPase
activity and cellular mechanics, but we further constrained by incorporating
cell-cell junctions, modeled as Hookean springs. The vessel is symmetric after
the tip cell, resulting in an odd number of cells at all times. Each cell retains
individual Rho GTPase activity (Gi), front nodes (x
f
i ), and back nodes (x
b
i),
resulting in 3n variables, governed by
dGi
dt
=
(
b+ f(Ti; βi) + γ
Gni
1 +Gni
)
(GT −Gi)−Gi, for i = 1, ..., n (4.9)
dxf1
dt
=
−k
ηf1
T1cos(θ1) (4.10)
dxfi
dt
=
−k
ηfi
Ticos(θi) +
kjunc
ηfi
T ijunccos(θ
i
junc), fori = 2, ..., n (4.11)
dxbi
dt
=
k
ηbi
Ticos(θi)−
kjunc
ηbi
T ijunccos(θ
i
junc), for i = 1, ..., n− 1 (4.12)
dxbi
dt
=
k
ηbi
Ticos(θi)−
kjunc
ηbi
T ijunccos(θ
i
junc), for i = 1, ..., n− 1 (4.13)
4.2.3 Experimental parametrization
After initial simulations, we gathered experimental parameters from lit-
erature searches to translate the model (Table 5). One full GTPase cycle
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Table 4. Initial model parameters of individual and multi-cell angiogenesis
Parameter Symbol Value
Cell resting length l0 1
Protrusion/extension length φ 0.75
Growth Constant p 4
Half-maximal GTPase activity Gh 0.3
Basal GTPase activation rate b 0.1
Positive feedback activation γ 1.5
Growth Constant n 4
Total GTPase GT 2
Feedback Strength β 0.16
Decay constant α 10
Velocity gradient εb 0.1
Front-back asymmetry δ 0.9
Cell stiffness k 1
Junction Stiffness kjunc 10
Resting Junction Length Ljunc .1
Sprout Thickness llumen 1
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corresponds to 100 seconds, from experimentally demonstrated Rho GTPase
cycling [153]. During a GTPase cycle, the cell can move protrude outward or
contract, at a rate of 15 nm/sec [153], which modifies φ to be 1.5 μm. We
have selected 15 μm for l0 [154]. Cell-cell junctions connect the front node
of the back cell to the back node of the front cell and are represented as a
Hookean Spring with a length of 25 nm [155, 156], and a stiffness of 3.1 kPa
per μm of cell-cell contact [157], which we assume to be approximately 12% of
l0 (kjunc = 5.58), with doubled cell-cell contact area between the sprout and
the parental vessel (kw = 11.16).
4.2.4 Numerical methods
We used explicit Euler’s method to solve our system of ODEs. We specify
all initial model parameters in Table 4 for the base model and Table 5 for the
experimentally-based parameter set. Single cell models have initial conditions
of G(0) = 1, and we defined the nodes so that the initial cell length is 0.6.
Our initial conditions are displayed in Table 6. We used time steps of dt = 0.1
for the base model and dt = 1 for the experimentally-based parameter model.
4.2.5 Mitosis
Multi-cell models began with one cell and undergo mitosis at specified
intervals, and could occur in specified or random cells. After 10 mitotic events
(21 total cells), the Rho GTPase cycling continued but mitosis was inactivated.
For the base parameter set, we used 5000 time steps to force mitosis to occur
outside the GTPase cycle. We used Tmitosis = tperiod ∗200 (approximately 5000
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Table 5. Experimental parameters of multi-cell angiogenesis
Parameter Symbol Value Ref.
Cell size l0 15 μm [154]
Protrusion/extension length φ 1.8 μm [153]
Growth Constant p 4
Half-maximal GTPase activity Gh 0.3
Basal GTPase activation rate b 0.1
Positive feedback activation γ 1.5
Growth Constant n 4
Total GTPase GT 2
Feedback Strength (tip cell) β 0.16
Feedback Strength (stalk cell) β 0.1
Decay constant α 10
Velocity gradient εb 0.1
Front-back asymmetry δ 0.9
Cell stiffness k 1 kPa [158]
Junction Stiffness kjunc 5.58 kPa [157]
Resting Junction Length Ljunc 0.025 μm [155, 156]
Sprout Thickness llumen
1
4 l0
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time steps) to force mitosis to occur near the peak of the GTPase cycle. For
the experimentally-based parameter set, we used the equation
Tmitosis =
tperiod ∗ 60 ∗ 60 ∗ 24
100 ∗ dt
(4.14)
to force mitosis to occur every 24 hours.
Table 6. Initial conditions for computational model
Parameter Base model Experimentally
parametrized model
Initial cell
length
0.6 9
Initial active
GTPase
1 1
Initial junction
length
0.1 0.025
4.3 Results and Discussion
4.3.1 Mitosis location affects length, tension, and GTPase frequency
We first adapted the model to restrict a “migrating” cell’s movement
(Figure 4.3). After expanding the model to multiple cells, including “mitotic”
events, we investigated the effect mitosis has on vessel length, cellular tension,
and GTPase activity. We incorporated mitosis in any cell in the vessel as there
is supporting evidence for both tip cell and stalk cell mitosis [159, 160]. We
also excluded the effects of individual cell elongation because proliferation rate
has a greater effect on vessel length than migration [160].
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Figure 4.2.
Video of single cell model. The wall junction length is set so
that forward migration can be visualized, yet restricted by the
wall.
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Initially, we wanted to confirm GTPase activity as a significant contribu-
tor to our model of angiogenesis. As mitosis occurs, there is near instantaneous
elongation of the vessel, with the majority projecting forward, but some pro-
jecting backwards into the parent vessel wall. This supports the push-pull
mechanism proposed by [65]. We believe that including a barrier that de-
grades over time would further force the vessel to elongate into the parent
vessel. We randomized the mitosis timing to be out of sync with the GTPase
activity, and interestingly, both mitosis conditions, in-sync and out-of-sync
with GTPase cycling, have similar maximal tensions. The vessel recovered
from out-of-sync GTPase signaling most of the time, but there were numerous
occasions where mitosis would further disrupt the GTPase cycle, and cause
cellular tension behave abnormally (Figure 4.4). These GTPase disruptions
cause the trailing cells to remain protruding into the wall (Figure 4.5), rather
than migrating out, which could be a source of turbulence, and disease pro-
gression. Rho GTPases are known to be key regulators of angiogenesis [143],
so disrupting the GTPase cycling should play a significant role in disrupting
angiogenic stability. However, this model offers the ability to investigate these
changes, which is not currently possible in vitro.
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Figure 4.3.
Video of multi-cellular model with randomized mitosis. The
wall junction length is set so that forward migration can be
visualized.
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(a) (b)
Figure 4.4. Average cellular tension after the final mitotic event has large distri-
bution. a) Average cell tension of cells if mitosis is not synced near GTPase peak.
b) Average cell tension of cells if mitosis is synced to GTPase peak.
We forced mitosis to only occur in the tip cell, the middle cell, or the end
cells (Figure 4.7). Cellular length was maximal with lead cell mitosis (8.0353),
then end cell mitosis (8.01), with middle cell mitosis resulting in the shortest
vessel (7.6428). Vessel length did not correlate to cellular tension, supporting
previous findings that migration is a minor determinant of vessel length [160].
Average tension in the lead cell, after the final mitotic event, was maximal
for the tip cell mitotic model (0.006046), followed by the trailing cell model
(0.00581), and middle cell mitosis (0.003065). Average tension in the end cell,
after the final mitotic event, was maximal for the trailing cell mitotic model
(0.04368), followed by the tip cell model (0.02758), and middle cell mitosis
(0.02116). Interestingly, there are two distinct groupings of cellular tension
when the mitosis is randomized (Figure 4.4b), the upper group, dominated by
end cell mitosis or end cell mitosis, and the lower group, dominated by lead
or middle cell mitosis.
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Figure 4.5. GTPase activity could become unstable. If cells do not undergo
mitosis near the peak of the GTPase cycle, instability can arise and compound.
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(a) Tip cell mitosis only
(b) Middle cell mitosis only
(c) End cell mitosis only
Figure 4.6. Mitosis of cells affects the GTPase activity of the entire vessel in
the base model. Time trace of distance with magnification of activity after last
mitotic event. a) Mitosis of only the tip cell results in GTPase activity becoming
sporadic with increasing mitotic events. b) mitosis of center cell only retains GTPase
frequency to a point (approx 5.75 days) then decreasing in frequency but increasing
in amplitude. c) Mitosis of only cell attached to wall retains GTPase periodicity,
but gains an additional harmonic.
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(a) Lead cell mitosis (b) Middle cell mitosis (c) End cell mitosis
Figure 4.7. Mitosis affects average tension after division events. After 11 mitotic
events, we averaged the tension for each cell. In all isolated cases the cell with the
lowest tension was the lead (Tip) cell and tension increased in a nearly linear fashion
toward the wall. The lowest overall tension, for all cells, occurred when the middle
(Stalk) cells underwent mitosis.
Table 7. Controlling which cell underwent mitosis had dramatic changes to the
cellular tension and vessel length.
Simulation Cell Parameter Value (a.u.)
Lead cell Mitosis Lead T 0.006046
End T 0.02758
- Length 8.0353
Middle cell Mitosis Lead T (average) 0.003065
End T (average) 0.02116
- Length (max) 7.6428
End cell Mitosis Lead T (average) 0.00581
End T (average) 0.04368
- Length (max) 8.01
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4.3.2 Experimentally parametrised model results
We altered the parameters of the initial model to translate some effects
witnessed. The biggest change to the model was to the junctional length. We
initially set the junctional length to be 10% of cell resting length, when in
experimentally junctional length is approximately 0.17%. Again, we forced
mitosis to only occur in the tip cell, the middle cell, or the end cells (Fig-
ure 4.8), with values in Table 8. Decreasing the junctional length, stiffened
the entire system considerable, making the differences in length and tension
less apparent. Cellular length was maximal in the case of lead cell mitosis
(156.7903 μm), then end cell mitosis (156.7136 μm), with middle cell mitosis
resulting in the shortest vessel (156.6945 μm). Average tension in the lead
cell, after the final mitotic event, was maximal for the end cell mitotic model
(0.0.0327 μm), followed by the lead cell model (0.0321 μm), and middle cell
mitosis (0.0268 μm). Average tension in the end cell, after the final mitotic
event, was maximal for the end cell mitotic model (0.1764 μm), followed by
the tip cell model (0.1400 μm), and middle cell mitosis (0.1191). Similar to the
base model, graphing the average cell tension shows two distinct populations,
one with higher tension from predominantly trail cell mitosis and the other
with lower tension from middle or tip cell mitosis (Figure 4.9). Interestingly,
most trailing cell tensions from random mitosis are below the tension for any
rigidly defined case, suggesting preferred mitosis locations to minimize average
cellular tension.
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(a) Tip cell mitosis only
(b) Middle cell mitosis only
(c) End cell mitosis only
Figure 4.8. Mitosis of cells affects the GTPase activity of the entire vessel in the
experimentally parametrised model. Time trace of distance with magnification of
activity after last mitotic event. a) Mitosis of only the lead cell. GTPase activity
appear consistent after final mitotic event but the cycling period increases. b)
mitosis of middle cell only. GTPase activity appears to become bimodal, with small
peaks occurring just before larger peaks. c) Mitosis of only cell attached to wall
retains GTPase periodicity, but becomes sporadic at times.
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Table 8. Controlling which cell underwent mitosis, in the experimentally
parametrised model, had dramatic changes to the cellular tension and vessel length.
Simulation Cell Parameter Value (μm)
Lead cell Mitosis Lead T 0.0321
End T 0.1400
- Length 156.7903
Middle cell Mitosis Lead T (average) 0.0268
End T (average) 0.1191
- Length (max) 156.6945
End cell Mitosis Lead T (average) 0.0327
End T (average) 0.1764
- Length (max) 156.7136
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Figure 4.9. Average cellular tension after the final mitotic event has large distri-
bution. a) Average cell tension of cells if mitosis is not synced near GTPase peak.
b) Average cell tension of cells if mitosis is synced to GTPase peak.
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4.4 Conclusions
We have established a minimal model of angiogenesis based on Rho GT-
Pase mechanics. The model expands the number of cells by a forces mitosis
event and continues elongating with mitosis. This model predicts cellular
dysfunction if mitosis, also dependent on Rho GTPases, becomes out-of-sync
which GTPase cycles. It further predicts that lead and stalk cell mitosis re-
tain Rho GTPase periodicity, while trailing cell mitosis, increases tension, and
introduces a secondary harmonic into GTPase cycling. This model affords
discrete control over, otherwise uncontrollable, cellular parameters.
This model has many limitations. We only account for Rho GTPase sig-
naling in the model, and while Rho GTPases are significant to angiogenesis,
there are other non-Rho pathways (such as PI3K or Src), that are also impor-
tant in angiogenesis. Expanding the model to include those interactions would
produce a more complete picture, but would complicate the model consider-
ably, as would individually modeling the major components individually. We
do not account for cellular elongation, beyond a resting length, but elongation
plays a role in vessel length, so including an elongation term may improve the
model. All of these limitations provide opportunities to enhance the model.
The model could be expanded to confirm the other outcomes in these
investigations. Incorporating paracrine effects would allow us to establish a tip
cell using paracrine signaling to coordinate Rho GTPase activity of the sprout.
Further expanding that model to include multiple receptors with different
outcomes (BMPR2, TGFBR3) would allow investigators to inactivate some to
see critical concentrations of ligands (BMP2) to activate alternative pathways.
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Incorporating a layer of ECM and adding terms for different adhesion strengths
to various ECM components would provide an alternative method for GTPase
activity to become dysregulated.
We believe this model has many translatable outcomes. We know that
Rho GTPases play a huge role in angiogenesis, but this model indicates that
not only must they be present, but synced to other physiological progesses
for homeostasis to continue. We hypothesize that Rho GTPase activation,
migration, and mitosis must be synced for angiogenesis to occur. We expect
that dysregulated Rho GTPase activity puts increased stress on endothelial
cells, increasing the likelihood that an individual cell, or cluster of cells, will
undergo EnMT. Future experiments could test this hypothesis by modifying
Rho GTPases—to increase their half-lives—and investigating sprouting angio-
genesis assays with them.
We hypothesize that mitosis is dependent on tension. The current model
specifies a time for mitosis to occur. There are two clearly distinct patterns of
cellular tension from our model, which we could elucidate preferential mitosis
locations/conditions using FRET-based tension sensors. Because there is a
correlation between cellular tension, Rho GTPases, and mitosis in the model,
investigating the effect of force on mitosis of angiogenic cells may provide the
ability to predict which cells will undergo mitosis.
We conclude this minimal model of angiogenesis identifies Rho GTPase cy-
cling as an important indicator of vessel stability. We believe post-translational
modifications (e.g., nitration, glycation, or methylation) lead to changes in
the half-life of the GTPases, changing the amplitude, frequency, and stabil-
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ity of GTPase cycles. These post-translational modifications lead to vascular
dysfunction, therefore we believe this model provides an in silico method to
investigate vascular disease.
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5.1 Rationale
Extracellular matrix (ECM) is all the macromolecules present outside of
the cell. These molecules can be lipids, proteins, glycoproteins, and polysac-
charides. Together they form a landscaping network for cells to survive in
and on. The landscapes can be nearly flat, seen in basement membranes,
or complex three-dimensional meshes. A lot of work goes into maintaining
and regulating the ECM, and the ECM influences all aspects of cell biology
[161]. The ECM provides structural support for cells, allowing cells to attach,
preventing cell movement, or providing a track to promote migration (Fig-
ure 5.1). But the ECM is also a primary source of signal initiation; ECM can
bind and release growth factors, transmit mechanical signaling forces through
integrins, or begin signaling pathways using fragments of broken down ECM.
It can also act to increase signaling by acting as a co-receptor to better present
signaling molecules. We hypothesize ECM from diseased lungs can change cell
phenotype, independent of organization and substrate stiffness.
Many factors contribute to the progressive nature of PAH including in-
creased ECM deposition, apoptosis, proliferation, and cellular contraction.
Macromolecules, like fibronectin, collagen, tenascin-c, and sphingosine-1 phos-
phate generally increase in PAH [162, 163]. The sphingosine-1 phosphate
pathway has become a novel target for treating PAH [164], due to their ability
to upregulate collagen, through TGFβ signaling [165], and fibronectin, through
Rho signaling [166]. Hypoxia and sphingosine-1 phosphate mediate HIF1α sig-
naling [167], and TGFβ signaling [163].
One of the major contributors to PAH progression is hypoxia. Hypoxia
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Figure 5.1. Mechanisms of ECM function. The versatile functions of the ECM de-
pend on its diverse physical, biochemical, and biomechanical properties. Anchorage
to the basement membrane is essential for various biological processes, including
asymmetric cell division in stem cell biology and maintenance of tissue polarity
(stage 1). Depending on contexts, the ECM may serve to block or facilitate cell mi-
gration (stages 2 and 3). In addition, by binding to growth factor signaling molecules
and preventing their otherwise free diffusion, the ECM acts as a sink for these sig-
nals and helps shape a concentration gradient (stage 4). Certain ECM components,
including heparan sulfate proteoglycans and the hyaluronic acid receptor CD44, can
selectively bind to different growth factors and function as a signal coreceptor (stage
5) or a presenter (stage 6) and help determine the direction of cell–cell communica-
tion. The ECM also direct signals to the cell by using its endogenous growth factor
domains (not depicted) or functional fragment derivatives after being processed by
proteases such as MMPs (stage 7). Finally, cells directly sense the biomechanical
properties of the ECM, including its stiffness, and change a wide variety of behaviors
accordingly (stage 8). Reproduced from [161].
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increases hypoxia-inducible factor 1α, which causes vascular remodeling, with
partial HIF1α+/− knockouts attenuating disease[168, 169]. Due to chronic
hypoxia and vascular remodeling, PAH becomes fibrosis-like with general in-
creases in ECM deposition of major ECM components such as collagen, laminin,
fibronectin, and tenascin C. In PAH the changes in ECM lead to changes in
the structural micro-niches. A lot of work has investigated the role of ECM
on disease progression [26, 170, 171, 60, 67, 68]. Many diseases come with a
characteristic change to the mechanical properties: increased stiffness in fibro-
sis and PAH, decreased stiffness in emphysema, making tissue slices or ex vivo
recellularization strategies dual-variable experiments.
Elucidating the composition-induced effect is more challenging, yet crit-
ically important. To date, no one knows if there is a critical ratio of ECM
protein that is capable of inducing disease, regardless of the surrounding cir-
cumstances. However, we culture cells on isolated proteins all the time and
hope to recapitulate disease, or certain aspects of disease. Incorporating more
aspects of aspects of a disease into in vitro investigations will produce more
translatable results. We hypothesize that incorporating diseased ECM com-
position into mechanical experiments better reproduces the cellular pheno-
type of disease. We begin to unravel that mystery here by describing gross,
non-pathway, changes in cell morphology and phenotype in response to ECM
composition, independent of stiffness.
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5.2 Method
5.2.1 Decellularizing Lung Tissue
We decellularized lung tissue based on the same procedure described in
[172] (a graphical depiction using porcine lungs is shown in Figure Figure 5.2),
with some minor changes. We obtained healthy and sugen hypoxia (Su/CHx)
lung lobes from rats (courtesy of the Farkas Lab). Sugen was administered by
a single subcutaneous injection of 20 mg·kg−1 SU5416 at day 0 and exposure
to chronic hypoxia for up to 4 weeks, followed by normoxia for 2 weeks [25]. We
carefully minced the tissue into small pieces to maximize the surface area for
decellularization while minimizing the diffusion distance. We rinsed the tissue
three times with PBS between each step. We submerged the lung tissue in 0.1%
Triton X-100 solution for 24 hr at 4 °C, followed by 2%sodium deoxycholate for
24 hr at 4°C. We drew the sodium dexoycholate out of the tissue by submerging
the tissue in filtered NaCl solution for 1 hr at 4 °C. We removed the NaCl from
the tissue with three rinses of UPW. Then to remove the DNA, we submerged
the tissue in filtered DNase solution for 1 hr at 4 °C, followed by three rinses
with 1x PBS.
After decellularization, we lyophilized and cryomilled the tissue, to form
a powder. We acid digested 10 mg of the powder in 1 mL of 0.01 M HCl with 1
mg of pepsin, under constant agitation, at room temperature for 4 hours. We
neutralized the acid with 0.1 M NaOH at a 1:10 ratio, and stored the solution
at -80 °C.
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Figure 5.2. Representative overview of decellularization protocol using porcine
lungs. This is a graphical representation of the method to produce protein solution
from lungs. Beginning with en bloc pig lung decellularization occurs leaving only
opaque white or translucent tissue that is comprised of ECM proteins. Then after
removing any remaining water, and increasing the surface area to optimize acid
digestion the tissue is solubilized. Neutralization of the acid and increasing the salt
to physiological levels creates the pregel solution. Reproduced from [172]
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5.2.2 Quantifying dsDNA as a measure of decellularization effi-
ciency
To measure decellularization efficiency, we used PicoGreen to measure
Double-stranded DNA (dsDNA), based on [173]. We added intact or decel-
lularized lung tissue to 1 mL papain digest solution (125 μg/ml papain, 242
μg/ml L-Cysteine, 0.333 M EDTA in PBS). The tissue was homogenized three
times, for 30 seconds each time, in a BeadBug tissue homogenizer. After
homogenization, we measured the protein concentration using a microplate
reader (BioTek, Take3 Micro-Volume Plate). The samples digested overnight
at 65 °C. The following day, we vortexed the samples and digested again at
65 °C for 30 more minutes, and then diluted the protein solution 10 times in
TE buffer. We then added 100 μlof the protein solution to a black, 96-well
microplate. We diluted the PicoGreen reagent 1:200 in TE buffer and added
100 μlto each well. The samples incubated for 2 minutes at room temperature
and we read the 480/520 fluorescence of each well.
5.2.3 Protein differences in Diseased ECM
After decellularization, before lyophilization, we took intact and decellu-
larized tissues for quantitative mass spectrometry. We placed approximately
10 mg of tissue with PBS into a BeadBug tissue homogenizer. The tissue
was homogenized three times for 30 seconds each time, vortexing in between
homogenization. We then gave the tissue to the VCU mass spectrometry core
for protein determination and quantification.
86
5.2.4 Sphingolipid differences in Diseased ECM
After decellularization, before lyophilization, we took intact and decellu-
larized tissues for quantitative mass spectrometry. We placed approximately
10 mg of snap frozen tissue into a cryogrinder. We then gave the tissue to the
VCU Lipidomics core for lipid determination and quantification.
5.2.5 Cell culture and ECM stiffness experiments
Cell culture of CD117+ EC clones is as previously described in Section
3.2.2. Healthy and diseased ECM covalently bonded to 1 kPa and 20 kPa PAGs
(Matrigen) overnight. We used 1 kPa to mimic normal lung tissue and 20 kPa
to mimic severely stiff arteries [98], and combined them with healthy and
diseased ECM to better isolate the role of stiffness and composition in disease
progression. This established two expected environments 1 kPa +healthy ECM
and 20 kPa +Su/CHx ECM, and two unusual environments 1 kPa +Su/CHx
ECM and 20 kPa +healthy ECM. We added 20,000 cells /cm2 to the PAGs
and allowed them to attach for 24 hours.
5.2.6 Phenotype shifts measured through qPCR mRNA quantifi-
cation
qPCR was run as described in Section 3.2.4, with the additional primers
in Table 12
5.2.7 Statistics
We used the methods described in subsection 3.2.6 for statistical analysis.
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Table 9. Table of primers used to measure phenotype shifts through qRT-PCR
Gene Forward Sequence Reverse Sequence Product ID
Col3a1 TTTCAAGATCAACAC
TGAGG
TATTCTCCGCTCTTG
AGTTC
R Col3a1 1
Fn1 AAGCCAATAGCTGAG
AAA
AAGTACAGTCCACCA
TCATC
R FN1 1
HIF1α GAAAGGATTACTGAG
TTGATGG
CAGACATATCCACCT
CTTTTTG
R HIF1a 1
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5.3 Results and Discussion
5.3.1 Quantifying dsDNA as a measure of decellularization effi-
ciency
Decellularization of tissues was successful at removing>95% of dsDNA/mg
protein. The current gold standard for decellularization is <50 ng/mg dry
weight. Because our sample size was small, we used wet weight, commonly
reported with equivalent decellularization occurring with >95% reduction in
dsDNA [174, 175]. We expect, due to the gentle nature of chunk decellulariza-
tion, our ECM contains a better representation of the compositional changes
compared to pressure/perfusion decellularization techniques.
5.3.2 Compositional Differences in Diseased ECM
Many proteins and lipids differences found through mass spectrometry of
PAH lungs were also present in our Su/CHx tissue (Table 10). In similar fold
changes to our results, Myosin light chain, Myosin-6, Laminin Beta-2, Syne-
min, Fibrinogen α, Calveolin, Histone-1 have been shown upregulated in PAH
as well [176, 177]. Additionally, we found changes in Ribosomal protein 30,
desmyokin, keratin 78, β-actin, hemoglobina2, histone H3, unknown RGD pro-
tein, and endonuclease 1. Chunk decellularization efficacy depends on deter-
gent contact time and piece size, to increase decellularization efficiency, smaller
pieces and longer periods in contact with detergents may improve decellular-
ization. Due to the gentle nature of chunk decellularization, relying on diffu-
sion to achieve decellularization, we expect we retain a good approximation of
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Figure 5.3. Chunk decellularization reduces dsDNA by 95%. Intact and decellu-
larized lung tissue were homogenized and papain digested to release dsDNA. Using
the original protein concentration, we determined the concentration of dsDNA per
mg protein.
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the ECM composition after decellularization. Many of the proteins, Riboso-
mal protein-30, Myosin light chain, Desmoyokin, keratin-78, myosin-6, β-actin,
hemoglobin-a2, synemin, histone-H3, Caveolin, Histone-1, and endonuclease-1
are all found within cells. These intracellular proteins could act as damage-
associated molecular patterns (DAMPs), eliciting an immunogenic response,
causing the cellular phenotype shifts we see (Section 5.3.4.2). We expect a
general increase in DMAPs in decellularized tissue; however, decellularized
tissues are used clinically for tissue repair.
Extracellular proteins found in significantly different quantities in the de-
cellularized tissues include Fibrinogen α, unknown RGD protein, and Laminin-
β2. Fibrinogen concentration is both associated with PAH and linked to disease
severity [178]. Fibrinogen can decrease barrier integrity [179] The unknown
RGD protein appears to have come from a coiled-coil protein. There are two
significant proteins found in the ECM Laminin and Tenascin-c [180]. Tenascin-
C increases are correlated with PAH, so it is not likely that this RGD protein
is part of Tenascin-C; however, the increased proteolytic activity decreases
and fragments laminin [181]. Laminins changes occur in vascular remodeling,
so having decreased laminin RGD motif, may indicate vascular instability. In
our decellularized tissue we may have two laminin components, unknown RGD
from a coiled-coil motif was down-regulated, while Laminin -β2 was increased.
Laminin -β2 increases occur the microvessels in tumors [182], which may be
more indicative of unstable vessels, similar to those seen in the plexiform le-
sions.
Lipid analysis of intact healthy and Su/CHx tissues shows increased sph-
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Table 10. Significant protein differences between decellularized healthy and
Su/CHx lung tissues. Fold change is Su/CHx over healthy. See Appendix B for com-
plete protein differences. p-values * p<0.05, ** p<0.01, ***p<0.001, **** p<0.0001;
n=1
Protein Accession Fold change p-value Ref
Ribosomal protein 30 RL30 7.19 **
Myosin Light chain D3ZHA7 4.69 ** [176]
Desmoyokin Q38PF8 3.48 **
Keratin 78 A0A0G2K4H7 3.15 **
Myosin-6 G3V885 3.04 ** [176]
Laminin beta-2 M0R6K0 2.38 * [176]
Beta-actin A0A068F1Y2 1.96 **
Hemoglobin-a2 A0A0G2JSV6 1.81 *
Synemin G3V9G5 1.5 * [176]
Fibrinogen alpha Q7TQ70 1.4 * [177]
Histone H3 D3ZJ08 0.63 *
Caveolin B1WBN8 0.57 * [176]
Histone-1 H2A1E 0.46 * [176]
RGD Protein A0A0G2JXY0 0.4 **
Endonuclease 1 EEPD1 0.12 ***
92
Table 11. Significant protein differences between intact and decellularized
Su/CHx lung tissues. Fold change is decellularized over intact. See Appendix B
for complete protein differences. p-values * p<0.05, ** p<0.01, ***p<0.001, ****
p<0.0001; n=1
Protein Accession Fold change p-value
Unknown Protein M0R5B3 424.28 ***
Nucleosome binding protein HMGN5 29.37 **
Myosin-4 MYH4 12.76 **
Actin-2 ACTG 6.34 *
F-Box protein FBX30 5.47 **
Myosin-6 G3V885 5.17 **
Protein Alex ALEX 3.27 *
Myosin-10 MYH10 3.19 *
Keratin-78 A0A0G2K4H7 2.93 **
Hemoglobin-a2 A0A0G2JSV6 2.66 *
Laminin C F1MAA7 2.60 *
Protein RGD D3ZKN0 0.47 **
Myosin heavy chain Q9R0H4 0.36 *
Beta-actin A0A068F1Y2 0.30 ***
Histone H2 H2A1E 0.02 ***
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ingosine, dihydrosphingosine, sphingosine-1 phosphate (S1P), and dihydro-
sphingosine -1 phosphate (dHS1p), with minimal changes to other lipids (Fig-
ure 5.4). S1P is upregulated in PAH [183]. Dihydrosphingosine -1 phosphate
opposes sphingosine-1 phosphate in PAH; dHS1P prevents S1P-induced TGFβ-
like fibrosis [163]. We received similar trends in decellularized matrices, but
the only significance difference is in dHS1P, which may explain the lack of
differences we see in phenotype shifts.
(a) Decellularized (b) Intact
Figure 5.4. Lipid differences between healthy and diseased lungs. Subspecies of
sphingomyelins, ceramides, and monohexosylceramides have been normalized indi-
vidually and then combined together. a) Lipid differences after decellularization. b)
Lipid differences between intact healthy and intact Su/CHx lungs. n=3, not age or
gender matched. *p<0.05, ***p<0.001
5.3.3 Protein solution as an in vitro coating
These are the first experiments investigating ECM composition indepen-
dent of stiffness and structure. We first wanted to make sure that inherent
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differences between collagen, healthy ECM, and Su/CHx ECM did not have
baseline differences in coating. We added ECM to non-tissue treated plates
overnight, rinsed twice with PBS, and then performed a BCA analysis on the
adsorbed protein. Because we were measuring protein adsorbed to the well,
minute changes in volume or concentration probably cause the large variance
seen. But there was no significant difference between collagen, healthy ECM,
and Su/CHx ECM coatings. We used a concentration of 0.05 mg/ml for coat-
ing because it was shown to be the optimal concentration for cell attachment
and proliferation [184]. Coating TCP and PAGs with 0.05 mg/ml protein
produced similar coating efficacy compared to collagen on the same surface.
(a) (b)
Figure 5.5. Characterization of ECM coating. a) Adsorption of heterogenous
ECM protein is similar to collagen coating on TCP. ECM coating measured through
BCA. n=3 b) Adsorption of heterogenous ECM protein is similar to collagen coating
on PAGs. ECM coating measured through BCA. n=3
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5.3.4 CD117+ EC clones response to diseased ECM
5.3.4.1 Cell attachment and proliferation on different ECMs
Cell proliferation on different ECMs does not have an effect on CD117+
EC clones proliferation. After ensuring that we did not have dsDNA differ-
ences to cause immunogenic response to CD117+ EC clones, we measured cell
proliferation. On TCP, cell proliferation was not significantly different between
ECM groups. Similarly, on different stiffness, increases stiffness produced a
slight increase in proliferation, but there were no differences between different
ECMs, though a slight decrease in proliferation occured on Su/CHx ECM.
(a) (b)
Figure 5.6. Characterization of ECM coating on PAG. a) Su/CHx ECM does
not affect CD117+ EC clones proliferation. CD117+ EC clones plated on collagen,
healthy matrix, and Su/CHx matrix have similar proliferation after 24 hours. n=3 b)
Su/CHx ECM does not affect CD117+ EC clones proliferation on PAGs. CD117+
EC clones plated on collagen, healthy matrix, and Su/CHx matrix have similar
proliferation on different stiffnesses after 24 hours. n=1, 2 replicates
Cellular morphology (Figure 5.7) and phenotype (Figure 5.8) changes in
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response to with diseased ECM. ECM from Su/CHx tissue causes cell clus-
tering, indicative of EnMT [185] and vessel instability [186]. These effects
may be transitive, because most vessels need support cells for stability [187,
188]. However, CD117+ EC clones form vasculature from a single cell that is
functional [22].
5.3.4.2 PH ECM alters CD117+ EC clones phenotype
ECM from Su/CHx lung tissue changes CD117+ EC clones phenotype,
primarily on normal substrate stiffnesses. BMP2, Col1a1, ITGB5, Col3a1 and
Vcam1 mRNAs increased after 48 hours on 1 kPa Su/CHx ECM. Many of
these lose significance after 96 hours on stiffness, which we believe is due to
the absence of positive feedback for PAH (i.e. the absence of diseased cells or
the diseased cytokines are used up), and the transient condition halts.
Pro-angiogenic mRNAs BMP2, Vcam1, and VWF changed expression
in response to Su/CHx ECM. BMP2 increases on softer substrates[189], but
increases more on Su/CHx ECM, suggesting a role for BMP2 in PAH pro-
gression. We expect signaling in early onset PAH (softer substrates) is pro-
angiogenic, thus the increases in BMP2 and Vcam1. Decreases in VWF indi-
cate at least some of these cells lose the endothelial marker, possibly undergo-
ing EnMT.
Col1a1 and Col3a1 increases initially on softer substrates with Su/CHx
ECM and paradoxically decreases on 20 kPa Su/CHx substrates. We expect
that signaling from the Su/CHx matrix indicates to cells that the substrate
must be stiffer, increasing collagen production. However, on stiffer substrates,
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1 kPa Healthy
1 kPa Sugen
20 kPa Healthy
20 kPa Sugen
24 hrs 72 hrs
Figure 5.7. Diseased ECM changes cell morphology. Cells were plated on hy-
drogels from healthy and diseased ECM. After 24 hours in all conditions tubule
exist. After 72 hours, tubules are still present on 1 kPa healthy, whereas clustering,
indicative of EnMT exists on 1 kPa Sugen. 20 kPa with both ECMs have increased
proliferation though it appears there may be some tubulogenesis in the 20 kPa Sugen
group. scale bar 100 μm
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there is already signaling confirming the stiffness and with increased colla-
gen content in the Su/CHx ECM, therefore the 20 kPa Su/CHx ECM group
downregulates production of collagen.
Interestingly, integrin β5 is known to bind to fibronectin, so the absence
of fibronectin mRNA production suggests an increased presence of fibronectin
in the Su/CHx ECM groups, yet the stiffness affords more focal adhesions to
be formed, requiring more integrin β5.
5.4 Conclusions
These results suggest that ECM changes initially may propagate PAH,
if not prevented by another physiological process. We believe that mRNA
changes on soft substrates with Su/CHx ECM initiate signalling process of
what is expected to be there—i.e., Su/CHx ECM should be stiffer with in-
creased angiogenesis attempting to repair the disease—therefore those are the
proteins being produced. We hypothesize that cells from diseased tissues would
provide alternative, longer-lasting effects, but these CD117+ EC clones are
from healthy tissues, and, in the absence of further insult (i.e. hypoxia, in-
flammation, etc.), may be capable of repairing much of the pathology caused
by the Su/CHx ECM.
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Figure 5.8. Su/CHxECM modifies CD117+ EC clones phenotype. CD117+
EC clones were added to ECM coated PAGs for the indicated times. a) Col1a1—
Collagen type I α1; b) BMP2—Bone Morphogenic Protein-2; c) Fn1—Fibronectin 1;
d) VWF—von Willebrand Factor; e) Itgb5—Integrin β5; f) VCAM1—Vascular cell
adhesion molecule-1; g) Col3a1—Collagen type III α1. Changes are normalized to
1 kPa healthy for each gene. n=2, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001,
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6.1 Rationale
The current obstacle limiting lung tissue engineering is reestablishing the
air-blood barrier. Currently, bioengineered lungs only remain patent for 3
days [55]. The investigators seeded HUVECs through both the right ventricle
and left atrium in attempt to recellularize the entire pulmonary circuit of the
lung circulatory system. Other studies demonstrate worse outcomes [3, 190].
Much of the work done uses homologous populations of microvascular cells or
induced pleuripotent stem cells.
A variety of recellularization techniques are currently used in tissue en-
gineering, however many of them only focus on one aspect of the lungs and
consequently only investigate one mechanical environment. Epithelial recellu-
larization commonly only look at ventilatory tidal volume [191, 192]. While
endothelial recellularization techniques commonly use flow [56, 193, 194]. Yet,
to be functional lungs, recellularized scaffolds must have a complete functional
barrier, capable of withstanding shear stress, and stretch due to ventilation.
We hypothesize that reseeding lungs with the highly proliferative CD117+
endothelial cells, are better attuned to complete recellularization of tissue en-
gineered scaffolds. These endothelial cells clonally expand [195], and CD117
deficient mice demonstrated impaired vessel formation [196]. We have shown
their enhanced signaling in response to mechanical changes (subsection 3.3.5,
subsection 3.3.6,subsection 3.3.7), enhanced barrier formation (subsection 3.3.2)
and they are expected to have increased proliferative capacity [21].
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6.2 Methods
6.2.1 Decellularizing Lung Tissue
We decellularized lung tissue based on the same procedure described in
[172]. A detailed protocol is written in Appendix A.3. We obtained healthy
lungs from Long-Evans rats. We cannulated the trachea, the left atrium and
the right ventricle for perfusion. We perfused the three cannulas with 0.1%
Triton X-100 solution for 24 hr at 4 °C, followed by 2%sodium deoxycholate for
24 hr at 4°C. We drew the sodium dexoycholate out of the tissue by submerging
the tissue in filtered NaCl solution for 1 hr at 4 °C. We removed the NaCl from
the tissue with three rinses of UPW. Then to remove the DNA, we submerged
the tissue in filtered DNase solution for 1 hr at 4 °C, followed by three rinses
with 1x PBS. The lungs were stored in PBS with 5% anti-anti.
6.2.2 Tissue Engineering with CD117+ cells
We added 25 million CD117+ ECs to each cannula of the pulmonary cir-
culation circuit, 50 million total cells for each set of lungs, and allowed them
to attach for 24 hours. Over the first four hours, we placed the lungs hori-
zontally and rotated 90°every hour. After the first four hours, we suspended
the lungs in a bioreactor for the remaining 20 hours. After 24 hours, we per-
fused the lungs with media through the pulmonary circuit at 4 ml/min using a
peristaltic pump, while a syringe pump pumped air 10 times per minute. We
investigated two different volumes, 3 ml, the average tidal volume for a normal
rat, or 10 ml, the approximate total lung capacity for an average rat. We ran
103
a resazurin cell proliferation assay on 3 days and 7 days, after cell seeding, by
adding 50 uM resazurin (Sigma 7017) to media and injecting it into the can-
nulas. Resazurin fluorescence (560 ex/590 em) determined cell proliferation,
as measured on a plate reader.
On day 7 we also ran a dextran permeability assay to measure barrier
function. We injected 70 kDa (final concentration 1 mg/ml) and 4 kDa dextran
(final concentration 2 mg/ml) in PBS to the vascular cannulas and removed
fluid that leaked out of the lungs at 5 and 10 minutes to measure barrier
function. We quantified dextran fluorescence (488 ex/525 em and 595 ex/615
em) quantify the amount of dextran that leaked out.
6.2.3 Statistics
We used the methods described in subsection 3.2.6 for statistical analysis.
6.3 Results and Discussion
6.3.1 Tissue Engineering with CD117+ cells
At both 3 and 7 days, the lungs receiving different tidal volumes of air
displayed similar cell proliferation, measured by resazurin fluorescence (Fig-
ure 6.1). Visually, these recellularization attempts appear to be below com-
monly imaged recellularized lungs, but other groups present approximately
2000 RFU after 24 hours [194], similar to our results after 3 days. Addition-
ally, they provide a growth curve for calculating the number of cells, they
increased cell numbers by 25-50% after 7 days. We need to do a growth curve
to directly compare our results, but based on their growth curve a 6-fold change
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in RFU, corresponds to an 8-fold change in cell numbers [194]. Using their
formula, scaffolds seeded with CD117+ EC clones increase cell numbers ap-
proximately 10-fold in both tidal volumes, with 10 ml tidal volumes increasing
slightly more. Dextran permeability demonstrates improved dextran retention
in the 10 ml tidal volume group with approximately 60% of dextran being re-
tained in the vasculature after 5 minutes (Figure 6.1). Other groups performed
dextran experiments differently [56]; they instilled fractions through the pul-
monary artery, and subsequently removed from the left ventricle. They show
fluorescencein ≈ fluorescenceout, but we show what actually leaks out from
the vasculature into the trachea or the surrounding media. However, visually
their representative images look as though they have vasculature [56].
6.4 Conclusion
Animals have a tightly controlled range of homeostatic conditions, blood
pressure too high can cause atherosclerotic plaque formation. One concern
that we believe exists in tissue engineering is whether engineered lungs need to
be conditioned to the mechanical environment. For rats, the cardiac output is
approximately 25 ml/min/100 g body weight [197]. The lungs must be capable
of receiving all of that volume, and therefore familiar with the associated shear
stress. Many groups use lower shear stresses of 1- 4 ml/min [56, 193], although
shear stresses two-fold higher are safe for cell viability [194], but no one has
looked upwards of those rates.
A wide range of tidal volumes are currently being used for lung recellular-
ization protocols. Rat tidal volumes are approximately 1 ml, but range from
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(a) (b) (c)
(d) (e) (f)
Figure 6.1. CD117+ cells proliferate on decellularized lungs and initiate barrier
formation. Physiological tidal volume 3 ml was compared to total lung capacity 10
ml ventilation volume A) Resazurin cell proliferation assay demonstrating increased
proliferation after 7 days of ex vivo culture. B) 3 ml tidal volume resazurin assay,
pink indicates viable cells. C) 10 ml tidal volume resazurin assay. D) Dextran
permeability assay shows increased retention of dextran in 10 ml ventilation group.
E) 3 ml tidal volume dextran permeability assay, purple shows regions retaining
dextran. C) 10 ml tidal volume dextran permeability assay. n=1, three replicates
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0.2 to 0.5 ml/100 g body weight [198, 199], which reaches maximal volumes
around 2 ml. Rats on ventilators experience protective ventilation with tidal
volumes of 0.3-0.9 ml/100 g [200, 201], reaching maximal volumes around 4
ml, after which cell injury begins [202]. Rat lungs used for tissue engineer-
ing received tidal volumes of 0.03 ml/100 g [191] up to 10 ml / lung [192].
We hypothesize that tissue engineered lungs will only be successful after the
establishment of a completely intact air-blood barrier which also sustains phys-
iological mechanical forces.
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7.1 Rationale
Pathologies, such as PAH or COPD, have characteristic changes to the
ECM. Up to 90% of chronic obstructive pulmonary disease (COPD) occurs
with Group III pulmonary hypertension [203, 204]. A lot of work has inves-
tigated the role of the ECM on disease progression, in fibrosis, the monocro-
taline model of pulmonary hypertension, and emphysema [26, 171, 60, 67, 68].
COPD has generalized decrease in elastin, and small proteoglycans, with col-
lagen changes being controversial [205]. However, the remodeled ECM fibers
are visibly disorganized [206].
Fibroblasts are the primary cell responsible for maintaining the ECM.
Additionally, fibroblasts are essential for successful angiogenesis [187]. Fibro-
blasts have abnormal repair abilities and altered phenotypes in COPD [207].
In COPD, we expect changes in α-smooth muscle actin (acta2, increased),
advanced glycation end product-associated proteins (RAGE) ligands (e.g.,
S100b, HMGB1, increased), proliferation (e.g., Ki67, decreased), and senes-
cence marker (e.g., Cdkn1, Cdkn2, increased) production [208, 209, 210, 211,
212]. Even though α-smooth muscle actin is expected to increase, fibroblasts
from COPD contract 3D hydrogels less than non-COPD fibroblasts [213].
COPD changes the mechanical environment of the lungs. Shear stress
from cyclic stretch is increased overall due to alveolar wall destruction which
redistributes septal stretch [206, 214]. Substrate stiffness becomes more het-
erogeneous than before; enzymatic degradation and remodeling of the ECM
is thought to decrease local substrate stiffness [206], but smooth muscle cells
become chronically activated, increasing the substrate stiffness [205].
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Using polyacrylamide hydrogel systems with tunable substrate stiffness
are well established; however, they fail to reconstruct all the properties of
diseased ECM [215]. In COPD, there is a great deal of ECM remodeling—
the ECM becomes degraded and disorganized [206]—but it is unknown if the
composition, degradation, or disorganization plays a significant role in bio-
chemical signal transduction. We hypothesize that ECM from COPD lungs
can propagate diseased cellular phenotypes, independent of organization and
the mechanical environment.
7.2 Method
7.2.1 Decellularizing Lung Tissue
We received decellularized human lung tissue from COPD and non-COPD
lungs as a powder from a collaborator. We acid digested 10 mg of the powder
in 1 mL of 0.01 M HCl with 1 mg of pepsin, under constant agitation, at room
temperature for 4 hours. We neutralized the acid with 0.1 M NaOH at a 1:10
ratio, and stored the solution at -80 °C.
7.2.2 Cell culture and ECM stiffness experiments
We cultured Normal Human Lung Fibroblasts (NHLF) in DMEM + 15%
FBS + 1% Anti-Anti. COPD and non-COPD ECM adsorbed to 1 kPa and 20
kPa PAGs or bioflex stretch plates for 1 hour. We used 1 kPa to mimic normal
lung tissue and 20 kPa to mimic severely stiff arteries [98], and combined
them with healthy and diseased ECM to better isolate the role of stiffness
and composition in disease progression. This established two physiological
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environments 1 kPa + non-COPD and 20 kPa + COPD ECM, and two non-
physiological environments 1 kPa + COPD and 20 kPa + non-COPD ECM.
We added 20,000 cells /cm2 to the PAGs and allowed them to attach for 24
hours. After 24 hours, we changed the media and cultured the fibroblasts for
48 hours.
7.2.3 Fibroblast stretch
We coated BioFlex plates with 0.05 mg/ml non-COPD or COPD ECM
for 1 hour at room temperature. We then rinsed the wells with PBS and added
20,000 cells/cm2. Cells attached for 24 hours and then we changed the media
and the cells were cultured for 24 additional hours under 15% equibiaxial
strain.
7.2.4 Phenotype shifts measured through qPCR mRNA quantifi-
cation
qPCR was run as described in Section 3.2.4, with the additional primers
in Table 12
7.2.5 Immunofluorescence staining
Cells were fixed using 4% paraformaldehyde for 30 minutes. The paraformalde-
hyde was removed and rinsed twice with PBS. We removed the PBS and per-
meabilized the cells with 0.05% Triton-x 100 in PBS for 2 minutes. After
permeablization, we blocked the cells with 0.1% BSA in PBS for 5 minutes.
We coated the coverslips with primary antibody solution (diluted in 0.1% BSA
according to the manufacturers guidelines) for 30 minutes at 37·C. We returned
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Table 12. Table of primers used to measure phenotype shifts through qRT-PCR
Gene Forward Sequence Reverse Sequence
Acta2 CCGACCGAATGCA
GAAGGA
ACAGAGTATTTGCGCT
CCGAA
Cdkn2a TGTCCGTCAGAACC
CATGC
AAAGTCGAAGTTCCAT
CGCTC
Ciz1 ACATCGCCAAGGAAA
AACGC
GTCTGTTTCGGTACTGT
CATCC
Cdkn1a GTGTATAGGGTCGGCC
ATCAA
CCTGCCGTTGTTACCT
GAGAG
Col1a1 GTGCGATGACGTGATC
TGTGA
CGGTGGTTTCTTGG
TCGGT
Ki67 TGACCCTGATGAGAAAG
CTCAA
CCCTGAGCAACACTGT
CTTTT
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the cells to 0.1% BSA for five more minutes and then added secondary anti-
body and phalloidin (diluted in 0.1% BSA according to the manufacturers
guidelines) for 30 minutes at 37·C. Once more, we returned the cells to 0.1%
BSA for five minutes. We added DAPI Prolong gold to mount the cells to a
glass slide. The mounting media dried for at least 1 hour at room temperature
before images were taken.
7.2.6 Statistics
We used the methods described in subsection 3.2.6 for statistical analysis.
7.3 Results and Discussion
7.3.1 NHLF response to COPD ECM
We investigated the effects of a different, though not entirely separate,
ECM and cell type. In up to 90% of COPD cases, pulmonary hypertension
exists concurrently, and is the most common cause of pulmonary hypertension
[203, 204]. COPD is not commonly associated with increased ECM stiffness,
yet COPD is commonly associated with chronic activation of smooth muscle
cells, which increase the stiffness of focal regions [205]. Stiffness in combination
with ECM has changes in Acta2, Col1a1, HIF1α, and Hmgb1 that are con-
sistent across stiffnesses (Figure 7.1). Gene sequences on Ki67, Cdkn2a and
S100b had changes irrespective of stiffness. There are many ways to iinterpret
how COPD propagates into PH using this data.
We believe that Antigen-Ki67 (Ki67) indicates the state of prolifera-
tion of pulmonary hypertension, early-stage pulmonary hypertension has cell-
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Figure 7.1. COPD ECM modifies NHLF phenotype. a) NHLFs phenotype
changes in response to COPD ECM and stiffness. Acta2—α-smooth muscle actin;
Col1a1—Collagen type I α1; Hif1a1—Hypoxia inducible factor-1; HMGB1—High
mobility group box 1; Ki67—Antigen KI-67; P16—cyclin-dependent kinase inhibitor
2A; S100b—calcium-binding protein B. n=3, *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001,
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apoptosis, which increases later as the disease progresses, through other mecha-
nisms. Cyclin-dependent kinase inhibitor 2 (Cdkn2a) is a marker of senescence
whose protein, P16, prevents cellular mitosis in a variety of circumstances; the
decrease seen with increased stiffness provides an alternative mechanism by
which cellular proliferation occurs. Intracellularly, calcium-binding protein B
(S100b) increases cell proliferation, migration, and hypertrophy [216]. Like-
wise, S100b is a ligand for receptor for RAGE [216]. Hmgb1, similar to S100b,
implicated in pulmonary hypertension [217], and leads to the vascular remod-
eling seen in pulmonary hypertension [218].
Increases in HIF1α, High mobility group box 1 (Hmgb1), and Acta2 exist
in response to COPD matrix, while decreases exist in Col1a1. Hif1α is im-
plicated in cell survival, angiogenesis, and ECM production. Upregulation of
Hif1αmay be a source of the vascular remodeling phenotype seen in pulmonary
hypertension [219], and we show that ECM composition regulates transcrip-
tion. ECM appears to play a role in Acta2, Col1a1, Hif1α, and HMGB1
production, while substrate stiffness in combination with ECM composition
plays a role in Ki67, P16, and S100b production, which brought us to question
how stretch in combination with ECM can change phenotype.
ECM combined with with increased cyclic mechanical stretch increase
cyclin-dependent kinase inhibitor 1 (Cdkn1a) , Cip1-interacting zinc finger
protein (Ciz1), and Cdkn2a, while Col1a1 decreased and Acta2 increased para-
doxically (Figure 7.2). Bronchioalveolar wall collapse causes air to be retained
in the alveoli. Attempting to force this air out causes dynamic hyperinflation,
which leads to increased cell stretch and inflammation [214]. The only trend
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that seems consistent in response to ECM across stretch is Col1a1, which de-
creases in response to ECM. While these changes are unique and consistent
between stretch and stiffness, they are controversial in COPD [205].
Figure 7.2. COPD ECM modifies NHLF phenotype. NHLFs phenotype
changes in response to COPD ECM and 15% cyclic stretch. Acta2—α-smooth mus-
cle actin; CipV1— cyclin-dependent kinase inhibitor 1; Col1a1—Collagen type I
α1; P16—cyclin-dependent kinase inhibitor 2A. *p<0.05, **p<0.01, ***p<0.001,
****p<0.0001,
Stretch decreases Acta2 expression in fibroblasts [220], but expression
increases in the bronchi of COPD patients [210]. These changes are likely due
to increased TGFβ production in response to inflammatory cytokines [221].
Cellular senescence increases in COPD [211], and in stretch [222]. How-
ever, our results do not indicate that cyclic stretch increases cellular senescence
markers on its own, only in conjunction with COPD ECM. Stretch combined
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with COPD ECM increase Ckdn1a, Cdkn2a, and Ciz1. Cdkn1a and Cdkn2a,
translated to P16 and P21, regulate cellular proliferation by inhibiting cyclins,
allowing cells to senescence. Ciz1 binds to P21 and translocates it from the
nucleus to the cytoplasm, allowing cellular proliferation [223]. This provides
an additional mechanism by which cellular proliferation may progress beyond
Ki67. Taken together, these results provide evidence that ECM composition
plays a role in disease progression.
7.4 Conclusions
This study is the first investigation to illustrate the role of COPD ECM
composition in propagating diseased cellular phenotype. While ECM and the
mechanical environment are coupled physiologically, the ECM in COPD de-
grades and becomes disorganized [206]. This study took non-COPD matrix
and COPD matrix, degraded them equally and disorganized them equally to
determine the effect of composition. We took those investigations further to
isolate the role of the composition independent of the mechanical environ-
ment. We hypothesize that minor changes to the ECM are less transient than
inflammatory cytokines and may therefore be more responsible for continuous
disease progression.
We propose a mechanism in which the extracellular matrix found in
COPD propagates pulmonary hypertension (Figure 7.3). Through various
mechanisms, primarily inflammation and proteolysis, DAMPs become part of
the ECM. These DAMPs include AGEs, HMGB1, S100b, and ECM protein
fragments activate Toll-like receptors (TLR) 2/3/4 and RAGE, which produce
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a positive feedback mechanism of increasing AGEs and crosslink ECM.
Hmgb1 up-regulates in response to mechanical stretch [224] and function
in many intracellular and extracellular roles. Extracellularly, AGEs crosslink
the vascular matrix, stiffening the ECM of arteries in hypertension [225]. AGEs
also function as ligands for RAGE and TLR to increase AGE production, which
completing the positive feedback mechanism of AGE production. Intracellular
and extracellular AGEs can induce angiogenesis through activation of Hif1a
[226].
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Figure 7.3. Proposed mechanism of COPD ECM inducing pulmonary hyper-
tension. Advanced glycation endproducts (AGEs) are capable of crosslinking ECM
proteins, stiffening the matrix. AGEs, HMGB1, S100b, and fragmented proteins
from the ECM, activate receptor for advanced glycation endproducts (RAGE) and
Toll-like receptors (TLR). TLRs and RAGE increase inflammatory cytokine produc-
tion, which increases AGE, HMGB1, and S100b production. The AGEs produced
can be secreted to crosslink ECM or activate RAGE or TLRs. Alternatively, in-
tracellular HMGB1 and S100b increase proliferation by inhibiting P16 and P21.
Various mechanisms can induce angiogenesis through Hif1a pathways.
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CHAPTER 8
CONCLUSIONS AND FUTURE DIRECTIONS
We provide micro-environmental mechanisms to explain how CD117+ EC
clones contribute to the propagation of PAH. We first show CD117+ EC
clones respond to mechanical cues, whereas CD117 depleted ECs do not. We
take those results one step further to predict angiogenesis based on cellular
mechanobiological cues. We continue by showing that PAH ECM can elicit
phenotypic changes, independent of other mechanical cues. We initiated inves-
tigations to look at the role of COPD ECM on fibroblasts, and to investigate
the use of CD117+ EC clones in tissue engineering applications.
The endothelium is a heterogenous group of cells, of which, we show
CD117+ EC clones, rather than CD117 depleted ECs, are a major responder
to mechanical perturbations. We have shown that CD117- ECs respond min-
imally to changes in the mechanical environment. Additionally, CD117+ EC
clones form a better barrier compared to CD117- ECs. The results of these
investigations indicates CD117+ EC clones may have a managerial role in the
endothelium.
PAH results in changes to the mechanical environment such as disturb-
ing blood flow, increasing substrate stiffness, and increasing stretch. Flow,
altered by the constriction of arterioles, modifies the angiogenic potential and
phenotype of CD117+ EC clones. Turbulence is a form of disturbed fluid
flow, which increases EnMT markers and decreases angiogenic potential of
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CD117+ EC clones. While disturbed flow is associated with increased EnMT
markers, it also increases angiogenesis, but our results suggest that disturbed
flow-induced angiogenesis does not occurs through CD117+ EC clones. These
results may seem controversial at first, but we believe these results indicate a
role for CD117+ EC clones in PAH. In PAH, plexiform lesions arise from a
single endothelial cell, proximal to vessel constriction.
Constriction of arterioles, hypertrophy and hyperplasia of contractile cells,
and increased ECM deposition associated with PAH lead to regions of in-
creased stiffness. Increased substrate stiffness enhances expression of EnMT
markers by CD117+ EC clones, which further suggests a role for these CD117+
EC clones in the pathophysiological manifestation of PAH. Similarly, changes
to the % stretch experienced by CD117+ EC clones increases EnMT markers
while partially decreasing angiogenic markers. We expect a range of stretch
to induce angiogenesis under normal conditions, but stretch increased beyond
physiological conditions to become pathogenic long term. We took these re-
sults further to suggest a mechanism for stretch-induced angiogenesis, through
BMP2. We show that CD117+ EC clones exposed to BMP2 increases angio-
genic potential, while BMP2 neutralizing antibody, given during stretch, de-
creases angiogenesis of CD117+ EC clones. We believe these results can have
a translational impact on lung tissue engineering.
We wanted to tie in intracellular mechanisms to mechanically-activated
angiogenesis, so we modified a model of mechanically-activated GTPase sig-
naling to form a computational model of angiogenesis. The computational
model of angiogenesis we created suggests vessel stability depends on which
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cells predominantly undergo mitosis. Interestingly, we found that increased
cellular tension occurs when the lead cells undergo mitosis more often, and
cellular tension is increased in the cells closer to the parental wall. However,
in this case, GTPase cycling became erratic, indicating an instability of the
vessel. We initially thought there would be a threshold tension, which would
allow cells to undergo angiogenesis, but now believe that it is a band of tension
which allows cells to undergo mitosis. Cellular tension that is too low corre-
sponds to low relative levels of activated GTPase; if mitosis occurs outside the
peak of GTPase activation our model suggests instability occurs. Similarly,
increased cellular tension probably requires additional intracellular resources
devoted to maintaining cellular integrity, making it unlikely that these cells
would undergo mitosis.
There is a link between the extracellular matrix composition, the mechan-
ical environment, and cellular phenotype. Many investigations have looked at
the role of the mechanical environment alone or the combined role of ECM and
the mechanical environment, but we are the first to investigate the role of the
ECM independent of the mechanical environment. Our results indicate a ECM
composition plays a role in controlling some phenotypic changes independent
of substrate stiffness. We removed many confounding factors (DNA, protein
adhesion, and proliferation) as contributors, all of which could be attributed
to the resulting phenotypic changes seen in response to Su/CHx protein. We
identified compositional changes between lung tissue types through protein and
lipid mass spec to elucidate the macromolecules contributing to the phenotypic
shifts. The Su/CHx ECM composition seems to play an important role in a
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disease-like phenotype of CD117+ EC clones on softer matrices. We believe
this indicates ECM composition plays a role early in disease progression, and
could lead to clinical tests capable of determining pathogenesis before symp-
tomatic progression. We took those results one step further, to investigate the
potential for diseased ECM to induce pathogenesis of a separate, but often
correlated disease. Using lung fibroblasts and COPD-derived ECM, we show
phenotypic changes and propose a mechanism by which COPD can progress
into pulmonary hypertension.
This project has raised more questions than it has answered.
Do CD117+ ECs act in a managerial role? Follow-on experiments should
attempt to identify a ratio of CD117+ ECs to in healthy versus disease states.
These experiments may provide a therapeutic “dosage” of CD117+ EC clones for
use as a cell therapy.
By what mechanism is BMP2-induced angiogenesis controlled, canoni-
cal or non-canonical signaling? Future experiments, could focus on inhibiting
various aspects of the different signaling cascades to try to identify an intracel-
lular signaling mechanism behind these our results. These works may provide
novel ways to inhibit pathogenic angiogenesis, as in cancer or PAH, or enhance
angiogenesis in wound healing or tissue engineering.
Is it the signaling pathway different under different mechanical stim-
uli? Investigating the pathways associated with different mechanical stimuli,
stretch, stiffness, and flow, can be done through similar experiments to those
previously described.
Does cellular or junctional tension play a role in mitosis? FRET-based
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tension sensors, incorporated into endothelial cells, can be used to investigate
the role of junctional tension on mitosis. Alternatively, Live Cell AFM can be
used to investigate the role of cellular tension on mitosis.
There is clearly a link between ECM composition and disease progres-
sion, but is it based on one, targetable component or does it require a pro-
portion of signaling from a specific set of macromolecules? There are many
macromolecules that exist in different concentrations in pathological condi-
tions, but future investigations could look at the most likely contributors and
add them to healthy culture conditions to identify targetable molecules. Iden-
tifying ECM components that cause cells to become phenotypically disease-like
has the potential to identify early onset markers of disease, or to develop novel
therapeutics to treat disease.
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Appendix A
PROTOCOLS
A.1 Materials
A.1.1 Consumables
• polyester sheets (Serva, Gel-Fix for PAG; 42999.01)
• Dichlorodimethylsilane (DCDMS; Sigma, 440272)
• Acrylamide (40%; Sigma, A4058)
• Bis-acrylamide (2%; Thermo Fisher Scientific, BP1404)
• Tetramethylethylenediamine (TEMED; Bio-Rad, 161-0300)
• Ammonium Persulfate (APS; Bio-Rad, 161-0700)
• N-Hydroxysuccinimide (NHS; Sigma, 130672)
• Dimethylsulfoxide
• Anti-Anti (Antibiotic-Antimycotic; Thermo FIsher Scientific, 15240062)
• Endothelial Growth Medium for Microvascular vessels-2 (EGM-MV2;
PromoCell, C-22121)
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• sulfosuccinimidyl 6-(4’-azido-2’-nitrophenylamino)hexanoate (Sulfo-SANPAH;
Sigma, 803332)
• Rat tail collagen, type I (RTC; Corning, 354236)
• Softwell EasyCoat polyacrylamide coated plates (Matrigen, SW6-EC)
• 0.25% trypsin/EDTA (Thermo FIsher Scientific, 25200056)
• Triton X-100 (Fisher Scientific, BP151-100)
• Sodium Deoxycholate (Sigma-Aldrich, D6750-100g)
• Magnesium Sulfate (Sigma-Aldrich, M7506-500g)
• Calcium Chloride (Sigma-Aldrich, C1016-500g)
• DNase (Sigma-Aldrich, D5025-150KU)
• HCl (Sigma-Aldrich, 258148-500ML)
• Pepsin (Sigma-Aldrich, P6887-5G)
• Sodium Hydroxide (Fisher Scientific, BP359-500)
• PBS 10x (Quality Biological, 119-069-151)
• PBS (VWR, 45000-448)
• Filter Paper (Whatman, 8519)
• BD 10ml syringes
• KiCqStart Primers
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• RNeasy RNA isolation Kit (Qiagen 74106)
• iScript cDNA Synthesis Kit (Bio-Rad, 1708891)
• Pierce BCA Protein Assay (Thermo Fisher, 23227)
A.1.2 Non-consumables
• BioTek Epoch Plate Reader
• BioTek Take3 Micro-Volume Plate
• Cellmax Quad System
• Hand pump (Fisher Scientific, 10-239-1)
• Graduate Beaker (VitLab 445941)
• Cryomill (SPEX , 6700)
• Lyophilizer (FTS FlexiDry)
• Rheometer (Discovery, HR-2)
• Olympus ZX10 microscope
• BioTek CFX Connect qPCR reader
• GenieTouchTM Syringe Pump (Kent Scientific)
• Smart2Pure UV/UF Water Purifier (Barnstead)
• Centrifuge 5810 R (Eppendorf)
• ECIS ΖΘ (Applied BioPhysics)
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A.2 Polyacrylamide gel formation
Polyacrylamide gels (PAG) of stiffnesses approximately 20 kPa and 1 kPa
were used for stiffness experiments. PAGs were made based on [101, 227], as
outlined here. We punched out polyester sheets to fit in a 6-well plate (32 mm
diameter). The sheets were washed with ethanol and left to dry.
A glass sheet (12” x 18”) was rinsed with ethanol and coated with Dichlorodimethyl-
silane (DCDMS), and used a microscope slide to spread the DCDMS evenly
over the surface. The DCDMS evaporated in a fume hood and then we rinsed
the glass with UltraPure water (UPW) and allowed it to air dry.
We combined acrylamide (40%), bis-acrylamide (2%) and UPW in the
quantities outlined in Table 13. Once the polyester sheets and glass were dry,
we quickly added Tetramethylethylenediamine (TEMED), Ammonium Persul-
fate (APS; 10% in UPW), and N-Hydroxysuccinimide (NHS; 8% in DMSO)
to the acrylamide solution in the quantities describe in Table 13. We vortexed
the solution briefly to mix thoroughly before pipetting 110 μl of the solution
onto the DCDMS coated glass. We then quickly covered the acrylamide so-
lution with the polyester sheet and allowed to gel for 60 minutes. The PAGs
were stored in 2% Antibiotic-Antimycotic (Anti-Anti) in PBS. 20 kPa stiffness
gels were confirmed through atomic force microscopy, using an NT-MDT tip
with a spring constant of 0.5 N/m.
To covalently bond ECM proteins to the PAGs we added sulfosuccinimidyl
6-(4’-azido-2’-nitrophenylamino)hexanoate (Sulfo-SANPAH) to the formed PAGs.
To make Sulfo-SANPAH stock concentration, we added 500 μl DMSO to 50
mg Sulfo-SANPAH. We then made a 0.5 mM solution of Sulfo-SANPAH in
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Table 13. Reagents for making polyacrylamide gels
1 kPa 20 kPa
40% Acrylamide 18.75 μl 50 μl
2% Bis-acrylamide 12.5 μl 33 μl
UPW (Ultrapure water) 218.75 μl 167 μl
TEMED (Tetramethylethylenediamine) 1.5 μl 1.5 μl
APS (Ammonium Persulfate; 8% in DMSO) 2.5 μl 2.5 μl
NHS (N-Hydroxysuccinamide; 10% in UPW) 3.75 μl 3.75 μl
HEPES Buffer by adding 600 ml HEPES (1M) to 11.37 ml UPW and 30
μl stock Sulfo-SANPAH. We removed the Anti-Anti, and added the working
Sulfo-SANPAH to the PAGs. To activate the Sulfo-SANPAH, we exposed the
PAGs to UV light (365 nm bulb, 2.5 inches away) for 30 minutes. We then
rinsed the surface three times with 50 mM HEPES. We added rat tail collagen
(RTC; 5 μg/cm2; 0.05 mg/ml) to 50 mM HEPES and covered the PAGs with
the ECM solution. The plates were left overnight in a refrigerator. The plates
were rinsed again three times with 50 mM HEPES before cells were added.
A.3 Decellularization of lung tissue
From [172]
1. Obtain, an en bloc normal porcine lung, from a slaughterhouse, with
heart and vasculature intact.
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2. Use tissue scissors or a scalpel to dissect away the heart, cutting vas-
culature as close as possible to the heart, remaining vasculature will be
used in later steps for perfusion.
3. Carefully dissect away the connective tissue surrounding the trachea,
bronchi, and vasculature using a scalpel or scissors.
NOTE: Determine the best lung to use for the rest of the procedure by
choosing a lung without large cuts or punctures through the pleura and
large amounts of atelectasis or vascular occlusion that may impede the
effectiveness of the decellularization process.
4. Cut away the suboptimal lung leaving as much bronchus attached to the
trachea as possible (heart, connective tissue and the lobes of the removed
lung may be disposed of). There should be one lung remaining attached
to the trachea and vasculature.
NOTE: Retain sections for histology if desired.
5. Close disconnected bronchi with clamps or suture to prevent excess back-
flow.
6. Prepare the decellularization solutions and refrigerate at 4 °C until needed
(Table 14).
7. Using a hand pump cannulated to fit the pulmonary artery, perfuse the
lung tissue 3 times with DI water through both pulmonary artery and
trachea. Perfuse vasculature first each time. Begin with around 1 L into
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vasculature and 1.5 L into trachea for each perfusion, but as cellular
debris is removed more liquid can be perfused through the system.
8. Perfuse both vasculature and trachea with Triton X-100 solution.
9. Submerge lung tissue in Triton X-100 solution for 24 hr at 4 °C.
10. Perfuse vasculature and trachea 3 times with DI water to rinse.
11. Perfuse both vasculature and trachea with deoxycholate solution.
12. Submerge the tissue sections in deoxycholate for 24 hr at 4°C.
13. Perfuse vasculature and trachea 3 times with DI water to rinse.
14. Perfuse both vasculature and trachea with NaCl solution.
15. Submerge tissue in filtered NaCl solution for 1 hr at 4 °C.
16. Perfuse vasculature and trachea 3 times with DI water to rinse.
17. Perfuse both vasculature and trachea with DNase solution.
18. Submerge tissue in filtered DNase solution for 1 hr at 4 °C.
19. Perfuse both vasculature and trachea 5 times with PBS.
20. Dissect away noticeable cartilaginous tissue, trachea and all tubules 2
mm or larger in diameter (primarily found around the hilum and medial
portions of the lungs) from conducting airways, leaving only respiratory
zones (primarily the peripheral areas).
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21. Dissect tissue into 1 inch sections or smaller. Orientation of the tissue
does not matter for this step.
22. Pour off excess liquid and place tissue in 50 ml conical tubes. Freeze the
tissue at -80 °C.
NOTE: Retain sections for histology to ensure removal of cells and cellu-
lar debris, if desired. We use H&E, α-galactosidase, picogreen, 9 hydrox-
yproline, ninhydrin, alcian blue, SDS-PAGE, and mass spectrometry to
characterize.
A.3.1 Decellularized Lung Processing
1. Remove lids from frozen tubes containing decellularized lung tissue.
2. Place filter paper over the tube opening and secure with rubber band.
NOTE: Tube and contents should still be frozen otherwise place in -80
°C until frozen.
3. Lyophilize the tissue until all excess liquid is gone, using a freeze dryer
according to manufacturer directions. Store at -80 °C until ready to mill.
4. Before beginning add liquid nitrogen to freezer mill to cool insulation
and internal components to working conditions.
5. Remove magnetic mill bar from mill tube and add tissue to cover bottom.
6. Replace mill bar and add loosely packed tissue. The mill bar should still
move freely.
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Table 14. Solutions Required for Tissue Decellularization. Make the solutions
above for the decellularization process. Store at 4 °C. Approximately 2.5 L will be
needed for one porcine lung.
Solution Sterile Filter Directions
DiH2O Yes DiH2O; Sterile Filter .
0.1% Triton X-100 Solution Yes Under fume hood add 100 μl Triton-X 100 Solution to 100
ml DiH2O and agitate until dissolved; sterile filter.
2% Deoxycholate Solution Yes Under fume hood add 2 g Sodium Deoxycholate solution
per 100 ml DiH2O and agitate until dissolved; sterile filter.
1 M NaCl Yes Add 58.44 g NaCl to 1 L of DiH2O; agitate until dissolved;
sterile filter.
DNase solution Yes Add 12,000 units DNase to 1 L DiH2O; Add 0.156 g MgSO4
(Anhydrous), and 0.222 g CaCl2 ; agitate until dissolved;
sterile filter.
PBS Yes Combine 27.2 g Na2HPO4· 7H2O (dibasic heptahydrate),
80 g NaCl, and 2 g KCl with 10 L DiH2O; agitate until
dissolved; adjust pH to 7.4; sterile filter.
7. Close the mill tube and place in freezer mill.
8. Fill liquid nitrogen to max fill line.
9. Freezer mill all tissue into fine powder (approximately 5 min, impaction
rate of 600 min−1 ), in a polycarbonate cylinder with a stainless steel im-
pactor as well as stainless steel end plugs using the freezer mill according
to manufacturer directions. Store at -80 °C until ready for use.
From [172].
A.4 Quantitative, real-time polymerase chain reaction
To perform two-step Quantitative, Reverse Transcription Polymerase Chain
Reaction (qRT-PCR) , we used manufacturer methods for Ribonucleic acid
(RNA) isolation and Complementary Deoxyribonucleic Acid (DNA) conver-
sion. We used the RNeasy (Qiagen) protocol was used for RNA isolation,
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and iScript cDNA synthesis (BioRad, 1708891) for cDNA conversion. A brief
description of each follows.
To perform RNA isolation, we lysed the cells using RLT buffer (Qiagen) at
the given time points. We then isolated the RNA using RNeasy kit protocol
(Qiagen). In brief, cell lysate was resuspended in 70% ethanol. Then the
lysate suspension was centrifuged at 8,000 rcf for 30 seconds, at which point
the nucleic acids were attached to the spin column filter. I washed the filter
with detergents (RW1 and RLP) to remove proteins and DNA, leaving only
the RNA attached to the spin column. Finally, I detached the RNA from
the spin column using DEPC treated water. The RNA was quantified using
260/280 absorbance ratio on a Take3 reader (BioTek). We either used the
isolated RNA immediately or stored it in the -80◦C for later use.
We converted the RNA to cDNA using an established protocol with iScript
(Bio-Rad; iScript cDNA Synthesis Kit). We balanced the RNA to 20 ng·μl,
bringing the total volume up to 15 μl. We then added that concentration
to 4 μl 5x iScript Reaction Mix and 1 μl reverse transcriptase. The mixture
remained at room temperature for 5 minutes, 42◦C for 20 minutes, and 90◦C
for 1 minute. We then placed the cDNA into the refrigerator to cool. We
either used the isolated cDNA immediately or stored it in the -80 for later use.
Our qRT-PCR protocol was based on one published by Sigma Aldrich. We
used predesigned KiCqStart Primers (Sigma Aldrich) for forward and reverse
primers. We combined 0.09 μl Forward Primer (450 nM final concentration),
0.09 μl Reverse Primer (450 nM final concentration) 4.82 μl DEPC water, and
10 μl SYBR green for each well. We added 4 μl of cDNA to each well for
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a total volume of 20 μl in each well. The plate was covered with a cover,
placed of a plate shaker for 2 min and centrifuged at 1,200 RPM for 2 min.
Then the plate was placed on a CFX Connect Real-Time System (BioRad) for
thermocycling. The cycles were set to 95◦C for 15 seconds, 58◦C for 30 seconds,
and then 72◦C for 15 seconds to promote denaturing, primer annealing, and
extension, respectively.
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qPCR protocol
1. Calculate amount of cDNA needed for each Target gene
Amount(µl) = ((# ofsamples+NTCs) ∗ 3(triplicate)) ∗ (1 + 10%)
2. Dilute cDNA from cDNA conversion step 1:5 with DEPC to final volume
calculated above
3. Vortex cDNA and spin down in a minicentrifuge (MidSci, C1301R)
4. After thawing forward and reverse primers, vortex and centrifuge in a
mini centrifuge
5. Calculate amounts of forward primer, reverse primer, water, and SYBR,
needed for plate
Item (Samples+NTC) ∗ 3 Amount per well Total needed
DEPC Water 4.82 μl
Forward Primer 0.09 μl
Reverse Primer 0.09 μl
SYBR 10 μl
Table 15. This does not include 10% extra for error
6. Combine Forward, Reverse, DEPC, and SYBR
7. Vortex SYBR and spin down in a minicentrifuge
8. Pipette 16 μl SYBR mix into appropriate wells of 96-well plate
9. Pipette 4 μl diluted cDNA (or DEPC for NTC wells) into appropriate
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wells
10. Cover with polyester sheets and seal each well
11. Place on rotator for 2 min
12. Centrifuge 280 rcf for 2 minutes
13. Place plate in CFX Connect
14. Select Sigma 50 cycles 20 μl as protocol
15. Complete and save plate layout
16. Confirm protocol and layout on final screen
17. Begin PCR
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MASS SPECTROMETRY
B.0.1 Mass spectrometry results of decellularized sugen hypoxia
lung compared to healthy lung
Heise_373
Experiment: Heise_373
Report created: 1/31/2019 2:56:35 PM
Overview image
Data Processing Methods
Peak processing method Profile data
Peptide ion detection method High resolution
Experiment Design
Condition Decell 711 Decell M1
Replicates 3 3
Proteins
Protein building options
Protein grouping Group similar proteins
Protein quantitation Relative Quantitation using Hi-3
Accession Peptides Score Anova(p)* Fold Tags Description
Average Normalised
Abundances
Decell 711 Decell M1
G3V6P7_RAT 45 (2) 382.91 0.06 1.77 Myosin, heavy polypeptide 9, non-muscle OS=Rattus norvegicus GN=Myh9PE=1 SV=1 6.67e+004 1.18e+005
A0A0G2K6S9_RAT 39 (34) 379.77 0.52 1.10 Myosin-11 OS=Rattus norvegicus GN=Myh11 PE=1 SV=1 1.09e+005 1.19e+005
MYH9_RAT 45 (3) 374.63 0.13 1.53 Myosin-9 OS=Rattus norvegicus GN=Myh9 PE=1 SV=3 1.38e+004 2.11e+004
G3V9Y1_RAT 38 (2) 312.24 0.65 1.05 Myosin, heavy polypeptide 10, non-muscle, isoform CRA_b OS=Rattusnorvegicus GN=Myh10 PE=1 SV=1 6.29e+004 6.59e+004
MYH10_RAT 38 (2) 304.77 0.18 1.70 Myosin-10 OS=Rattus norvegicus GN=Myh10 PE=1 SV=1 4850.98 2854.98
ACTG_RAT 18 (5) 189.71 0.45 1.20 Actin, cytoplasmic 2 OS=Rattus norvegicus GN=Actg1 PE=1 SV=1 5.38e+004 6.46e+004
ACTA_RAT 14 (3) 144.21 0.91 1.08 Actin, aortic smooth muscle OS=Rattus norvegicus GN=Acta2 PE=2 SV=1 5.31e+004 4.92e+004
A0A068F1Y2_RAT 10 (3) 107.24 6.81e-003 1.96 Beta-actin (Fragment) OS=Rattus norvegicus GN=Actb PE=2 SV=1 4.95e+004 2.53e+004
D3ZRN3_RAT 9 (2) 77.18 0.54 1.10 Protein Actbl2 OS=Rattus norvegicus GN=Actbl2 PE=1 SV=1 2.68e+004 2.94e+004
F1LNH3_RAT 8 (8) 61.42 0.58 1.08 Procollagen, type VI, alpha 2, isoform CRA_a OS=Rattus norvegicusGN=Col6a2 PE=1 SV=2 5.95e+004 6.42e+004
Q6P6R6_RAT 8 (8) 61.39 0.65 1.20 Transglutaminase 2, C polypeptide OS=Rattus norvegicus GN=Tgm2 PE=2SV=1 1.33e+005 1.11e+005
A0A0G2JSQ4_RAT 4 (4) 40.07 0.64 1.04 Tropomyosin 1, alpha, isoform CRA_p OS=Rattus norvegicus GN=Tpm1 PE=1SV=1 5.83e+004 6.09e+004
Q38PF8_RAT 4 (1) 37.92 8.71e-003 3.48 AHNAK 1 (Fragment) OS=Rattus norvegicus PE=2 SV=1 8477.98 2438.75
Q38PG2_RAT 4 (1) 36.19 0.03 2.32 AHNAK 1 (Fragment) OS=Rattus norvegicus PE=2 SV=1 2.19e+004 9446.97
B1WBN8_RAT 3 (1) 32.83 0.03 1.74 Caveolin OS=Rattus norvegicus GN=Cav1 PE=2 SV=1 2.83e+004 4.91e+004
CAV1_RAT 3 (1) 30.71 0.04 1.49 Caveolin-1 OS=Rattus norvegicus GN=Cav1 PE=1 SV=3 5.22e+004 7.76e+004
A0A0G2JSV6_RAT 2 (2) 28.47 0.02 1.81 Protein Hba-a2 OS=Rattus norvegicus GN=Hba-a2 PE=1 SV=1 1.10e+005 6.06e+004
H2A1E_RAT 3 (3) 28.40 0.03 2.19 Histone H2A type 1-E OS=Rattus norvegicus PE=1 SV=2 726.04 1593.11
M0R6K0_RAT 4 (4) 26.85 0.03 2.38 Laminin subunit beta-2 OS=Rattus norvegicus GN=Lamb2 PE=1 SV=1 3.66e+004 1.53e+004
F1MAA7_RAT 3 (3) 23.23 0.06 1.55 Protein Lamc1 OS=Rattus norvegicus GN=Lamc1 PE=1 SV=1 2.76e+004 1.78e+004
A0A0G2K2F8_RAT 3 (3) 21.71 0.13 1.36 Protein Zfp106 OS=Rattus norvegicus GN=Zfp106 PE=4 SV=1 4.98e+004 6.78e+004
D3ZJ08_RAT 2 (2) 18.87 0.03 1.60 Histone H3 OS=Rattus norvegicus GN=Hist2h3c2 PE=1 SV=1 4.78e+004 7.65e+004
D3ZHA7_RAT 2 (2) 17.64 2.89e-003 4.69
Similar to Myosin light chain 1 slow a (Predicted) OS=Rattus norvegicus
GN=RGD1560334_predicted PE=4 SV=1 5.47e+004 1.17e+004
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Q6MG75_RAT 3 (3) 16.23 0.54 1.09 Protein Nelfe OS=Rattus norvegicus GN=Nelfe PE=1 SV=1 2.15e+004 2.34e+004
Q7TQ70_RAT 3 (3) 16.20 0.02 1.40 Ac1873 OS=Rattus norvegicus GN=Fga PE=1 SV=1 2.29e+004 1.64e+004
A0A0G2JSW3_RAT 1 (1) 16.02 0.26 1.48 Hemoglobin subunit beta-1 OS=Rattus norvegicus GN=Hbb PE=1 SV=1 9.26e+004 6.26e+004
RL30_RAT 1 (1) 11.51 4.01e-003 7.19 60S ribosomal protein L30 OS=Rattus norvegicus GN=Rpl30 PE=3 SV=2 1.22e+004 1701.10
M0R5B3_RAT 1 (1) 11.38 0.07 2.30 Uncharacterized protein OS=Rattus norvegicus PE=4 SV=2 2.72e+004 1.18e+004
FBX30_RAT 1 (1) 11.04 0.14 2.66 F-box only protein 30 OS=Rattus norvegicus GN=Fbxo30 PE=1 SV=1 8503.15 2.26e+004
G3V6E1_RAT 2 (2) 10.76 0.16 1.27 Protein Myh1 OS=Rattus norvegicus GN=Myh2 PE=1 SV=3 8549.08 6733.80
G3V9G5_RAT 2 (2) 10.38 0.04 1.50 Protein Synm OS=Rattus norvegicus GN=Synm PE=1 SV=2 1.76e+004 1.18e+004
A0A0G2K4H7_RAT 2 (1) 10.11 1.31e-003 3.15 Protein Krt78 OS=Rattus norvegicus GN=Krt78 PE=3 SV=1 1.01e+004 3200.99
B1WC01_RAT 1 (1) 6.14 0.37 1.24 Kinesin-like protein OS=Rattus norvegicus GN=Kif20a PE=1 SV=1 9496.51 7684.23
Q64592_RAT 1 (0) 5.89 --- --- Delta3, delta2-enoyl-CoA isomerase OS=Rattus norvegicus PE=2 SV=1 --- ---
B4F7A5_RAT 1 (1) 5.80 0.08 2.16 Cd99 protein OS=Rattus norvegicus GN=Cd99 PE=1 SV=1 1.23e+004 5699.36
EEPD1_RAT 1 (1) 5.60 6.27e-004 8.65 Endonuclease/exonuclease/phosphatase family domain-containing protein 1OS=Rattus norvegicus GN=Eepd1 PE=1 SV=1 3967.58 3.43e+004
G3V885_RAT 1 (1) 5.40 5.94e-003 3.04 Myosin-6 OS=Rattus norvegicus GN=Myh6 PE=1 SV=2 9.94e+004 3.27e+004
A0A0G2JXY0_RAT 1 (1) 5.25 6.33e-003 2.51 Protein RGD1565536 OS=Rattus norvegicus GN=RGD1565536 PE=1 SV=1 7803.11 1.96e+004
F1M5A1_RAT 1 (1) 5.14 0.84 1.09 Protein Calr4 OS=Rattus norvegicus GN=Calr4 PE=1 SV=2 1.42e+004 1.30e+004
Tags
G3V6P7_RAT
Myosin, heavy polypeptide 9, non-muscle OS=Rattus norvegicus GN=Myh9 PE=1 SV=1
45 peptides
Sequence PeptideIon Score Hits Mass Charge Tags Conflicts Modifications
In
quantitation
Average Normalised
Abundances
Decell 711 Decell M1
 ADFCIIHYAGKVDYK 230 5.82 1 1798.8570 2 4 [4] Carbamidomethyl C no 1.51e+005 4.39e+004
 AGVLAHLEEER 949 5.59 1 1222.5556 2 2 no 7.85e+004 3.74e+004
 ALEEAMEQK 175 6.89 4 1047.4867 2 1 no 4.23e+004 6.21e+004
 ALEEAMEQK 14555 6.10 1 1047.4841 1 1 no 427.36 769.37
 ALEEAMEQK 7074 6.89 4 1047.4777 1 1 no 1918.06 3121.60
 ALEQQVEEMK 571 6.48 4 1203.5671 2 1 no 5.81e+004 3.43e+004
 ALEQQVEEMKTQLEELEDELQATEDAK 5271 6.23 3 3146.4883 3 1 no 15.99 3.53e+004
 ALEQQVEEMKTQLEELEDELQATEDAK 1841 6.21 5 3146.4712 3 1 no 3.33e+004 60.29
 ALEQQVEEMKTQLEELEDELQATEDAK 2916 6.21 5 3146.4780 4 1 no 6119.39 262.19
 ALEQQVEEMKTQLEELEDELQATEDAK 7390 6.23 3 3146.4733 4 1 no 0.00 8315.90
 DEQSEEKK 4449 5.16 1 991.4321 1 1 no 1.01e+004 7788.70
 DFSALESQLQDTQELLQEENR 3394 6.44 6 2492.1390 3 1 no 2.29e+004 1.95e+004
 DFSALESQLQDTQELLQEENRQK 3011 5.69 2 2748.2761 3 1 no 510.76 769.93
 DKADFCIIHYAGK 6160 5.63 1 1536.8260 3 3 [6] Carbamidomethyl C no 127.37 5125.44
 DLEAHIDTANK 1703 5.27 1 1225.5889 3 1 no 5915.49 5359.46
 DLEGLSQR 4814 6.07 1 916.4287 1 1 no 4838.02 1518.82
 DLGEELEALKTELEDTLDSTAAQQELR 13925 6.60 3 3016.4007 4 1 no 2070.62 19.70
 DLGEELEALKTELEDTLDSTAAQQELR 3193 6.60 4 3016.4421 3 1 no 3.41e+004 5212.75
 DLGEELEALKTELEDTLDSTAAQQELR 523 6.95 4 3016.4777 3 1 no 4.15 1.97e+004
 DLGEELEALKTELEDTLDSTAAQQELR 9992 5.19 1 3016.4038 4 1 no 165.07 11.57
 DLGEELEALKTELEDTLDSTAAQQELR 2977 6.95 4 3016.4653 4 1 no 74.97 1483.63
 DLQGRDEQSEEK 2953 5.89 1 1432.6318 2 1 no 756.62 8021.56
 DLQGRDEQSEEK 1274 5.89 1 1432.6427 3 1 no 866.40 7779.39
 ELEDATETADAMNR 224 6.99 6 1564.6775 2 1 no 8.82e+004 6.56e+004
 ELETQISELQEDLESER 6149 5.63 2 2046.9618 3 1 no 6713.77 4493.59
 ELETQISELQEDLESER 4066 5.63 2 2046.9306 2 1 no 4638.31 3543.26
 EMEAELEDER 15878 6.75 5 1249.5113 1 1 no 90.31 910.06
 EMEAELEDER 399 6.75 6 1249.5286 2 1 no 5.04e+004 4.62e+004
 EMEAELEDERK 192 6.96 5 1377.6439 3 1 no 3.14e+004 5.86e+004
 EMEAELEDERK 478 6.96 5 1377.6065 2 1 no 2.39e+004 5.31e+004
 EQLEEEEEAKR 350 6.68 5 1388.6331 2 0 yes 1.03e+004 4.75e+004
 EQLEEEEEAKR 79 6.68 5 1388.6439 3 0 yes 3.00e+004 8.58e+004
 ERNTDQASMPDNTAAQK 1591 5.34 1 1875.8376 3 2 no 6477.92 8233.18
 ERNTDQASMPDNTAAQK 13283 5.53 1 1875.8446 2 1 no 66.68 7.86
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B.0.2 Mass spectrometry results of decellularized sugen hypoxia
lung compared to intact sugen hypoxia lung
Heise_373
Experiment: Heise_373
Report created: 1/31/2019 3:35:50 PM
Overview image
Data Processing Methods
Peak processing method Profile data
Peptide ion detection method High resolution
Experiment Design
Condition Intact 711 Decell 711
Replicates 3 3
Proteins
Protein building options
Protein grouping Group similar proteins
Protein quantitation Relative Quantitation using Hi-3
Accession Peptides Score Anova(p)* Fold Tags Description
Average Normalised
Abundances
Intact 711 Decell 711
G3V6P7_RAT 53 (2) 406.82 0.98 1.04 Myosin, heavy polypeptide 9, non-muscle OS=Rattus norvegicus GN=Myh9 PE=1SV=1 6.38e+004 6.67e+004
MYH9_RAT 53 (3) 398.53 0.02 1.52 Myosin-9 OS=Rattus norvegicus GN=Myh9 PE=1 SV=3 9537.42 1.45e+004
A0A0G2K6S9_RAT 41 (36) 379.77 0.84 1.46 Myosin-11 OS=Rattus norvegicus GN=Myh11 PE=1 SV=1 7.44e+004 1.09e+005
G3V9Y1_RAT 44 (2) 326.96 0.09 1.48 Myosin, heavy polypeptide 10, non-muscle, isoform CRA_b OS=Rattus norvegicusGN=Myh10 PE=1 SV=1 4.23e+004 6.29e+004
MYH10_RAT 44 (2) 319.48 0.03 3.19 Myosin-10 OS=Rattus norvegicus GN=Myh10 PE=1 SV=1 1523.05 4850.98
ACTG_RAT 24 (4) 189.71 0.01 6.34 Actin, cytoplasmic 2 OS=Rattus norvegicus GN=Actg1 PE=1 SV=1 3.41e+005 5.38e+004
ACTA_RAT 17 (3) 144.21 0.82 1.21 Actin, aortic smooth muscle OS=Rattus norvegicus GN=Acta2 PE=2 SV=1 4.40e+004 5.31e+004
A0A068F1Y2_RAT 11 (3) 107.24 5.82e-004 3.28 Beta-actin (Fragment) OS=Rattus norvegicus GN=Actb PE=2 SV=1 1.62e+005 4.95e+004
D3ZRN3_RAT 14 (2) 77.18 0.36 1.14 Protein Actbl2 OS=Rattus norvegicus GN=Actbl2 PE=1 SV=1 2.86e+004 2.50e+004
Q6P6R6_RAT 12 (11) 75.89 0.07 1.79 Transglutaminase 2, C polypeptide OS=Rattus norvegicus GN=Tgm2 PE=2 SV=1 7.61e+004 1.36e+005
F1LNH3_RAT 12 (12) 75.21 0.67 1.87 Procollagen, type VI, alpha 2, isoform CRA_a OS=Rattus norvegicus GN=Col6a2PE=1 SV=2 3.17e+004 5.95e+004
Q38PF8_RAT 5 (1) 42.77 0.39 1.31 AHNAK 1 (Fragment) OS=Rattus norvegicus PE=2 SV=1 5439.61 7133.33
Q38PG2_RAT 5 (1) 41.04 0.42 1.17 AHNAK 1 (Fragment) OS=Rattus norvegicus PE=2 SV=1 2.21e+004 1.90e+004
A0A0G2JSQ4_RAT 4 (4) 40.07 0.60 1.11 Tropomyosin 1, alpha, isoform CRA_p OS=Rattus norvegicus GN=Tpm1 PE=1 SV=1 6.45e+004 5.83e+004
E9PSN4_RAT 7 (6) 36.63 0.07 1.32 Protein Zc3h13 OS=Rattus norvegicus GN=Zc3h13 PE=1 SV=2 1.85e+004 2.43e+004
M0R6K0_RAT 6 (6) 36.32 0.12 1.57 Laminin subunit beta-2 OS=Rattus norvegicus GN=Lamb2 PE=1 SV=1 2.28e+004 3.57e+004
A0A0G2JT65_RAT 6 (5) 36.14 0.11 1.40 Protein Zfp106 OS=Rattus norvegicus GN=Zfp106 PE=4 SV=1 6.96e+004 4.98e+004
A0A0G2K4H7_RAT 4 (2) 33.81 3.94e-003 2.93 Protein Krt78 OS=Rattus norvegicus GN=Krt78 PE=3 SV=1 1.09e+004 3.20e+004
B1WBN8_RAT 6 (4) 32.83 0.61 1.08 Caveolin OS=Rattus norvegicus GN=Cav1 PE=2 SV=1 5.97e+004 5.53e+004
CAV1_RAT 3 (1) 30.71 0.98 1.02 Caveolin-1 OS=Rattus norvegicus GN=Cav1 PE=1 SV=3 3.29e+004 3.34e+004
A0A0G2JSV6_RAT 3 (3) 28.47 0.03 2.66 Protein Hba-a2 OS=Rattus norvegicus GN=Hba-a2 PE=1 SV=1 2.74e+004 7.30e+004
H2A1F_RAT 3 (3) 28.40 1.23e-004 45.46 Histone H2A type 1-F OS=Rattus norvegicus PE=3 SV=3 3.30e+004 726.04
G3V6E1_RAT 6 (4) 26.88 0.69 1.18 Protein Myh1 OS=Rattus norvegicus GN=Myh2 PE=1 SV=3 8894.54 7514.21
MYH4_RAT 5 (1) 25.16 3.76e-003 12.76 Myosin-4 OS=Rattus norvegicus GN=Myh4 PE=1 SV=1 1190.92 1.52e+004
F1LRV9_RAT 5 (0) 25.05 --- --- Protein Myh1 OS=Rattus norvegicus GN=Myh1 PE=1 SV=2 --- ---
G3V9G5_RAT 5 (5) 24.47 0.27 1.27 Protein Synm OS=Rattus norvegicus GN=Synm PE=1 SV=2 5.07e+004 6.46e+004
F1MAA7_RAT 3 (3) 23.23 0.02 2.60 Protein Lamc1 OS=Rattus norvegicus GN=Lamc1 PE=1 SV=1 1.06e+004 2.76e+004
Q6MG75_RAT 4 (4) 20.33 0.25 1.25 Protein Nelfe OS=Rattus norvegicus GN=Nelfe PE=1 SV=1 2.69e+004 2.15e+004
FBX30_RAT 3 (3) 19.85 3.33e-003 5.47 F-box only protein 30 OS=Rattus norvegicus GN=Fbxo30 PE=1 SV=1 1.91e+004 1.04e+005
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D3ZK97_RAT 4 (4) 18.87 0.22 1.63 Histone H3 OS=Rattus norvegicus GN=H3f3c PE=3 SV=1 9.48e+004 5.82e+004
G3V885_RAT 4 (4) 18.65 6.10e-003 5.17 Myosin-6 OS=Rattus norvegicus GN=Myh6 PE=1 SV=2 1.23e+004 6.34e+004
F1M5A1_RAT 3 (3) 18.56 0.71 1.10 Protein Calr4 OS=Rattus norvegicus GN=Calr4 PE=1 SV=2 3.92e+004 4.31e+004
D3ZHA7_RAT 2 (2) 17.64 0.36 1.41 Similar to Myosin light chain 1 slow a (Predicted) OS=Rattus norvegicusGN=RGD1560334_predicted PE=4 SV=1 3.89e+004 5.47e+004
Q7TQ70_RAT 3 (3) 16.20 0.11 1.25 Ac1873 OS=Rattus norvegicus GN=Fga PE=1 SV=1 1.83e+004 2.29e+004
HBB1_RAT 2 (2) 16.02 0.31 1.24 Hemoglobin subunit beta-1 OS=Rattus norvegicus GN=Hbb PE=1 SV=3 6.72e+004 8.36e+004
D3ZKN0_RAT 3 (3) 14.69 5.62e-003 2.11 Protein RGD1565536 OS=Rattus norvegicus GN=RGD1565536 PE=1 SV=2 2.31e+004 1.09e+004
B1WC01_RAT 2 (2) 14.06 0.28 1.47 Kinesin-like protein OS=Rattus norvegicus GN=Kif20a PE=1 SV=1 2.90e+004 1.97e+004
G3V6D8_RAT 3 (1) 13.60 0.68 4.21 Myosin-3 OS=Rattus norvegicus GN=Myh3 PE=1 SV=1 1684.22 7091.40
HMGN5_RAT 3 (3) 13.14 2.51e-003 29.37 High mobility group nucleosome-binding domain-containing protein 5 OS=Rattusnorvegicus GN=Hmgn5 PE=2 SV=1 125.76 3693.14
RL30_RAT 1 (1) 11.51 0.45 1.32 60S ribosomal protein L30 OS=Rattus norvegicus GN=Rpl30 PE=3 SV=2 9259.27 1.22e+004
M0R5B3_RAT 1 (1) 11.38 4.32e-003 7.91 Uncharacterized protein OS=Rattus norvegicus PE=4 SV=2 3442.79 2.72e+004
EEPD1_RAT 2 (2) 10.37 0.12 1.86 Endonuclease/exonuclease/phosphatase family domain-containing protein 1 OS=Rattusnorvegicus GN=Eepd1 PE=1 SV=1 1.01e+004 1.89e+004
Q8CIU0_RAT 1 (1) 9.40 0.98 3.02 Profilaggrin (Fragment) OS=Rattus norvegicus GN=Flg PE=4 SV=1 1.79e+004 5.41e+004
Q64592_RAT 1 (0) 5.89 --- --- Delta3, delta2-enoyl-CoA isomerase OS=Rattus norvegicus PE=2 SV=1 --- ---
B4F7A5_RAT 1 (1) 5.80 0.28 1.61 Cd99 protein OS=Rattus norvegicus GN=Cd99 PE=1 SV=1 7656.59 1.23e+004
A0A0G2K3D6_RAT 1 (1) 4.95 4.35e-004 424.28 Uncharacterized protein OS=Rattus norvegicus PE=4 SV=1 365.59 1.55e+005
Q9R0H4_RAT 1 (1) 4.65 0.01 2.75 Beta cardiac myosin heavy chain (Fragment) OS=Rattus norvegicus GN=Myh7 PE=2SV=1 2.06e+004 7477.87
Q7TPA7_RAT 1 (1) 4.57 0.78 1.38 Ab1-013 OS=Rattus norvegicus GN=LOC690435 PE=2 SV=1 1.18e+005 8.55e+004
ALEX_RAT 1 (1) 4.28 0.01 3.27 Protein ALEX OS=Rattus norvegicus GN=Gnas PE=1 SV=1 2.87e+004 9.39e+004
A0A0U1RRN6_RAT 1 (1) 3.96 0.45 22.29 Protein Krt78 OS=Rattus norvegicus GN=Krt78 PE=3 SV=1 263.90 11.84
F1LSG7_RAT 1 (1) 0.00 0.30 1.55 Fibroblast growth factor receptor OS=Rattus norvegicus GN=Fgfr2 PE=1 SV=1 1.53e+004 9838.44
Tags
G3V6P7_RAT
Myosin, heavy polypeptide 9, non-muscle OS=Rattus norvegicus GN=Myh9 PE=1 SV=1
53 peptides
Sequence PeptideIon Score Hits Mass Charge Tags Conflicts Modifications
In
quantitation
Average Normalised
Abundances
Intact 711 Decell 711
 ADFCIIHYAGKVDYK 230 5.82 1 1798.8570 2 4 [4] Carbamidomethyl C no 6.32e+004 1.51e+005
 AGVLAHLEEER 949 5.59 1 1222.5556 2 2 no 3.94e+004 7.85e+004
 ALEEAMEQK 7074 6.89 4 1047.4777 1 1 no 320.46 1918.06
 ALEEAMEQK 14555 6.10 1 1047.4841 1 1 no 350.20 427.36
 ALEEAMEQK 175 6.89 4 1047.4867 2 1 no 2.73e+004 4.23e+004
 ALEQQVEEMK 571 6.48 4 1203.5671 2 1 no 2.74e+004 5.81e+004
 ALEQQVEEMKTQLEELEDELQATEDAK 7390 6.23 3 3146.4733 4 1 no 94.07 0.00
 ALEQQVEEMKTQLEELEDELQATEDAK 1841 6.21 5 3146.4712 3 1 no 2941.47 3.33e+004
 ALEQQVEEMKTQLEELEDELQATEDAK 5271 6.23 3 3146.4883 3 1 no 53.71 15.99
 ALEQQVEEMKTQLEELEDELQATEDAK 2916 6.21 5 3146.4780 4 1 no 1078.61 6119.39
 DEQSEEKK 4449 5.16 1 991.4321 1 1 no 3128.85 1.01e+004
 DFSALESQLQDTQELLQEENR 3394 6.44 6 2492.1390 3 1 no 4131.55 2.29e+004
 DFSALESQLQDTQELLQEENRQK 3011 5.69 2 2748.2761 3 1 no 1.56e+004 510.76
 DKADFCIIHYAGK 6160 5.63 1 1536.8260 3 3 [6] Carbamidomethyl C no 80.27 127.37
 DLEAHIDTANK 1703 5.27 1 1225.5889 3 1 no 1400.06 5915.49
 DLEGLSQR 4814 6.07 1 916.4287 1 1 no 5166.08 4838.02
 DLGEELEALKTELEDTLDSTAAQQELR 3193 6.60 4 3016.4421 3 1 no 1.50e+004 3.41e+004
 DLGEELEALKTELEDTLDSTAAQQELR 2977 6.95 4 3016.4653 4 1 no 1291.12 74.97
 DLGEELEALKTELEDTLDSTAAQQELR 523 6.95 4 3016.4777 3 1 no 1.06e+004 4.15
 DLGEELEALKTELEDTLDSTAAQQELR 9992 5.19 1 3016.4038 4 1 no 1991.75 165.07
 DLGEELEALKTELEDTLDSTAAQQELR 13925 6.60 3 3016.4007 4 1 no 46.48 2070.62
 DLQGRDEQSEEK 2953 5.89 1 1432.6318 2 1 no 4060.04 756.62
 DLQGRDEQSEEK 1274 5.89 1 1432.6427 3 1 no 2426.95 866.40
 EAELEDERK 13287 0.00 1 1117.5192 3 1 no 0.00 55.02
 EAELEDERK 552 0.00 2 1117.5227 2 1 no 1.47e+004 1.90e+004
 ELEDATETADAMNR 224 6.99 6 1564.6775 2 1 no 1.94e+004 8.82e+004
 ELETQISELQEDLESER 4066 5.63 2 2046.9306 2 1 no 248.93 4638.31
 ELETQISELQEDLESER 6149 5.63 2 2046.9618 3 1 no 1289.92 6713.77
 EMEAELEDER 399 6.75 6 1249.5286 2 1 no 1.31e+004 5.04e+004
 EMEAELEDER 15878 6.75 5 1249.5113 1 1 no 0.00 90.31
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B.0.3 Mass spectrometry results of sugen hypoxia lung compared
to healthy lung
Heise_373 Decell vs Intact
Experiment: Heise_373
Report created: 12/13/2018 1:03:39 PM
Overview image
Data Processing Methods
Peak processing method Profile data
Peptide ion detection method High resolution
Experiment Design
Condition 711 M1
Replicates 6 6
Proteins
Protein building options
Protein grouping Group similar proteins
Protein quantitation Relative Quantitation using Hi-3
Accession Peptides Score Anova(p)* Fold Tags Description
Average Normalised
Abundances
711 M1
G3V6P7_RAT 34 (2) 303.68 0.03 1.50 Myosin, heavy polypeptide 9, non-muscle OS=Rattus norvegicus GN=Myh9PE=1 SV=1 6.54e+004 9.78e+004
A0A0G2K6S9_RAT 32 (28) 300.60 0.30 1.19 Myosin-11 OS=Rattus norvegicus GN=Myh11 PE=1 SV=1 7.61e+004 9.02e+004
MYH9_RAT 34 (2) 295.63 0.07 1.43 Myosin-9 OS=Rattus norvegicus GN=Myh9 PE=1 SV=3 1.12e+004 1.60e+004
G3V9Y1_RAT 26 (24) 231.63 0.28 1.15 Myosin, heavy polypeptide 10, non-muscle, isoform CRA_b OS=Rattusnorvegicus GN=Myh10 PE=1 SV=1 4.88e+004 5.60e+004
ACTG_RAT 15 (5) 144.73 0.07 6.19 Actin, cytoplasmic 2 OS=Rattus norvegicus GN=Actg1 PE=1 SV=1 2.00e+005 3.23e+004
ACTC_RAT 11 (3) 108.04 0.14 2.42 Actin, alpha cardiac muscle 1 OS=Rattus norvegicus GN=Actc1 PE=2 SV=1 6.47e+004 2.67e+004
A0A068F1Y2_RAT 8 (2) 86.63 0.07 6.19 Beta-actin (Fragment) OS=Rattus norvegicus GN=Actb PE=2 SV=1 1.16e+005 1.88e+004
D3ZRN3_RAT 6 (0) 43.31 --- --- Protein Actbl2 OS=Rattus norvegicus GN=Actbl2 PE=1 SV=1 --- ---
Q6P6R6_RAT 6 (6) 41.12 0.70 1.09 Transglutaminase 2, C polypeptide OS=Rattus norvegicus GN=Tgm2 PE=2SV=1 4.85e+004 5.28e+004
A0A0G2JSQ4_RAT 4 (4) 32.82 0.52 1.06 Tropomyosin 1, alpha, isoform CRA_p OS=Rattus norvegicus GN=Tpm1PE=1 SV=1 5.69e+004 6.02e+004
F1LNH3_RAT 5 (5) 29.84 0.22 1.21 Procollagen, type VI, alpha 2, isoform CRA_a OS=Rattus norvegicusGN=Col6a2 PE=1 SV=2 3.61e+004 4.38e+004
Q38PF8_RAT 3 (1) 24.91 0.92 2.12 AHNAK 1 (Fragment) OS=Rattus norvegicus PE=2 SV=1 5376.81 1.14e+004
HBA_RAT 2 (2) 22.11 0.40 1.48 Hemoglobin subunit alpha-1/2 OS=Rattus norvegicus GN=Hba1 PE=1 SV=3 7.44e+004 5.03e+004
Q38PG2_RAT 3 (1) 17.86 0.48 1.03 AHNAK 1 (Fragment) OS=Rattus norvegicus PE=2 SV=1 1.75e+004 1.71e+004
HBB1_RAT 1 (1) 16.02 0.18 1.69 Hemoglobin subunit beta-1 OS=Rattus norvegicus GN=Hbb PE=1 SV=3 7.29e+004 4.32e+004
LAMB2_RAT 2 (2) 15.82 0.94 1.13 Laminin subunit beta-2 OS=Rattus norvegicus GN=Lamb2 PE=2 SV=1 1.63e+004 1.44e+004
B1WBN8_RAT 2 (1) 12.01 4.31e-003 4.55 Caveolin OS=Rattus norvegicus GN=Cav1 PE=2 SV=1 1081.29 4924.04
CAV1_RAT 2 (1) 11.68 0.72 1.30 Caveolin-1 OS=Rattus norvegicus GN=Cav1 PE=1 SV=3 5699.69 4398.38
M0R5B3_RAT 1 (1) 11.38 0.24 1.31 Uncharacterized protein OS=Rattus norvegicus PE=4 SV=2 1.53e+004 2.01e+004
FBX30_RAT 1 (1) 11.04 0.29 1.23 F-box only protein 30 OS=Rattus norvegicus GN=Fbxo30 PE=1 SV=1 1.80e+004 2.22e+004
FIBA_RAT 2 (2) 10.90 0.42 1.15 Fibrinogen alpha chain OS=Rattus norvegicus GN=Fga PE=1 SV=3 1.94e+004 1.68e+004
G3V6E1_RAT 2 (2) 10.76 0.04 1.40 Protein Myh1 OS=Rattus norvegicus GN=Myh2 PE=1 SV=3 7562.97 5384.14
H2A1E_RAT 1 (1) 7.82 0.81 27.19 Histone H2A type 1-E OS=Rattus norvegicus PE=1 SV=2 2.11e+004 775.27
D3ZK97_RAT 1 (1) 6.83 0.99 1.37 Histone H3 OS=Rattus norvegicus GN=H3f3c PE=3 SV=1 2.86e+004 3.93e+004
189
B1WC01_RAT 1 (1) 6.14 0.11 1.48 Kinesin-like protein OS=Rattus norvegicus GN=Kif20a PE=1 SV=1 5225.34 7715.26
D3ZHA7_RAT 1 (1) 6.09 0.05 2.26 Similar to Myosin light chain 1 slow a (Predicted) OS=Rattus norvegicusGN=RGD1560334_predicted PE=4 SV=1 3.53e+004 1.56e+004
Q64592_RAT 1 (0) 5.89 --- --- Delta3, delta2-enoyl-CoA isomerase OS=Rattus norvegicus PE=2 SV=1 --- ---
A0A0U1RS20_RAT 1 (1) 5.88 0.41 1.23 Protein Lamc1 (Fragment) OS=Rattus norvegicus GN=Lamc1 PE=1 SV=1 1.24e+004 1.53e+004
B4F7A5_RAT 1 (1) 5.80 0.49 1.59 Cd99 protein OS=Rattus norvegicus GN=Cd99 PE=1 SV=1 9982.34 1.59e+004
RL30_RAT 1 (1) 5.76 0.07 1.98 60S ribosomal protein L30 OS=Rattus norvegicus GN=Rpl30 PE=3 SV=2 5382.72 2715.91
A0A0G2JT65_RAT 1 (1) 5.69 0.64 1.01 Protein Zfp106 OS=Rattus norvegicus GN=Zfp106 PE=4 SV=1 5.61e+004 5.58e+004
G3V885_RAT 1 (1) 5.40 0.35 1.85 Myosin-6 OS=Rattus norvegicus GN=Myh6 PE=1 SV=2 6.05e+004 3.27e+004
A0A0G2JXY0_RAT 1 (1) 5.25 1.00 1.11 Protein RGD1565536 OS=Rattus norvegicus GN=RGD1565536 PE=1 SV=1 1.05e+004 1.17e+004
F1M5A1_RAT 1 (1) 5.14 0.04 2.02 Protein Calr4 OS=Rattus norvegicus GN=Calr4 PE=1 SV=2 8726.59 1.76e+004
A0A0G2K4H7_RAT 1 (0) 0.00 --- --- Protein Krt78 OS=Rattus norvegicus GN=Krt78 PE=3 SV=1 --- ---
Tags
G3V6P7_RAT
Myosin, heavy polypeptide 9, non-muscle OS=Rattus norvegicus GN=Myh9 PE=1 SV=1
34 peptides
Sequence PeptideIon Score Hits Mass Charge Tags Conflicts Modifications
In
quantitation
Average Normalised
Abundances
711 M1
 ADFCIIHYAGKVDYK 230 5.82 1 1798.8570 2 3 [4] Carbamidomethyl C no 1.07e+005 5.73e+004
 ALEEAMEQK 7074 6.89 4 1047.4777 1 1 no 1119.26 1948.03
 ALEEAMEQK 14555 6.10 1 1047.4841 1 1 no 388.78 460.57
 ALEEAMEQK 175 6.89 4 1047.4867 2 1 no 3.48e+004 4.51e+004
 ALEQQVEEMK 571 6.48 4 1203.5671 2 1 no 4.28e+004 2.58e+004
 ALEQQVEEMKTQLEELEDELQATEDAK 2916 6.21 5 3146.4780 4 1 no 3599.00 1.18e+004
 ALEQQVEEMKTQLEELEDELQATEDAK 5271 6.23 3 3146.4883 3 1 no 34.85 1.78e+004
 ALEQQVEEMKTQLEELEDELQATEDAK 7390 6.23 3 3146.4733 4 1 no 47.04 4180.36
 ALEQQVEEMKTQLEELEDELQATEDAK 1841 6.21 5 3146.4712 3 1 no 1.81e+004 4.39e+004
 DEQSEEKK 4449 5.16 1 991.4321 1 1 no 6623.80 7378.36
 DFSALESQLQDTQELLQEENR 3394 6.44 6 2492.1390 3 1 no 1.35e+004 1.50e+004
 DLEAHIDTANK 1703 5.27 1 1225.5889 3 1 no 3657.78 4562.12
 DLGEELEALKTELEDTLDSTAAQQELR 523 6.95 4 3016.4777 3 1 no 5285.56 5.31e+004
 DLGEELEALKTELEDTLDSTAAQQELR 3193 6.60 4 3016.4421 3 1 no 2.45e+004 1.65e+004
 DLGEELEALKTELEDTLDSTAAQQELR 2977 6.95 4 3016.4653 4 1 no 683.05 5962.95
 DLQGRDEQSEEK 1274 5.89 1 1432.6427 3 1 no 1646.68 5079.95
 DLQGRDEQSEEK 2953 5.89 1 1432.6318 2 1 no 2408.33 7498.25
 ELEDATETADAMNR 224 6.99 6 1564.6775 2 1 no 5.38e+004 6.90e+004
 ELETQISELQEDLESER 6149 5.63 2 2046.9618 3 1 no 4001.84 3909.22
 ELETQISELQEDLESER 4066 5.63 2 2046.9306 2 1 no 2443.62 3537.53
 EMEAELEDER 399 6.75 6 1249.5286 2 1 no 3.17e+004 3.61e+004
 EMEAELEDER 15878 6.75 5 1249.5113 1 1 no 45.16 480.76
 EMEAELEDERK 478 6.96 5 1377.6065 2 1 no 1.98e+004 4.44e+004
 EQLEEEEEAKR 350 6.68 5 1388.6331 2 0 yes 2.21e+004 4.34e+004
 EQLEEEEEAKR 79 6.68 5 1388.6439 3 0 yes 4.78e+004 6.25e+004
 ERNTDQASMPDNTAAQK 13283 5.53 1 1875.8446 2 1 no 655.31 9.41
 ERNTDQASMPDNTAAQK 1591 5.34 1 1875.8376 3 2 no 1.15e+004 9655.75
 HEAMITDLEER 1853 5.77 1 1342.6176 2 1 no 7488.22 6221.48
 HEMPPHIYAITDTAYRSMMQDR 4519 5.04 1 2694.2070 3 1 [3] Oxidation M|[19]Oxidation M no 3855.22 1270.44
 IAQLEEELEEEQGNTELINDR 8263 6.36 6 2471.1385 2 0 no 966.24 2142.45
 KLEEDQIIMEDQNCK 1815 6.53 3 1891.8590 2 1 [14] CarbamidomethylC no 9914.32 7347.21
 KLEEDQIIMEDQNCK 383 6.53 3 1891.8565 3 1 [14] CarbamidomethylC no 2.91e+004 1.98e+004
 KLEGDSTDLSDQIAELQAQIAELK 10039 5.98 1 2614.3059 3 1 no 134.96 6599.75
 KMQQNIQELEEQLEEEESAR 2228 6.23 3 2460.1499 3 1 no 8246.65 7972.39
 KMQQNIQELEEQLEEEESAR 9585 5.46 1 2460.1336 3 1 no 1225.14 6317.19
 KQELEEICHDLEAR 7401 5.61 2 1768.8374 3 1 [8] Carbamidomethyl C no 396.78 1.69e+004
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B.0.4 Mass spectrometry results of decellularized lung compared
to intact lung
Heise_373 Decell vs Intact
Experiment: Heise_373
Report created: 12/13/2018 1:02:30 PM
Overview image
Data Processing Methods
Peak processing method Profile data
Peptide ion detection method High resolution
Experiment Design
Condition Decell Intact
Replicates 6 6
Proteins
Protein building options
Protein grouping Group similar proteins
Protein quantitation Relative Quantitation using Hi-3
Accession Peptides Score Anova(p)* Fold Tags Description
Average Normalised
Abundances
Decell Intact
G3V6P7_RAT 34 (2) 303.68 0.28 1.32 Myosin, heavy polypeptide 9, non-muscle OS=Rattus norvegicus GN=Myh9PE=1 SV=1 9.27e+004 7.05e+004
A0A0G2K6S9_RAT 32 (28) 300.60 0.65 1.82 Myosin-11 OS=Rattus norvegicus GN=Myh11 PE=1 SV=1 1.07e+005 5.90e+004
MYH9_RAT 34 (2) 295.63 0.01 1.59 Myosin-9 OS=Rattus norvegicus GN=Myh9 PE=1 SV=3 1.67e+004 1.05e+004
G3V9Y1_RAT 26 (24) 231.63 0.11 1.25 Myosin, heavy polypeptide 10, non-muscle, isoform CRA_b OS=Rattusnorvegicus GN=Myh10 PE=1 SV=1 5.83e+004 4.66e+004
ACTG_RAT 15 (5) 144.73 0.32 4.32 Actin, cytoplasmic 2 OS=Rattus norvegicus GN=Actg1 PE=1 SV=1 4.36e+004 1.89e+005
ACTC_RAT 11 (3) 108.04 0.98 1.28 Actin, alpha cardiac muscle 1 OS=Rattus norvegicus GN=Actc1 PE=2 SV=1 4.00e+004 5.14e+004
A0A068F1Y2_RAT 8 (2) 86.63 0.32 4.32 Beta-actin (Fragment) OS=Rattus norvegicus GN=Actb PE=2 SV=1 2.54e+004 1.10e+005
D3ZRN3_RAT 6 (0) 43.31 --- --- Protein Actbl2 OS=Rattus norvegicus GN=Actbl2 PE=1 SV=1 --- ---
Q6P6R6_RAT 6 (6) 41.12 0.47 1.15 Transglutaminase 2, C polypeptide OS=Rattus norvegicus GN=Tgm2 PE=2SV=1 4.72e+004 5.41e+004
A0A0G2JSQ4_RAT 4 (4) 32.82 0.53 1.07 Tropomyosin 1, alpha, isoform CRA_p OS=Rattus norvegicus GN=Tpm1PE=1 SV=1 5.67e+004 6.04e+004
F1LNH3_RAT 5 (5) 29.84 0.01 1.96 Procollagen, type VI, alpha 2, isoform CRA_a OS=Rattus norvegicusGN=Col6a2 PE=1 SV=2 5.29e+004 2.70e+004
Q38PF8_RAT 3 (1) 24.91 0.04 3.28 AHNAK 1 (Fragment) OS=Rattus norvegicus PE=2 SV=1 3923.46 1.29e+004
HBA_RAT 2 (2) 22.11 4.30e-003 2.08 Hemoglobin subunit alpha-1/2 OS=Rattus norvegicus GN=Hba1 PE=1 SV=3 8.42e+004 4.06e+004
Q38PG2_RAT 3 (1) 17.86 0.01 1.92 AHNAK 1 (Fragment) OS=Rattus norvegicus PE=2 SV=1 1.19e+004 2.27e+004
HBB1_RAT 1 (1) 16.02 0.02 2.02 Hemoglobin subunit beta-1 OS=Rattus norvegicus GN=Hbb PE=1 SV=3 7.76e+004 3.84e+004
LAMB2_RAT 2 (2) 15.82 0.96 1.07 Laminin subunit beta-2 OS=Rattus norvegicus GN=Lamb2 PE=2 SV=1 1.48e+004 1.59e+004
B1WBN8_RAT 2 (1) 12.01 0.05 2.71 Caveolin OS=Rattus norvegicus GN=Cav1 PE=2 SV=1 4385.22 1620.11
CAV1_RAT 2 (1) 11.68 0.02 2.43 Caveolin-1 OS=Rattus norvegicus GN=Cav1 PE=1 SV=3 7154.74 2943.33
M0R5B3_RAT 1 (1) 11.38 0.29 1.23 Uncharacterized protein OS=Rattus norvegicus PE=4 SV=2 1.95e+004 1.59e+004
FBX30_RAT 1 (1) 11.04 0.16 1.58 F-box only protein 30 OS=Rattus norvegicus GN=Fbxo30 PE=1 SV=1 1.55e+004 2.46e+004
FIBA_RAT 2 (2) 10.90 0.61 1.11 Fibrinogen alpha chain OS=Rattus norvegicus GN=Fga PE=1 SV=3 1.91e+004 1.71e+004
G3V6E1_RAT 2 (2) 10.76 0.02 1.44 Protein Myh1 OS=Rattus norvegicus GN=Myh2 PE=1 SV=3 7641.44 5305.66
H2A1E_RAT 1 (1) 7.82 0.02 102.81 Histone H2A type 1-E OS=Rattus norvegicus PE=1 SV=2 210.55 2.16e+004
D3ZK97_RAT 1 (1) 6.83 0.02 3.10 Histone H3 OS=Rattus norvegicus GN=H3f3c PE=3 SV=1 5.14e+004 1.66e+004
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B1WC01_RAT 1 (1) 6.14 0.04 1.97 Kinesin-like protein OS=Rattus norvegicus GN=Kif20a PE=1 SV=1 8590.37 4350.23
D3ZHA7_RAT 1 (1) 6.09 0.02 2.39 Similar to Myosin light chain 1 slow a (Predicted) OS=Rattus norvegicusGN=RGD1560334_predicted PE=4 SV=1 3.58e+004 1.50e+004
Q64592_RAT 1 (0) 5.89 --- --- Delta3, delta2-enoyl-CoA isomerase OS=Rattus norvegicus PE=2 SV=1 --- ---
A0A0U1RS20_RAT 1 (1) 5.88 1.61e-003 3.68 Protein Lamc1 (Fragment) OS=Rattus norvegicus GN=Lamc1 PE=1 SV=1 2.18e+004 5920.72
B4F7A5_RAT 1 (1) 5.80 0.16 1.88 Cd99 protein OS=Rattus norvegicus GN=Cd99 PE=1 SV=1 9003.72 1.69e+004
RL30_RAT 1 (1) 5.76 0.48 1.14 60S ribosomal protein L30 OS=Rattus norvegicus GN=Rpl30 PE=3 SV=2 3789.77 4308.86
A0A0G2JT65_RAT 1 (1) 5.69 0.43 1.28 Protein Zfp106 OS=Rattus norvegicus GN=Zfp106 PE=4 SV=1 4.91e+004 6.28e+004
G3V885_RAT 1 (1) 5.40 0.02 2.44 Myosin-6 OS=Rattus norvegicus GN=Myh6 PE=1 SV=2 6.61e+004 2.71e+004
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Appendix C
MATLAB CODE
C.1 One-dimension general cell model
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Lic = 9;
Ginit = 1;
JLic = 0.025;
Lu = 1;
% define parameters
b = 0.1;
gam = 1.5;
GT = 2;
n = 4;
alpha = 10;
l0 = 15;
phi = 1.8;
Gh = 0.3;
pp = 4;
ep = 0.1;
fep = 0.1*ep;
k = 1;
kwall = 5.58;
Lw = 1;
L0junc = 0.025;
beta = 0.16;
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kjunc= 5.58;
eta = k/ep;
mitjunc = 0.025;% L0junc;
period = 38.24;
dt = 1;
tmitosis = ceil(period*60*60*24/(100*dt));
% a = 2*mitosisevents;
mitosisend = tmitosis*10+1;
Ttot = ceil(mitosisend*(1.2)*dt);
t = 0:dt:Ttot;
mitosisevents = floor(length(t)/tmitosis);
single cell model from Zmurchok, Bhaskar, Edelstein-Keshet Physical Bi-
ology 15 (2018) 046004 collect state variables
G = nan(length(t),mitosisevents*2+1);
x = nan(length(t),mitosisevents*4+2);
y = nan(length(t),mitosisevents*4+2);
G(1,1) = Ginit;
x(1,1:2) = [Lic,0];
y(1,1:2) = [0,0];
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Tcomb = nan(length(t),mitosisevents*4+2);
cellfront = [1]; % these are the nodes at the front of the cells
cellback= [2]; % these are the nodes at the backs of the cells
cellnum = [1];
mitosistrack = []; %This will track the cells that undergo mitosis
c = [cellfront cellback cellnum nan(1,1);
cellfront cellback cellnum nan(1,1)];
[~,idx] = sort(c(:,3));
d = c(idx,:);
cell=length(cellnum);
for l = 1:length(t)-1
if cell == 1 %%% for single cell case
L1 = sqrt((x(l,1)-x(l,2))^2 + (y(l,1)-y(l,2))^2);
La = sqrt(x(l,2)^2 + (Lw-y(l,2))^2);
Lb = sqrt(x(l,2)^2 + (Lw+y(l,2))^2);
L0 = l0 - phi*G(l,1).^pp./(Gh^pp + G(l,1).^pp);
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T = L1 - L0;
Ta = La - Lw;
Tb = Lb - Lw;
f = beta./(1 + exp(-alpha*T));
epf = (ep+fep) - 2*fep./(1 + exp(-alpha*T));
etaf = k/epf; % front of the cell eta term
ctheta1 = (x(l,1)-x(l,2))/L1; stheta1 = (y(l,2)-y(l,1))/L1;
cthetaa = x(l,2)/La; sthetaa = (Lw-y(l,2))/La;
cthetab = x(l,2)/Lb; sthetab = (Lw+y(l,2))/Lb;
dG = (b + f + gam*G(l,1).^n./(1 + G(l,1).^n)).*(GT - G(l,1)) - G(l,1);
% dL = -ep*(L-L0);
dx = [-k/etaf*T*ctheta1; ...
k/eta*T*ctheta1-kwall/eta*Ta*cthetaa-kwall/eta*Tb*cthetab];
dy = [k/etaf*T*stheta1; ...
-k/eta*T*stheta1+kwall/eta*Ta*sthetaa-kwall/eta*Tb*sthetab];%bottom
G(l+1,1) = G(l,1) + dt*dG;
for j = 1:2*cell
x(l+1,j) = x(l,j) + dt*dx(j);
y(l+1,j) = y(l,j);
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end
if rem(l,tmitosis) < 1
mitosiscell=1;
G(l+1,[mitosiscell mitosiscell+1 mitosiscell+2])= G(l+1,mitosiscell);
x(l+1,5) = x(l+1,2);
x(l+1,6) = x(l+1,2);
xshift = 0.5*(x(l+1,mitosiscell)-x(l+1,mitosiscell+1)-mitjunc);
x(l+1,2) = x(l+1,1)- xshift;
x(l+1,3) = x(l+1,2)-mitjunc;
x(l+1,4) = x(l+1,2)-mitjunc;
y(l+1,3) = y(l+1,2)+1/2*Lu;
y(l+1,5) = y(l+1,2)+ 1/2*Lu;
y(l+1,4) = y(l+1,2)-1/2*Lu;
y(l+1,6) = y(l+1,2)-1/2*Lu;
cellnum(end+1,1)=mitosiscell+1;
cellfront(end+1,1) = 3;
cellback(end+1,1) = 5;
cellnum(end+1,1)=mitosiscell+2;
cellfront(end+1,1) = 4;
cellback(end+1,1) = 6;
newcells = [cellfront(end-1) cellback(end-1,1) cellnum(end-1) inf(1,1);
cellfront(end) cellback(end,1) cellnum(end) inf(1,1)];
cell=cell+2;
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c = [c; newcells];
c(1,4) = 3; c(2,4) = 4;
% cellindex = sparse(c(:,1),c(:,2),c(:,3));
[~,idx] = sort(c(:,3));
d = c(idx,:);
mitosistrack(end+1)=mitosiscell;
end
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
else % for multiple cell case %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
[m n] = size(x);
% cellindex=[1 2];
% for i = 3:2:cell
% cellindex(i-1,1)=2*i-3;
% cellindex(i-1,2) = 2*i-1;
% cellindex(i,1)=2*i-2;
% cellindex(i,2) = 2*i;
% end
% L = ((x(l,cellindex(:,1))-x(l,cellindex(:,2))).^2+...
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% (y(l,cellindex(:,1))-y(l,cellindex(:,2))).^2).^(1/2);
for i = 2:length(c)
L(i-1,:) = [c(i,1) c(i,2) sqrt((x(l,c(i,1))-x(l,c(i,2)))^2+(y(l,c(i,1))-y(l,c(i,2)))^2)];
ctheta(i-1,:) = [c(i,1) c(i,2) (x(l,c(i,1))-x(l,c(i,2)))./L(i-1,3)];
stheta(i-1,:) = [c(i,1) c(i,2) (y(l,c(i,1))-y(l,c(i,2)))./L(i-1,3)];
end
% cthetaspar = sparse(cellindex(:,1),cellindex(:,2),(x(l,cellindex(:,1))-x(l,cellindex(:,2)))./L);
% sthetaspar = sparse(cellindex(:,1),cellindex(:,2),(y(l,cellindex(:,1))-y(l,cellindex(:,2)))./L);
% ctheta = [c(:,1) c(:,2) (x(l,c(2:end,1))-x(l,c(2:end,2)))./L(:,3)];
% stheta = (y(l,c(2:end,1))-y(l,c(2:end,2)))./L(:,3);
up2x = x(l,2)+Lu/2*stheta(1,3); %x(l,2)+Lu/2*sthetaspar(1,2);
up2y = y(l,2)+Lu/2*ctheta(1,3); %y(l,2)+Lu/2*cthetaspar(1,2);
down2x = x(l,2)-Lu/2*stheta(1,3); %x(l,2)-Lu/2*sthetaspar(1,2);
down2y = y(l,2)-Lu/2*ctheta(1,3); %y(l,2)-Lu/2*cthetaspar(1,2);
Ljunc(1:2,:) = [2 d(3,1) (((up2x)-x(l,d(3,1))).^2 + ((up2y)-y(l,d(3,1))).^2).^(1/2);...
2 d(4,1) (((down2x)-x(l,d(4,1))).^2+((down2y)-y(l,d(4,1))).^2).^(1/2)];
for i = 3:length(c)
if d(i,4)==inf
Ljunc(i,:) = [d(i,2) inf(1,1) inf(1,1)];
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else
Ljunc(i,:) = [d(i,2) d(i,4) sqrt((x(l,d(i,2))-x(l,d(i,4)))^2 + ...
(y(l,d(i,2))-y(l,d(i,4)))^2)];
end
end
for i = find(Ljunc(:,3)==inf)
Ljunc(i(1),3) = sqrt(x(l,d(end-1,2))^2 + (Lw+0.5*Lu-y(l,d(end-1,2)))^2);
Ljunc(i(2),3) = sqrt(x(l,d(end,2))^2 + (Lw+0.5*Lu+y(l,d(end,2)))^2);
end
cthetajunc = [2 d(3,1) (x(l,2)-x(l,d(3,1)))/Ljunc(1,3);...
2 d(4,1) (x(l,2)-x(l,d(4,1)))/Ljunc(2,3)];
sthetajunc = [2 d(3,1) (y(l,2)-y(l,d(3,1)))/Ljunc(1,3);...
2 d(4,1) (y(l,2)-y(l,d(4,1)))/Ljunc(2,3)];
for i = 3:cell-1
cthetajunc(i,:) = [d(i,2) d(i,4),...
(x(l,d(i,2))-x(l,d(i,4)))/Ljunc(i,3)];
sthetajunc(i,:) = [d(i-1,2) d(i+1,1),...
(y(l,d(i-1,2))-y(l,d(i+1,1)))/Ljunc(i,3)];
end
% for i=5:2:(n-3)/2
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% cthetajunc(end,1) = d(2,i-3
%
%
% % d(2:end,1),(x(l,juncindex(:,1))-x(l,juncindex(:,2)))./Ljunc’);
% sthetajuncspar = sparse(juncindex(:,1),juncindex(:,2),(y(l,juncindex(:,1))-y(l,juncindex(:,2)))./Ljunc’);
% sthetajuncspar(2,3)=(up2y-y(l,3))./L23;
% sthetajuncspar(2,4)=(down2y-y(l,4))./L24;
% T23=L23-L0junc;
% T24=L24-L0junc;
Lwall = Ljunc(find(Ljunc(:,2)==inf),3);
Ltop = Lwall(1);
Lbottom = Lwall(2);
% Lbottom = sqrt(x(l,d(end,2))^2 + (Lw+0.5*Lu+y(l,d(end,2)))^2);
cthetatop = x(l,d(end-1,2))/Ltop;
sthetatop = (+Lw+Lu-y(l,d(end-1,2)))/Ltop; %top
cthetabottom = x(l,d(end,2))/Lbottom;
sthetabottom = (-Lw-Lu-y(l,d(end,2)))/Lbottom; %bottom
for i=1:cell
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L0(i) = l0 - phi*G(l,i).^pp./(Gh.^pp + G(l,i).^pp);
T(i) = L(i,3) - L0(i);
f(i) = beta./(1 + exp(-alpha.*T(i)));
epf(i) = (ep+fep) - 2*fep./(1 + exp(-alpha*T(i)));
etaf(i) = k./epf(i); % front of the cell eta term
end
% Tspar = sparse(cellindex(:,1), cellindex(:,2), L - L0’);
% for i=1:(n-2)/2
% Tjuncspar = sparse(juncindex(i,1), juncindex(i,2), Ljunc(i)-L0junc);
% end
Tjunc = [Ljunc(:,1) Ljunc(:,2) Ljunc(:,3)-L0junc];
Tbottom = Lbottom - Lw;
Ttop = Ltop - Lw;
% etafspar = sparse(1,2,etaf(1));
% for i = 3:4:n/2
% etafspar(i,i+2)=etaf((i+1)/2);
% etafspar(i+1,i+3)=etaf((i+1)/2+1);
% end
% ODEs
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for j = 1:cell
dG(j) = (b + f(j) + gam*G(l,j)^n/(1 + G(l,j)^n))*(GT - G(l,j)) - G(l,j);
G(l+1,j) = G(l,j) + dt*dG(j);
end
dx = [-k./etaf(1).*T(1).*ctheta(1,3); ... %x1
k./eta.*T(1).*ctheta(1,3)-kjunc./eta.*Tjunc(1,3).*cthetajunc(1,3)-...
kjunc/eta.*Tjunc(2,3).*cthetajunc(2,3)];... %x2
% kjunc./etaf(2).*Tjunc(find(Tjunc(:,2)==3),3).*cthetajunc(find(Tjunc(:,2)==3),3)-...
% k/etaf(2).*T(2).*ctheta(2,3);... %X3
% kjunc./etaf(3).*Tjunc(find(Tjunc(:,2)==4),3).*cthetajunc(find(Tjunc(:,2)==4),3)-...
% k./etaf(3).*T(3).*ctheta(3,3)];... %x4
for i = 3:4:length(c)*2-2
if c(find(c(:,1)==i),4) == inf
dx(i:i+3)= [kjunc./etaf((i+1)/2).*Tjunc(find(Tjunc(:,2)==i),3).*cthetajunc(find(cthetajunc(:,2)==i),3)-...
k/etaf((i+1)/2).*T((i+1)/2).*ctheta((i+1)/2,3);... %x3
kjunc./etaf((i+3)/2).*Tjunc(find(Tjunc(:,2)==i+1),3).*cthetajunc(find(cthetajunc(:,2)==i+1),3)-...
k./etaf((i+3)/2).*T((i+3)/2).*ctheta((i+3)/2,3);... %x4
inf(1,1);...
inf(1,1)];
else
dx(i:i+3)= [kjunc./etaf((i+1)/2).*Tjunc(find(Tjunc(:,2)==i),3).*cthetajunc(find(cthetajunc(:,2)==i),3)-...
k/etaf((i+1)/2).*T((i+1)/2).*ctheta((i+1)/2,3);... %x3
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kjunc./etaf((i+3)/2).*Tjunc(find(Tjunc(:,2)==i+1),3).*cthetajunc(find(cthetajunc(:,2)==i+1),3)-...
k./etaf((i+3)/2).*T((i+3)/2).*ctheta((i+3)/2,3);... %x4
k/eta.*T((i+1)/2).*ctheta((i+1)/2,3)-...
kjunc./eta.*Tjunc(find(Tjunc(:,1)==i+2),3).*cthetajunc(find(cthetajunc(:,1)==i+2),3);... %x5
k/eta.*T((i+3)/2).*ctheta((i+3)/2,3)-...
kjunc./eta.*Tjunc(find(Tjunc(:,1)==i+3),3).*cthetajunc(find(cthetajunc(:,1)==i+3),3)]; %x6
end
end
for i = find(dx(:)==inf)
dx(i) = [k/eta.*T(d(end-1,3)).*ctheta(d(end-1,3),3)-...
kjunc/eta.*Ttop.*cthetatop,... %x9
k/eta.*T(d(end,3)).*ctheta(d(end,3),3)-kjunc/eta.*Tbottom.*cthetabottom];
end
dy = zeros(cell*2,1);
% dy = [k/etaf(1).*T(1)*stheta(1); ...
% -k/eta.*T(1).*stheta(1)+kjunc./eta.*Tjunc(1,3).*sthetajunc(1,3)+...
% kjunc./eta.*Tjunc(2,3)*sthetajunc(2,3);...
% -kjunc/etafspar(3,5).*Tjuncspar(2,3).*sthetajuncspar(2,3)+...
% k/etafspar(3,5).*Tspar(3,5).*sthetaspar(3,5);...
% -kjunc/etafspar(4,6).*Tjuncspar(2,4).*sthetajuncspar(2,4)+...
% k/etafspar(4,6).*Tspar(4,6).*sthetaspar(4,6);...
% -k/eta.*Tspar(3,5).*sthetaspar(3,5)+kjunc/eta.*Tb.*sthetatop;...
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% -k/eta.*Tspar(end).*sthetaspar(end)+kjunc/eta.*Ta.*sthetabottom;...
% 0;0;0;0;
% zeros(cell*2-2,1)];
for j = 1:cell*2
x(l+1,j) = x(l,j) + dt*dx(j);
y(l+1,j) = y(l,j);
end
if l<mitosisend
if rem(l,tmitosis) < 1
mitosiscell = length(cellnum)/2-1/2; %ceil(length(cellnum)*rand()/2);
%mid length(cellnum)/2-1/2;
% end cellnum(end-1);
% ceil(length(cellnum)*rand()/2);
if mitosiscell == 1
mitosiscell = 1;
elseif rem(mitosiscell,2) == 1
mitosiscell = mitosiscell+1;
end
mitosistrack(end+1)=mitosiscell;
% if mitosiscell == cellnum(cellnum==(mitosiscell))
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if mitosiscell == 1
[row, col] = find(isnan(x(l,:)));
for i = 2:length(cellnum)
if cellnum(i) >= mitosiscell
cellnum(i) = cellnum(i)+2;
end
end
G(l+1,mitosiscell)= G(l+1,mitosiscell);
G(l+1,[col(1)/2+0.5 col(1)/2+1.5])= G(l+1,mitosiscell);
x(l+1,col(3)) = x(l+1,2);
x(l+1,col(4)) = x(l+1,2);
xshift = 0.5*(x(l+1,1)-x(l+1,2)-mitjunc);
x(l+1,2) = x(l+1,1) - xshift;
x(l+1,col(1)) = x(l+1,2)-mitjunc; %<5*mitjunc x3 ends up higher than x2
x(l+1,col(2)) = x(l+1,2)-mitjunc;
y(l+1,col(1)) = y(l+1,2)+1/2*Lu;
y(l+1,col(3)) = y(l+1,2)+1/2*Lu;
y(l+1,col(2)) = y(l+1,2)-1/2*Lu;
y(l+1,col(4)) = y(l+1,2)-1/2*Lu;
cellnum(end+1,1)=mitosiscell+1;
cellfront(end+1,1) = col(1);
cellback(end+1,1) = col(3);
cellnum(end+1,1)=mitosiscell+2;
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cellfront(end+1,1) = col(2);
cellback(end+1,1) = col(4);
c = [1 2 1 inf(1,1); cellfront cellback cellnum inf(length(cellnum),1)];
else
[row, col] = find(isnan(x(l,:)));
G(l+1,col(1)/2+0.5) = G(l+1,mitosiscell);
G(l+1,col(1)/2+1.5) = G(l+1,mitosiscell);
G(l+1,mitosiscell) = G(l+1,mitosiscell);
for i = 2:length(cellnum)
if cellnum(i) >= mitosiscell+2
cellnum(i) = cellnum(i)+2;
end
end
xshift = 0.5*(x(l+1,d(mitosiscell+1,1))-x(l+1,d(mitosiscell+1,2)));
x(l+1,col(3)) = x(l+1,d(mitosiscell+1,2));
x(l+1,col(4)) = x(l+1,d(mitosiscell+1,2));
x(l+1,d(mitosiscell+1,2)) = x(l+1,d(mitosiscell+1,2))+ xshift;
x(l+1,d(mitosiscell+2,2)) = x(l+1,d(mitosiscell+1,2));
x(l+1,col(1)) = x(l+1,d(mitosiscell+1,2))-mitjunc;
% x(l+1,col(3)) = x(l+1,d(mitosiscell+1,2))-xshift;
x(l+1,col(2)) = x(l+1,col(1));
% x(l+1,col(4)) = x(l+1,d(mitosiscell+1,2))-xshift;
y(l+1,col(1)) = y(l+1,d(mitosiscell+1,2));
y(l+1,col(3)) = y(l+1,d(mitosiscell+1,2));
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y(l+1,col(2)) = y(l+1,d(mitosiscell+2,2));
y(l+1,col(4)) = y(l+1,d(mitosiscell+2,2));
cellnum(end+1)=mitosiscell+2;
cellfront(end+1) = cellfront(end-1)+4;
cellback(end+1) = cellback(end-1)+4;
cellnum(end+1)=mitosiscell+3;
cellfront(end+1) = cellfront(end-2)+5;
cellback(end+1) = cellback(end-2)+5;
c = [1 2 1 inf(1,1); cellfront cellback cellnum inf(length(cellnum),1)];
end
% cellindex = sparse(c(:,1),c(:,2),c(:,3));
[~,idx] = sort(c(:,3));
d = c(idx,:);
for i=1:length(d)-2
d(i,4) = d(i+2,1);
end
[~,idx] = sort(d(:,1));
c = d(idx,:);
cell = length(c)-1;
end
end % end mitosis stop
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end %end cell
Tcomb(l,1:length(T)) = T;
end % end of base
Tave = [c zeros(length(c),1)];
Tave(2:end,5) = nanmean(Tcomb(mitosisend+ceil(0.1*tmitosis):mitosisend+ceil(0.2*tmitosis),1:length(c)-1))’;
[~,idx] = sort(Tave(:,3));
d2 = Tave(idx,:);
d2 = d2(2:2:end,:);
wallT = x(:,[1 2 3:2:end]);
wallT = wallT( wallT<0.2 );
newt=t/tmitosis;
newtrange = [mitosisend+ceil(0.1*tmitosis) mitosisend+ceil(0.2*tmitosis)]/tmitosis;
if 1
figure;
subplot(1,3,1)
plot(newt,x)
xlim([0 max(newt)])
xlabel(’Time (days)’)
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ylabel(’Distance (\mum)’)
title(’Time Trace’)
subplot(1,3,2)
plot(newt,x)
xlim(newtrange/10)
ylim([9.2*l0 10.5*l0])
xlabel(’Time (days)’)
ylabel(’Distance (\mum)’)
title(’Time Trace’)
subplot(1,3,3);
plot(d2(:,5))
title(’Average cell tension after all cells’)
%vline(11)
ylim([-0.001 max(Tave(:,5))*1.1])
xlim([0 12])
xlabel(’Cell’)
ylabel(’Tension’)
labs = 1;
txt = ’lead cell \rightarrow’;
txt2 = ’\leftarrow Parent vessel wall’;
text(1,0,txt, ’HorizontalAlignment’, ’right’)
text(11,0,txt2, ’HorizontalAlignment’, ’left’)
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set(gca, ’XDir’,’reverse’)
end
if 0
subplot(2,2,1);
plot(d2(:,5))
title(’Average cell tension after all cells’)
vline(11)
ylim([min(d2(:,5))*.8 max(d2(:,5))*1.1])
xlim([0 12])
labs = 1;
txt = ’lead cell \rightarrow’;
text(1,d2(1,5),txt, ’HorizontalAlignment’, ’right’)
set(gca, ’XDir’,’reverse’)
subplot(2,2,2);
plot(newt(1:length(wallT)),wallT)
xlim([1 end])
title(’Wall Tension’)
subplot(2,2,[3,4]);
plot(x)
xlim([1 length(t)])
212
title(’Time Trace’)
end
if 0
h = figure;
filename = ’model.gif’;
for i = 1:40:length(t)
if i<tmitosis
plot(x(i,1), y(i,1), ’b.’,...
x(i,2), 0.5*Lu, ’r.’, x(i,2), -0.5*Lu,’r.’,...
[x(i,1) x(i,2)], [y(i,1) y(i,2)],’g-’,...
[0 x(i,2)], [Lw+0.5*Lu 0.5*Lu],’k-’,...
[0 x(i,2)], [-Lw-0.5*Lu -0.5*Lu],’k-’,...
[x(i,2) x(i,2)], [0.5*Lu -0.5*Lu],’g-’,...
’linewidth’,2,’markersize’,36);
title(num2str(t(i)));
axis([min(x(:)) max(x(:)) -1.7 1.7]);
elseif i<2*tmitosis
plot(x(i,1), y(i,1), ’b.’, ...
x(i,2), 0.5*Lu, ’r.’, x(i,2), -0.5*Lu,’r.’,...
x(i,3), y(i,3), ’b.’, x(i,4), y(i,4), ’b.’,...
x(i,5), y(i,5), ’r.’, x(i,6), y(i,6),’r.’,...
[x(i,1) x(i,2)], [y(i,1) y(i,2)],’g-’,...
[x(i,3) x(i,2)], [y(i,3) y(i,3)],’r-’,...
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[x(i,4) x(i,2)], [y(i,4) y(i,4)],’r-’,...
[x(i,3) x(i,5)], [y(i,3) y(i,5)],’g-’,...
[x(i,4) x(i,6)], [y(i,4) y(i,6)],’g-’,...
[x(i,5) 0], [y(i,5) 0.5*Lu+Lw],’k-’,...
[x(i,6) 0], [y(i,6) -0.5*Lu-Lw],’k-’,...
[x(i,2) x(i,2)], [0.5*Lu -0.5*Lu],’g-’,...
’linewidth’,2,’markersize’,36);
title(num2str(t(i)));
axis([min(x(:)) max(x(:)) -1.7 1.7]);
else
plot(x(i,1), y(i,1), ’b.’,...
x(i,2), 0.5*Lu, ’r.’, x(i,2), -0.5*Lu,’r.’,...
x(i,3), y(i,3), ’b.’, x(i,4), y(i,4), ’b.’,...
x(i,5), y(i,5), ’r.’, x(i,6), y(i,6),’r.’,...
x(i,7), y(i,7), ’b.’, x(i,9), y(i,9), ’r.’,...
x(i,8), y(i,8), ’b.’, x(i,10), y(i,10),’r.’,...
[x(i,1) x(i,2)], [y(i,1) y(i,2)],’g-’,...
[x(i,7) x(i,2)], [y(i,3) y(i,3)],’r-’,...
[x(i,8) x(i,2)], [y(i,4) y(i,4)],’r-’,...
[x(i,7) x(i,9)], [y(i,3) y(i,5)],’g-’,...
[x(i,8) x(i,10)], [y(i,4) y(i,6)],’g-’,...
[x(i,9) x(i,3)], [y(i,3) y(i,3)],’r-’,...
[x(i,10) x(i,4)], [y(i,4) y(i,4)],’r-’,...
[x(i,3) x(i,5)], [y(i,3) y(i,5)],’g-’,...
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[x(i,4) x(i,6)], [y(i,4) y(i,6)],’g-’,...
[x(i,5) 0], [y(i,5) 0.5*Lu+Lw],’k-’,...
[x(i,6) 0], [y(i,6) -0.5*Lu-Lw],’k-’,...
[x(i,2) x(i,2)], [0.5*Lu -0.5*Lu],’g-’,...
’linewidth’,2,’markersize’,36);
title(num2str(t(i)));
axis([min(x(:)) max(x(:)) -1.7 1.7]);
end
if i == 1
pause
end
drawnow;
% Capture the plot as an image
frame = getframe(h);
im = frame2im(frame);
[imind,cm] = rgb2ind(im,256);
% Write to the GIF File
if i == 1
imwrite(imind,cm,filename,’gif’, ’Loopcount’,inf);
else
imwrite(imind,cm,filename,’gif’,’WriteMode’,’append’);
end
end
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end
if 0 % Average tension
avgT=nanmean(Tcomb(:,1)-Tcomb(:,2));
for i=3:4:length(c)*2-2
avgT((i+1)/2) = nanmean(Tcomb(:,i)-Tcomb(:,i+2));
avgT((i+3)/2) = nanmean(Tcomb(:,i+1)-Tcomb(:,i+3));
end
figure;
plot(avgT)
end
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